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Cutaneous melanoma remains an increasing world health problem, emphasised by the 
lack of credible biomarkers able to identify the risk of disease progression of seemingly 
low risk tumours, or stratify such patients for early novel adjuvant precision-based 
therapies to prevent metastasis. Data leading to the present study identified the loss 
of epidermal differentiation proteins, AMBRA1 and Loricrin as putative prognostic 
biomarkers for AJCC stage I melanomas and their associated loss of expression with 
increased tumoural secretion of isoform specific TGF-β2. The aim of the present study 
was to validate the combined loss of AMBRA1 and Loricrin (AMLo) overlying AJCC 
stage I melanomas as a prognostic and companion biomarker marker to stratify high 
risk tumour subsets for novel adjuvant treatment strategies targeting TGF-β2 
signalling.  
Semi-quantitative immunohistochemical analysis of AMLo expression in 236 AJCC 
stage I melanomas identified a high risk subset (defined as tumours with complete loss 
of AMBRA1 and any break in epidermal Loricrin expression), for which univariate 
analysis demonstrated a significant decrease in disease free survival in tumours 
stratified as high risk. Addtionally, semi-quantitative immunohistochemical analysis of 
TGF-β2 in high risk AJCC stage I melanomas revealed the significant correlation 
between increased tumoural TGF-β2 expression and loss of epidermal AMLo. 
Furthermore, high risk AJCC stage I melanomas were associated with a concurrent 
loss of peri-tumoural endothelial AMBRA1 where treatment of endothelial cells with 
exogenous TGF-β2 induced the significant downregulation of AMBRA1 and junctional 
proteins VE-Cadherin or Claudin-5, the effect of which was partially rescued by the 
stable knockdown of TGF-β2 in melanoma cells. 
Combined bioinformatics of the AMBRA1 promoter, the analysis of TGF-β2 receptor 
expression and Smad signalling in endothelial cells revealed the contribution of non-
canonical TGF-β2 signalling to enhanced proliferation and loss of endothelial integrity. 
Finally, combined studies of ALK1 and ALK5 inhibition suggest, targeting ALK1 in high 
risk AJCC stage I melanomas may provide a novel adjuvant therapeutic strategy to 
prevent metastasis, for which the loss of AMLo is a companion biomarker.
 iii 
 
 
 
 
This work is dedicated to my parents 
 
Frank KH Tang & Bernadine SH Chieng 
 
Thank you for being my greatest supporters 
and always believing in me 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contents 
 iv  
 
Acknowledgements 
 
This work was funded by a British Skin Foundation Fellowship award, Melanoma 
Focus, the North Eastern Skin Research Fund and the South Tees Hospitals NHS 
Foundation Trust. 
My biggest thanks goes my main supervisor Professor Penny Lovat who has always 
been there for me as both a teacher and a friend. From the get-go, she took me under 
her wing and nurtured my transition from a clinician with no prior research experience 
into a now clinician-scientist. Her constant patience, enthusiasm and dedication 
towards her work and her research group is greatly admirable and I will always 
appreciate all she has done for me.  
To my other supervisor Rob Ellis, thank you for being such a great mentor and friend. 
Your cheerful disposition and ongoing optimism is always a breath of fresh air, which 
had helped me get through many a time when things have not gone as planned. I will 
always be grateful for your constant support and look forward to many more years of 
working together as a team! 
A massive thank you to my collaborators including Dr Gareth Inman and Lindsay 
Spender at the University of Dundee for their continued support of my work. A special 
thanks to Dr Marco Corazzari and the rest of the lab at the University of Rome ‘Tor 
Vergata’, for all their help and for making me feel so welcomed during my time there. 
They are reason I now have a soft spot for espressos and cornettis. Mr Stuart Horswell 
at Cancer Research UK has been a patient teacher and invaluable in helping me with 
statistics as well as prompt advice despite his ever busy schedule. 
I have grown to admire and respect Dr Paola Giglio, who has helped me tremendously 
in my work and played a massive role in aiding my development as scientist. Her 
attention to detail, dedication to her work and patience in teaching has inspired me and 
I can only hope to be as good a scientist as she is one day! In her, I have also made a 
friend for life. Grazie per tutto quello che hai fatto per me.  
Contents 
 v  
 
A special thanks to Miss Alison Greenwood at JCUH pathology for all her help with 
coordinating the retrieval and staining of patient tissue sections and for her dedicating 
so many of her precious weekends to help me meet my deadlines.  Also to all members 
of Penny’s group and dermatology, thanks for all the advice and help you have given 
me over the past 2 years and for putting up with my endless questions. 
Finally, I could not have done this without the love and support of my family, especially 
my parents whom this work is dedicated to and my sisters Jasmine and Lilian who 
have always been there for me. Also to Jae who has been my constant rock-thanks for 
always believing in me especially at times when I doubted myself. As always, you have 
been amazing and I could not have made it this far without you!
 vi 
 
Declarations 
 
 
This thesis is submitted for the degree of Doctor of Medicine at Newcastle University. 
The research was performed in the Department of Dermatological Sciences at the 
Institute of Cellular Medicine under the supervision of Professor Penny Lovat, as well 
as Dr Rob Ellis (Department of Dermatology, South Tees NHS Foundation Trust). This 
thesis is my own work unless otherwise stated within the text. I certify that none of the 
material offered in this thesis has been previously submitted by me for a degree or any 
other qualification at this, or any other university. 
 
 
 
 
 
 
 
 vii 
 
Contents 
 
 
Abstract ....................................................................................................................... i 
Dedication ................................................................................................................. iii 
Acknowledgements .................................................................................................. iv 
Declarations .............................................................................................................. vi 
Contents ................................................................................................................... vii 
Tables and Figures ................................................................................................. xvi 
Abbreviations ....................................................................................................... xxiv 
 
Contents 
viii 
 
1 Introduction 
 
1.1 Melanocyte development and role in melanin synthesis ................................ 3 
1.2 Cutaneous melanoma: a malignant transformation of melanocytes ............... 5 
1.2.1 Melanoma genesis: From melanocytes to metastases ............................ 5 
1.2.2 Incidence and mortality .......................................................................... 10 
1.2.3 Genetic and environmental risk factors .................................................. 12 
1.2.4 Oncogenic mutations in BRAF and NRAS ............................................. 14 
1.3 Melanoma Disease Staging, Biomarkers and Targeted therapies ............... 17 
1.3.1 The American Joint Committee on Cancer (AJCC) 7th edition melanoma 
staging criteria ....................................................................................... 17 
1.3.2 The American Joint Committee on Cancer (AJCC) 8th edition staging 
criteria .................................................................................................... 21 
1.3.3 Epidermal differentiation and tumour ulceration..................................... 22 
1.3.4 Biomarkers in melanoma ....................................................................... 25 
1.3.5 Current Pathway Targeted therapies ..................................................... 29 
1.4 Pilot data leading to present study: Down regulation of epidermal AMBRA1 and 
relationship with TGF-β signalling ................................................................... 32 
1.4.1 Role of AMBRA1 in cellular differentiation and proliferation .................. 32 
1.4.2 TGF-β signalling cascade and implications in melanoma ...................... 36 
1.4.3 Current strategies to target TGF-β2 signalling in tumourigenesis .......... 44 
1.5 Hypothesis, Aims and Objectives ................................................................. 47 
 
Contents 
ix 
 
2 Materials and Methods 
 
2.1 Growth and maintenance of primary human keratinocytes, endothelial cells, 
human endothelial and melanoma cell line ............................................................ 53 
2.1.1 Human Umbilical Vein Endothelial Cells (HUVEC) ................................ 53 
2.1.2 Primary Human Dermal Lymphatic Endothelial Cells (HDLEC) ............. 53 
2.1.3 CCD1106 Keratinocytes ........................................................................ 54 
2.1.4 Human A375 melanoma cells pre subjected to stable knockdown of ........ 
 TGF-β2 .................................................................................................. 54 
 Isolation, growth and calcium induced differentiation of primary human 
keratinocytes .................................................................................................. 55 
 Isolation of primary human dermal endothelial (HDEC) cells ....................... 56 
2.3.1 Isolation of HDEC using endothelial cell-specific antibody EN4 coated 
wells ....................................................................................................... 56 
2.3.2 Isolation of HDEC using PE anti human CD31 antibody and Miltenyi 
Biotech Magnetic Columns .................................................................... 57 
 Treatment of HUVEC, HDLEC cells and CCD1106 keratinocytes with human 
recombinant TGF-β2 in the presence or absence of an ALK5 inhibitor .......... 58 
 Treatment of HUVECs and HDLECs with TGF-β2 rich melanoma supernatants 
or supernatants derived from melanoma cells in which TGF-β2 has been stably 
knocked down ................................................................................................. 59 
 CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (MTS) ..... 60 
 siRNA-mediated knockdown of ALK1 in HUVEC cells ................................. 61 
 Real Time Reverse Transcriptase Polymerase Chain Reaction (qPCR) ...... 63 
 Western blotting ........................................................................................... 67 
Contents 
 x  
 
 Immunohistochemistry for formalin fixed paraffin embedded (FFPE) tissue .... 
  ..................................................................................................................... 70 
2.10.1 Immunohistochemistry for AMBRA1, Loricrin, CD31 and TGF-β2 using 
DAB counterstaining .............................................................................. 70 
2.10.2 Bleaching of FFPE melanoma tissue prior to analysis of TGF-β2 using 
DAB counterstaining .............................................................................. 72 
2.10.3 Immunohistochemistry for AMBRA1 and TGF-β2 using VIP 
counterstaining ...................................................................................... 72 
 Immunofluorescence for AMBRA1 and CD31 expression in FFPE HUVEC cell 
pellets and melanoma tissue .......................................................................... 74 
 Patient Cohort Selection and Database development .................................. 76 
 Analysis of Immunohistochemistry by Slide Scanner ................................... 80 
2.13.1 Analysis and scoring of epidermal and endothelial AMBRA1 expression .. 
  ............................................................................................................... 80 
2.13.2 Analysis and scoring of epidermal Loricrin expression .......................... 84 
2.13.3 Analysis of tumoural TGF-β2 expression ............................................... 85 
 Statistics and Bioinformatics Analysis .......................................................... 86 
Contents 
xi 
 
3  Combined loss of epidermal AMBRA1 and Loricrin 
(AMLo): A novel prognostic biomarker for AJCC stage I 
melanomas 
 
3.1 Introduction .................................................................................................. 92 
3.2 Results ......................................................................................................... 95 
3.2.1 Loss of AMBRA1 in the overlying AJCC stage I melanomas is a putative 
prognostic biomarker ............................................................................. 95 
3.2.2 Loss of Loricrin in the epidermis overlying AJCC stage I melanomas is a 
putative prognostic biomarker ................................................................ 99 
3.2.3 Validation of visual analysis of epidermal AMBRA1 expression as a robust 
mean of identifying ‘loss of AMBRA1 expression’ in AJCC stage I 
melanomas ................................................................................................ 
 ............................................................................................................. 105 
3.2.4 Combined loss of epidermal AMBRA1 and Loricrin (AmLo) identifies a 
high risk AJCC stage I melanoma subgroup ........................................ 110 
3.2.5 Combined loss of epidermal AMBRA1 and Loricrin (AmLo) identifies a 
high risk AJCC stage IB (AJCC 8th edition) melanoma subgroup. ....... 116 
3.3 Discussion .................................................................................................. 120 
 
Contents 
xii 
 
4 Melanoma secretion of TGF-β2 mediates the down 
regulation of epidermal and endothelial integrity  
 
4.1 Introduction ................................................................................................ 127 
4.2 Results ....................................................................................................... 129 
4.2.1 Increased TGF-β2 by AJCC stage I melanomas correlates with the 
decreased expression of epidermal AMBRA1 ..................................... 129 
4.2.2 High Risk AJCC stage I melanomas are associated with increased 
tumoural TGF-β2 ................................................................................. 135 
4.2.3 TGF-β2 induces the down regulation of calcium-induced differentiation of 
primary keratinocytes ........................................................................... 139 
4.2.4 TGF-β2 induces the down regulation of AMBRA1 and junctional proteins 
in endothelial cells ............................................................................... 141 
4.2.5 Knockdown of TGF-β2 in metastatic melanoma cell lines prevents TGF-
β2-induced down regulation of AMBRA1 and Claudin-5 in endothelial cells
 ............................................................................................................. 148 
4.2.6 Loss of endothelial AMBRA1 is associated with high risk AJCC stage I 
melanomas .......................................................................................... 153 
4.3 Discussion .................................................................................................. 160 
Contents 
xiii 
 
5 Contribution of canonical and non-canonical TGF-β2 
signalling to melanoma metastasis 
 
5.1 Introduction ................................................................................................ 168 
5.2 Results ....................................................................................................... 171 
5.2.1 Bioinformatics analysis of the AMBRA1 promoter identifies TGF-β2 
responsive elements ............................................................................ 171 
5.2.2 ALK1 and ALK5 are differentially expressed in keratinocytes and 
endothelial cells ................................................................................... 173 
5.2.3 TGF-β2-induced deregulation of keratinocyte (CCD1106) differentiation 
and AMBRA1 down regulation is mediated by canonical TGF-β signalling
 ............................................................................................................. 175 
5.2.4 TGF-β2 induces both canonical and non-canonical signalling in HUVEC 
endothelial cells ................................................................................... 178 
5.2.5 Non-canonical TGF-β2 signalling is increased in the endothelium of 
metastatic AJCC stage I melanomas ................................................... 180 
5.2.6 Inhibition of ALK5 prevents canonical TGF-β2 signalling-mediated down 
regulation of AMBRA1 in calcium-induced keratinocytes ..................... 182 
5.2.7 Inhibition of ALK5 in HUVEC endothelial cells exacerbates non-canonical 
TGF-β2 signalling and does not prevent TGF-β2-induced endothelial 
AMBRA1 down regulation. ................................................................... 184 
5.2.8 SiRNA-mediated knockdown of ALK1 prevents non-canonical TGF-β2 
mediated endothelial AMBRA1 downregulation. .................................. 186 
5.2.9 Inhibition of canonical TGF-β2 signaling by ALK5 inhibition promotes 
endothelial cell proliferation ................................................................. 190 
5.3 Discussion .................................................................................................. 194
Contents 
xiv 
 
 
6 Final discussion and future perspectives 
 
6.1 AMLo as a follow-up stratification tool for AJCC stage I melanoma following 
primary melanoma excision .......................................................................... 203 
6.2 AMLo as a companion biomarker for adjuvant therapy targeting TGF-β2 
signalling ....................................................................................................... 206 
6.3 The role of Vitamin D in TGF-β2 mediated AMBRA1 down regulation and 
melanoma metastasis ................................................................................... 208 
Contents 
xv 
 
 
 
References .............................................................................................................. 214 
Appendices .............................................................................................................. 234 
 Appendix 1: The REMARK guidelines ................................................. 235 
Published manuscripts, abstracts & submissions arising from this work ................. 239 
 
 
Tables and Figures 
xvi 
 
Tables and Figures 
 
 
Tables 
 
Table 1.1: Risk factors for melanoma. ...................................................................... 13 
Table 1.2: Tumour thickness (T) classification in TNM staging with associated 10-year    
survival. ..................................................................................................................... 18 
Table 1.3: AJCC 2009 Melanoma Staging and 5-year overall survival for stage I-II 
disease. ..................................................................................................................... 19 
Table 1.4: AJCC 2009 Melanoma Staging and 5-year overall survival for stage III-IV 
disease. ..................................................................................................................... 20 
Table 2.1: Duplex siRNA oligoribonucleotides targeting human ALK1. .................... 61 
Table 2.2: Constituents of a single Reverse Transcription Reaction. ........................ 64 
Table 2.3: Primer sets for amplification of L34, ALK1, ALK5 and AMBRA1 gene 
sequences. ................................................................................................................ 65 
Table 2.4: Constituents of a single qPCR reaction using the Maxima SYBR Green 
Assay. ....................................................................................................................... 66 
Table 2.5: Optimal primary and secondary antibody conditions for respective western 
blot analysis. .............................................................................................................. 69 
Table 2.6: Optimal conditions for AMBRA1, Loricrin, CD31 and TGF-β2 detection 
using the Ventana Benchmark XT automated IHC system. ...................................... 71 
Table 2.7: Optimal primary and secondary antibody conditions for 
immunofluorescence detection of AMBRA1 and CD31 expression. .......................... 75 
Table 2.8: Study cohort patient demographics. ......................................................... 79 
Tables and Figures 
 xvii  
 
 
Table 2.9: Visual scores of epidermal AMBRA1 expression/staining intensity overlying 
primary melanomas. .................................................................................................. 81 
Table 4.1: Stratification of 15 AJCC stage I melanomas with known epidermal 
AMBRA1 status according to peri-tumoural endothelial AMBRA1 status, associated 
AMLo score and eventual outcome. ........................................................................ 157 
Table 6.1: Potential effect of Vitamin D and Vitamin A status on prognosis of AJCC 
stage I melanomas in association with melanoma TGF-β2 secretion. ..................... 213
Tables and Figures 
xviii 
 
Figures 
 
Figure 1.1: Schematic of an epidermal melanin unit. .................................................. 4 
Figure 1.2: Model of melanocyte transformation and melanoma invasion. ................. 6 
Figure 1.3: Mechanism of melanoma cell entry into the vasculature for dissemination 
to secondary sites of metastasis. ................................................................................ 8 
Figure 1.4: Age specific incidence of malignant melanoma in the UK 2012 – 2014. 11 
Figure 1.5: Schematic representation of the MAPK signalling cascade. .................. 14 
Figure 1.6: Mutations in BRAF or NRAS lead to constitutive activation of the MAPK 
signalling pathway. .................................................................................................... 16 
Figure 1.7: Epidermal differentiation markers expression at different layers of the 
epidermis. .................................................................................................................. 23 
Figure 1.8: Epidermal differentiation is associated with increased expression of 
AMBRA1.................................................................................................................... 33 
Figure 1.9: Epidermal AMBRA1 loss is not associated with the degree of tumour 
invasion. .................................................................................................................... 34 
Figure 1.10: The canonical TGF-β/Smad signalling pathway. .................................. 37 
Figure 1.11: Schematic model for activation of TGF-β mediated ALK 1 and 5 signalling 
in endothelial cells. .................................................................................................... 38 
Figure 1.12: Effects of TGF-β on melanoma cells and the tumour microenvironment.
 .................................................................................................................................. 40 
Figure 1.13: Loss of Epidermal AMBRA1 overlying primary cutaneous melanomas 
correlates with increased tumoural secretion of TGF-β2. .......................................... 43 
 
Tables and Figures 
 xix  
 
 
Figure 1.14: Hypothesis for TGF-β2 mediated AMBRA1 down regulation, loss of 
epidermal and endothelial integrity, tumour ulceration and metastasis. .................... 48 
Figure 2.1: Graphical illustration of exclusion of samples from initial identification of 
potential samples using the JCUH Department of Plastic and Reconstructive surgery 
melanoma database, to inclusion in the final biomarker validation study cohort. ...... 77 
Figure 2.2: AMBRA1 expression in normal epidermis and the epidermis overlying 
primary AJCC stage I melanomas. ............................................................................ 81 
Figure 2.3: Peri-tumoural AMBRA1 and CD31 expression in primary AJCC stage I 
melanomas. ............................................................................................................... 83 
Figure 2.4: Loricrin expression in normal epidermis and the epidermis overlying 
primary melanomas. .................................................................................................. 84 
Figure 2.5: AMBRA1 upstream promoter sequence. ................................................ 89 
Figure 3.1: Loss of epidermal AMBRA1 expression overlying tumours correlates with 
decreased disease free survival in all AJCC stage melanomas. ............................... 96 
Figure 3.2: Loss of AMBRA1 expression in the epidermis overlying AJCC stage I 
melanomas correlates with decreased disease free survival..................................... 98 
Figure 3.3: Loss of Loricrin expression overlying primary melanomas of differing AJCC 
stage correlates with decreased disease free survival. ........................................... 100 
Figure 3.4: Loss of Loricrin expression in the epidermis overlying primary AJCC stage 
I melanomas correlates with decreased disease free survival. ................................ 101 
Figure 3.5: Combined loss of AMBRA1 and Loricrin expression overlying primary 
melanomas is a highly sensitive and specific prognostic biomarker for the prediction of 
disease free survival in AJCC stage I melanomas. ................................................. 103 
Figure 3.6:  Correlation of qualitative visual scoring of epidermal AMBRA1 expression 
with semi-quantitative scoring. ................................................................................ 107 
Tables and Figures 
 xx  
 
 
Figure 3.7: Comparison of ‘complete loss’ with a combination of ‘no or some loss’ of 
AMBRA1 expression in the epidermis overlying AJCC stage I melanomas with semi-
quantitative analysis. ............................................................................................... 109 
Figure 3.8: Loss of AMBRA1 expression in the epidermis overlying AJCC stage I 
melanomas is associated with decreased disease free survival. ............................. 111 
Figure 3.9: Loss of Loricrin expression in the overlying AJCC stage I melanomas is 
associated with decreased disease free survival. .................................................... 113 
Figure 3.10: Combined loss of epidermal AMBRA1 and Loricrin (AMLo) expression in 
the epidermis overlying AJCC stage I melanomas identifies a high risk sub group. 115 
Figure 3.11: Combined loss of epidermal AMLo expression is a prognostic biomarker 
in AJCC 8th edition criteria stage IA melanomas. ................................................... 118 
Figure 3.12: Combined loss of epidermal AMBRA1 and Loricrin (AMLo) identifies a 
high risk AJCC stage IB (AJCC 8th edition) melanoma subgroup. .......................... 119 
Figure 4.1: Visual analysis of the IHC expression of epidermal AMBRA1 and tumoural 
TGF-β2 in AJCC stage I melanomas revealed by DAB counterstaining suggests a 
potential association between loss of epidermal AMBRA1 and increased tumoural 
TGF-β2. ................................................................................................................... 130 
Figure 4.2: Loss of epidermal AMBRA1 overlying AJCC stage I melanomas does not 
correlate with increased tumoural TGF-β2 expression when compared by IHC using 
DAB counterstaining. ............................................................................................... 131 
Figure 4.3: IHC expression of tumoural TGF-β2 in AJCC stage I melanomas revealed 
by VIP counterstaining. ........................................................................................... 133 
Figure 4.4: Loss of epidermal AMBRA1 overlying AJCC stage I melanomas correlates 
with increased tumoural TGF-β2 expression revealed by VIP counterstaining. ...... 134 
 
 
Tables and Figures 
 xxi  
 
 
Figure 4.5: TGF-β2 expression (revealed following bleaching and automated IHC 
analysis with DAB counterstaining) is increased in high risk AJCC stage 1 melanomas.
 ................................................................................................................................ 136 
Figure 4.6: Tumoural TGF-β2 expression is increased in AJCC stage I melanomas 
that developed metastatic disease compared to localised tumours. ........................ 137 
Figure 4.7: High  risk AJCC stage I melanomas stratified by AMLo display significantly 
increased TGF-β2 expression compared to AMLo low risk tumours. ...................... 138 
Figure 4.8: TGF-β2 mediates the down regulation of AMBRA1 and Loricrin in calcium-
induced differentiated primary keratinocytes. .......................................................... 140 
Figure 4.9: TGF-β2 induces the down regulation of AMBRA1 and junctional protein 
expression in HUVEC endothelial cells. .................................................................. 142 
Figure 4.10: Isolation of human dermal endothelial cells from human foreskin samples 
using EN4 antibody coated wells results in mixed dermal endothelial cell and fibroblast 
subpopulations. ....................................................................................................... 143 
Figure 4.11: Isolation of human dermal endothelial cells from donor foreskin samples 
using human PE anti CD31 antibody with Miltenyi Biotech magnetic columns results in 
a mixed colony of dermal endothelial cells and fibroblasts. ..................................... 145 
Figure 4.12: TGF-β2 induces the down regulation of AMBRA1 and Claudin-5 in 
primary HDLECs. .................................................................................................... 147 
Figure 4.13: Culture of A375 cells subjected to TGFβ2 modulation in either complete 
ECCM or DMEM has no effect on cell viability. ....................................................... 149 
Figure 4.14: Treatment of HUVEC cells with TGF-β2-depleted melanoma 
supernatants derived from A375 melanoma cells with stable TGF-β2 knockdown 
prevents TGF-β2 induced down regulation of AMBRA1 and Claudin-5. .................. 150 
 
 
Tables and Figures 
 xxii  
 
 
Figure 4.15: Knockdown of TGF-β2 in melanoma cells inhibits TGF-β2 –mediated 
down regulation of AMBRA1 and Claudin-5 in primary HDLECs. ............................ 152 
Figure 4.16: Dual immunofluorescence (IF) expression of AMBRA1 and CD31 in 
HUVEC endothelial cells. ........................................................................................ 154 
Figure 4.17: Loss of epidermal AMBRA1 overlying AJCC Stage I melanomas is 
associated with a concurrent loss in endothelial AMBRA1. ..................................... 155 
Figure 4.18: Endothelial AMBRA1 expression is lost in metastatic AJCC stage I 
melanomas stratified as high risk by AMLo scoring. ................................................ 159 
Figure 5.1: Schematic model for activation of TGF-β2 mediated ALK1 and ALK5 
signalling in endothelial cells. .................................................................................. 170 
Figure 5.2: Bioinformatics analysis of the AMBRA1 promoter identifies TGF-β 
responsive elements. .............................................................................................. 172 
Figure 5.3: ALK1 and ALK5 are differentially expressed by the keratinocyte cell line 
CCD1106, primary keratinocytes and HUVEC endothelial cells. ............................. 174 
Figure 5.4: Activation of canonical TGF-β signaling in calcium-induced differentiated 
CCD1106 keratinocytes in response to exogenous TGF-β2. .................................. 176 
Figure 5.5: TGF-β2 activates both canonical and non-canonical signalling in HUVEC 
endothelial cells. ...................................................................................................... 179 
Figure 5.6: Absence of p-Smad 2/3 and the presence of p-Smad 1/5 expression is 
associated with metastatic AJCC stage I melanomas. ............................................ 181 
Figure 5.7: ALK5 inhibition results in blockade of canonical TGF-β2-induced down 
regulation of AMBRA1 in calcium-induced CCD1106 keratinocytes. ....................... 183 
Figure 5.8: ALK5 inhibition sustains TGF-β2 induced Smad 1/5 phosphorylation but 
does not prevent AMBRA1 down regulation in endothelial cells. ............................. 185 
 
Tables and Figures 
 xxiii  
 
 
Figure 5.9: Efficacy of siRNA mediated knockdown of ALK1 in HUVEC endothelial 
cells. ........................................................................................................................ 187 
Figure 5.10: Knockdown of ALK1 prevents TGFβ2-induced Smad 1/5 phosphorylation 
and loss of endothelial AMBRA1. ............................................................................ 189 
Figure 5.11: Effect of recombinant TGF-β2 on HUVEC and primary HDLEC 
endothelial cell proliferation. .................................................................................... 191 
Figure 5.12: ALK5 blockade results in increased TGF-β2 induced stimulation of 
HUVEC endothelial cell proliferation. ...................................................................... 193 
Figure 6.1: Hypothesis of the role of Vitamin D in TGF-β2 induced loss of 
epidermal/endothelial integrity and melanoma metastasis. ..................................... 211 
 
 xxiv 
 
Abbreviations 
 
 
°C Degrees Centigrade 
µl Microlitre 
µm Micrometre 
µM Micromolar 
1° Primary 
ACTH Adrenocorticotrophic hormone 
AJCC American Joint Committee On Cancer 
ALK Activin receptor-like kinase 
AMBRA1 Activating Molecule In Beclin-1 Regulated Autophagy Protein 1 
AMP Adenosine Monophosphate 
ANOVA Analysis Of Variance 
Atg Autophagy Related Protein 
BBE Bovine brain extract 
BRAF V-Raf Murine Sarcoma Viral Oncogene Homolog B1 
BS Buffer solution 
BSA Bovine Standard Albumin 
CAMP Cyclic Adenosine Monophosphate 
CDK Cyclin-dependent kinase 
CDK4 Cyclin-Dependent kinase 4 
Abbreviations 
 xxv  
 
CDKN2A Cyclin-Dependent Kinase Inhibitor 2A 
CI Confidence Interval 
cm Centimetre 
CO2 Carbon dioxide 
CREB CAMP responsive-element binding protein 
CSG Clinical Studies Group 
Ct Cycle threshold 
CTC Circulating tumour cells 
CTLA4 Cytotoxic T-lymphocyte antigen 
Ctrl Control 
DAPI 4’,6-diamidino-2-phenylindole 
DFS Disease Free Survival 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethyl Supfoxide 
DNA Deoxyribonucleic Acid 
DPX Distyrene Plasticizer And Xylene 
ECCM Endothelial cell culture media 
EDTA Ethylenediaminetetraacetic acid 
EMT Epithelial-Mesenchymal Transition 
EndoMT Endothelial-mesenchymal transition 
EORTC European Organisation For Research And Treatment Of Cancer 
Abbreviations 
 xxvi  
 
ERK Extracellular Signal-Regulated Kinase 
FCS Foetal Calf Serum 
FDA Food and Drug Administration of the United States 
FFPE Formalin-Fixed Paraffin-Embedded 
FGF Fibroblast growth factor 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GMCSF Granulocyte-macrophage colony stimulating factor 
GTP Guanosine Triphosphate 
HBSS Hanks’ balanced salt solution 
Hcl Hydrochloric 
HDEC Human dermal endothelial cells 
HDLEC Human dermal lymphatic endothelial cells 
HEGF Human epidermal growth factor 
HKGS Human keratinocyte growth supplement 
HR Hazard Ratio 
HUVEC Human Umbilical Vein Endothelial Cell 
IF Immunofluorescence 
IHC Immunohistochemistry 
IL Interleukin 
kDA Kilodalton 
LAP Latency associated proteins 
Abbreviations 
 xxvii  
 
LC3 Microtubule-Associated Protein Light Chain 3 
MAPK Mitogen-Activated Protein Kinase 
MC1R Melanocortin 1 Receptor 
MEK Mitogen Activated Protein Kinase kinase 
MIA Melanoma inhibitory activity 
min Minute 
ml Millilitre 
mm Millimetre 
mM Millimolar 
mRNA Messenger Ribonucleic Acid 
MT Metallothionein 
mTORC1 Mammalian Target Of Rapamycin 1 
MTS 
3-(4,5-Dimethylthiazol-2-yl)-5-(3-Carboxymethoxyphenyl)-2-(4-
Sulfophenyl)-2H- Tetrazolium 
NaCl Sodium Chloride 
ng Nanogram 
NICE The National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
NPV Negative predictive value 
NRAS Neuroblastoma Rat Sarcoma Viral Oncogene Homolog 
P/S Penicillin Streptomycin 
PBS Phosphate Buffered Saline 
Abbreviations 
 xxviii  
 
PBS/T Phosphate Buffered Saline and Tween 
PCR Polymerase Chain Reaction 
PD-1 Programmed death-1 
PE Phosphatidylethanolamine 
PE Phosphatidylethanolamine 
PI3K Phosphatidylinositol 3-Kinase 
PPV Positive predictive value 
PVDF Polyvinylidene difluoride 
qPCR Quantitative Real-time Polymerase Chain Reaction 
RAF V-Raf Murine Sarcoma Viral Oncogene Homolog 
RAR Retinoic acid receptors 
RAS Rat Sarcoma 
REMARK 
Reporting Recommendations For Tumour Marker Prognostic 
Studies 
RGP Radial growth phase 
RNA Ribonucleic acid 
ROS Reactive Oxygen Species 
SCC Squamous Cell Carcinoma 
SD Standard Deviation 
SDS Sodium Dodecyl Sulphate 
SEM Standard Error Of The Mean 
shRNA Short-Hairpin Ribonucleic Acid 
Abbreviations 
 xxix  
 
shRNA Short-Hairpin Ribonucleic Acid 
siRNA Short Interfering Ribonucleic Acid 
SLNB Sentinel lymph node biopsy 
SQSTM1 Sequestasome 1 
TBS Tris-buffered saline 
TBS Tris Buffered Saline 
TEM Trans endothelial migration 
TGF-β Transforming Growth Factor Β 
TNF-α Tumour Necrosis Factor Α 
TNM Tumour, Node and Metastasis 
UV Ultraviolet  
UVR Ultraviolet Radiation 
VDR Vitamin D receptors 
VE Vascular endothelial 
VEGF Vascular endothelial growth factor 
VGP Vertical growth phase 
α-MSH α-Melanocyte stimulating hormone 
 
 1 
 
 
 
Chapter 1 
 
  Introduction 
 2 
 
1: Introduction 
 
 
 Melanocyte development and role in melanin synthesis ................................ 3 
 Cutaneous melanoma: a malignant transformation of melanocytes ............... 5 
1.2.1 Melanoma genesis: From melanocytes to metastases ............................ 5 
1.2.2 Incidence and mortality .......................................................................... 10 
1.2.3 Genetic and environmental risk factors .................................................. 12 
1.2.4 Oncogenic mutations in BRAF and NRAS ............................................. 14 
 Melanoma Disease Staging, Biomarkers and Targeted therapies ............... 17 
1.3.1 The American Joint Committee on Cancer (AJCC) 7th edition melanoma 
  staging criteria ....................................................................................... 17 
1.3.2 The American Joint Committee on Cancer (AJCC) 8th edition staging 
criteria .................................................................................................... 21 
1.3.3 Epidermal differentiation and tumour ulceration..................................... 22 
1.3.4 Biomarkers in melanoma ....................................................................... 25 
1.3.5 Current Pathway Targeted therapies ..................................................... 29 
 Pilot data leading to present study: Down regulation of epidermal AMBRA1 and 
relationship with TGF-β signalling ................................................................... 32 
1.4.1 Role of AMBRA1 in cellular differentiation and proliferation .................. 32 
1.4.2 TGF-β signalling cascade and implications in melanoma ...................... 36 
1.4.3 Current strategies to target TGF-β2 signalling in tumourigenesis .......... 44 
 Hypothesis, Aims and Objectives ................................................................. 47 
 
 
 
   Chapter 1: Introduction 
3 
 
 
1.1 Melanocyte development and role in melanin synthesis 
Melanocytes, through production of the pigmented biopolymer melanin, play a crucial 
role in forming the defence barrier of the skin, particularly providing photo protection 
from ultraviolet radiation (UVR). In human skin, the degree and type of pigment 
production manifests as a skin ‘photo type’, describing skin colour and ease of tanning, 
which is the most useful predictor of skin cancer risk in the general population [1].  
Human melanocytes begin as pluripotent cells of neural crest origin, which dissociate 
from the developing neural tube and overlying ectoderm in the second month of 
embryogenesis. Subsets of these cells migrate along the dorsal lateral pathway, 
differentiate and are specified into melanoblasts, the precursors of melanocytes [2]. 
Controlled by a variety of signalling pathways, melanoblasts then proliferate and 
migrate to a range of destinations in the body including the skin, choroid and iris of the 
eye and leptomeninges of the brain where they undergo terminal differentiation and 
maturation into melanocytes [1].  
The main and most important function of melanocytes is to manufacture melanin 
(melanogenesis), which protects the skin from damage through its ability to absorb and 
scatter harmful ultraviolet radiation (UVR). Melanogenesis takes place within 
melanocytes in cytoplasmic organelles called melanosomes. Pigmentation differences 
arise from variation in the number, size and composition of melanosomes, with 
relatively constant melanocyte numbers. Melanosomes are translocated along the 
dendritic processes of melanocytes before being incorporated into keratinocytes, 
where in response to UV radiation, melanin granules accumulate over the sun exposed 
side of nuclei to form cap-like structures [3]. Multiple keratinocytes are supplied by the 
dendritic processes of melanocytes distributed along the basal layer as part of 
epidermal melanin units [4] (Figure 1.1). In the skin, melanocytes can also accumulate 
in clusters as naevi in the basal layer of the epidermis and occasionally in the dermis. 
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There are two main types of melanin produced – red/yellow pheomelanin and 
brown/black eumelanin. This process is largely regulated by the melanocortin-1-
receptor (MC1R) expressed on melanocytes. MC1R encodes a seven, 
transmembrane, G-protein-coupled receptor, which in response to UVR is activated by 
MC1R agonists (peptides derived from the precursor protein proopiomelanocortin), 
produced in the pituitary and skin in response to UVR) [5]. Activation of MC1R induces 
cyclic AMP (cAMP) production leading to phosphorylation of cAMP responsive-
element binding protein (CREB) transcription factor family members, ultimately leading 
to activation of various genes and transcription factors pivotal to the expression of 
pigment enzymes [1].  Agonists of human MC1R including α-melanocyte stimulating 
hormone (α–MSH) and adrenocorticotropic hormone (ACTH) lead to an increase in 
photoprotective eumelanin production. Polymorphisms of the MC1R gene however, 
lead to a relative increase in pheomelanin production, a less photoprotective melanin 
subtype responsible for the red-hair and fair skin phenotype. Such individuals have a 
higher susceptibility to UVR damage and a higher risk of developing melanoma and 
other non-melanoma skin cancers [6]. 
 
 
Figure 1.1: Schematic of an epidermal melanin unit. Melanocytes in the basal layer of the epidermis, 
through their dendritic processes, translocate melanosomes to supply several keratinocytes as part of 
epidermal melanin units. Adapted: Chichorek et al, 2013 [7]. 
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1.2 Cutaneous melanoma: a malignant transformation of melanocytes 
 
1.2.1 Melanoma genesis: From melanocytes to metastases 
Malignant melanoma arises from the malignant transformation of melanocytes and this 
process is often modelled by a stepwise progression beginning with in situ neoplastic 
transformation of cutaneous melanocytes, followed by invasion and subsequent 
metastases. Disrupted intracellular signalling regulating melanocyte proliferation and 
spread leads to naevi formation. Melanocytic naevi are generally benign but can 
become dysplastic and/or undergo malignant transformation to melanoma. However, 
it has been observed that only 20 – 30% of melanomas arise in histological association 
with melanocytic naevi, indicating that a large percentage arise de novo [8, 9].  
Melanomas begin in a radial growth phase (RGP) which is localised within the 
epidermis (in situ disease), followed by a vertical-growth phase (VGP) where 
melanoma cells cross the basement membrane and invade the dermis with higher 
metastatic potential (Figure 1.2 A – C) [10-13]. In VGP melanomas, accumulation of 
genetic mutations such as BRAF further facilitates progression to metastatic disease. 
[14]. However, not all melanomas progress through these sequential phases and RGP 
or VGP melanomas may both progress directly to metastatic disease [15]. 
Metastatic melanoma evolves when tumour cells spread through the lymph nodes to 
distant sites in the body. Tumour cells in invasive melanoma, via the dermal 
microvasculature and lymphatics, can spread to lymph nodes and subsequently distant 
sites (Figure 1.2 D), accelerated by alterations in the melanoma tumour 
microenvironment which include immune cell recruitment and angiogenesis. 
Angiogenesis is crucial for tumour growth and progression where several angiogenic 
growth factors such as vascular endothelial growth factor (VEGF), interleukin-8 or 
fibroblast growth factor (FGF) secreted by tumour-recruited mast cells or macrophages 
have been implicated in this process [16].  
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In addition, a process of epithelial – mesenchymal transition (EMT) has been well 
described in metastatic melanoma where tumour cells switch to a phenotype that 
exhibits higher migratory and invasive properties with alterations in the integrity of cell-
cell junctions resulting in loss of contact between neighbouring cells, thereby acquiring 
the ability to invade surrounding tissues or migrate to secondary sites of metastasis 
[17].  
 
 
 
Figure 1.2: Model of melanocyte transformation and melanoma invasion. A Normal skin showing 
even distribution of melanocytes within the epidermal basal layer. B Naevi formation following 
proliferation of melanocytes, of which some are dysplastic with morphological atypia. C RGP melanoma 
confined to the epidermis exhibiting upward migration or pagetoid spread. D VGP melanoma invading 
the dermis with malignant potential via infiltration of the vascular and lymphatic systems. Adapted: Gray-
Schopfer et al, 2007 [13]
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Melanoma dissemination and metastasis is dependent on disruption of 
endothelial cell junctions. 
Tumour induced angiogenesis results in formation of new blood vessels that have 
weak intercellular junctions, where barrier function is further reduced by locally 
secreted factors within the tumour microenvironment, enabling tumour cell entry into 
the vasculature [18]. During metastatic dissemination, melanoma cells can enter the 
circulation by direct migration through endothelial cell junctions, a process termed 
intravasation(Figure 1.3) [19]. Intravasation of cancer cells mainly occurs through 
endothelial cell junctions (paracellular transendothelial migration) [20] but can also 
occur transcellularly [21]. Paracellular TEM is facilitated by secretory factors from 
cancer cells or macrophages such as VEGF or transforming growth factor-β (TGF-β) 
that induce remodelling of endothelial junctions or cleavage of vascular endothelial 
Cadherin (VE-Cadherin), leading to the opening of endothelial cell junctions and loss 
of endothelial integrity (Figure 1.3) [22, 23]. Once within the vasculature, should these 
melanoma cells survive immune surveillance, they circulate through the bloodstream 
to potential secondary tumour sites where they leave the circulation by extravasation. 
During extravasation, cancer cells interact with platelets and leukocytes to facilitate 
adherence to endothelial cells and transmigration through the endothelial barrier after 
which they exit the circulation by invading the basement membrane [19, 24-26]. 
Following this, cancer cells can either proliferate within their new microenvironment 
giving rise to micro and macrometastases or equally can remain dormant or undergo 
cell death [19]. Both the processes of intravasation and extravasation of cancer cells 
require disruption of endothelial junctions to enable migration across the endothelium.  
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Figure 1.3: Mechanism of melanoma cell entry into the vasculature for dissemination to 
secondary sites of metastasis. Neovascularisation induced locally by melanoma tumours result in the 
formation of new blood vessels with weak intercellular junctions reduced barrier function. This is further 
exacerbated by tumour or tumour related secretory factors such as TGF-β or VEGF that induce opening 
of the endothelial cell junctions leading to endothelial cell junction remodelling or cleavage of tight and 
adherens junction proteins such as VE-Cadherin, resulting in reduced barrier endothelial function in the 
neovasculature or existing nearby blood vessels. Tumour cells may then enter the vasculature by 
intravasation through weakened endothelial cell junctions (paracellular transendothelial migration) and 
should they survive the shear-stress of immune-surveillance, migrate through the circulation to 
secondary sites of metastasis. Adapted: Reymond et al, 2013 [19].
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Crosstalk between tight and adherens junctions in maintenance of endothelial 
barrier integrity. 
In endothelial cells, tight  and adherens junctions are intermingled throughout cell-cell 
contact areas where their  functional interaction is required for  formation, maintenance 
and remodelling of barrier integrity in these areas [27]. As such, endothelial barrier 
function requires the functional adhesive activity of VE-Cadherin and Claudin-5, two 
proteins that are key components of adherens and tight junctions respectively. VE-
Cadherin and Claudin-5 expression are highly restricted to endothelial cell lineage 
where Claudin-5 represents the major claudin expressed in normal endothelial cells. 
VE-Cadherin has been demonstrated to be directly involved in the control of Claudin-
5 expression where it prevents the nuclear accumulation of Claudin-5 repressors 
Fox01 and β-catenin [28] suggesting that any alterations in VE-Cadherin function will 
also impact on tight junction function and overall barrier integrity. In addition, 
endothelial growth factors such as VEGF have been shown to reversibly disrupt VE-
Cadherin adhesion leading to subsequent disorganisation of tight junctions, where the 
chronic exposure (such as in a cancer tumour microenvironment) may lead to severe 
disruption of the endothelial barrier due to compromise of Claudin-5 expression [29, 
30]. Equally, tight junctional molecules have also been shown to regulate cadherin-
mediated adhesion in endothelial cells [31]. This interaction between VE-Cadherin and 
Claudin-5 expression further reinforces the functional relationship between tight and 
adherens junctions in maintaining endothelial barrier integrity. 
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1.2.2 Incidence and mortality 
Malignant melanoma is an increasing public health concern worldwide and now 
represents the fifth most common cancer in the United Kingdom, with over 14,000 new 
cases diagnosed in 2013, an incidence that has more doubled over the last decade 
[32]. In the UK alone, the incidence of malignant melanoma is predicted to increase 
overall by 7% by 2035 [32], with increasing rates of up to 5.5% per year in the 20 – 45 
year old age group - the 3rd highest internationally [33]. The incidence in males, 
particularly over the age of 65, is increasing faster than that of females with age 
standardised incidence rates in England (2007 – 2009) for males and females being 
16.6 and 17 per 100,000 respectively (Figure 1.4) [34]. This trend is also observed 
worldwide with incidence rates doubling every 10-20 years in countries with white 
populations, faster than any other cancer type [35].  
As the most aggressive form of skin cancer, malignant melanoma accounts for 75% of 
all skin cancer deaths, with steadily rising mortality rates in the UK. Metastatic disease 
carries an extremely poor prognosis with 5 year survival rates of only 5 – 15%; equating 
to 2500 melanoma associated deaths in the UK annually [32]. In both males and 
females, malignant melanoma is the 16th most common cause of cancer death, 
accounting for 2% of all male cancer deaths in the UK [32]. Highest mortality rates of 
malignant melanoma are in older males and females, with 54% of melanoma deaths 
per year occurring in people aged 70 or over [32, 34]. Cutaneous melanoma is also 
the most common cause of cancer related deaths in young individuals between 20 – 
35 years of age [36].  
While early stage melanomas is largely curative by surgical excision, metastatic 
disease represents the cause of death from melanoma in the vast majority of cases as 
there is still lack of consistently beneficial treatment regimens, resulting in 10 year 
survival rates of less than 15% [37] and emphasising the urgent need for credible 
biomarkers to identify high risk tumour subgroups as well as the stratification of such 
patients for more efficacious therapeutic approaches.
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Figure 1.4: Age specific incidence of malignant melanoma in the UK 2012 – 2014. Average number 
of new cases per year and age specific incidence rates of malignant melanoma per 100,000 population, 
UK. Source: Cancer Research UK (CRUK) [32].
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1.2.3 Genetic and environmental risk factors 
The genesis of melanoma consists of a complex interplay of several genetic and 
environmental factors. Through various epidemiology studies, several predisposing 
factors associated with increased melanoma risk have been established (Table 1.1).  
Exposure to UVR remains the strongest causative link with severe episodic sunburn in 
early life correlating best with melanoma risk [38, 39]. Furthermore, there is evidence 
that that use of indoor artificial tanning devices, which deliver UVR to the skin, is also 
linked to melanoma risk in a dose dependent manner [40]. This corresponds with the 
observation that Queensland, Australia, due to its geographical location exposing its 
predominantly fair skin population to intense UVR has the highest rate of melanoma. 
Exposure of children to intense UVR also resulted in the development of melanocytic 
naevi early in life and in large numbers [41]. However, until recently relatively few 
studies have shed light on the precise molecular mechanisms by which UVR induces 
acquired naevi formation or drives melanoma genesis.  
It is now known that heritable mutations in the cell cycle regulatory genes CDKN2A 
and CDK4 increases melanoma susceptibility more than tenfold, with a higher 
incidence in people living at lower latitudes, indicating close interactions between 
genetic susceptibility and UV exposure [42]. Moreover, recently, TP53 tumour 
suppressor (a UVR target gene in non-melanoma skin cancers) mutations have been 
linked to UVR-induced DNA damage in human melanoma with mutations in 
Trp53/TP53 accelerating BRAFV600E-driven melanoma genesis [43] and providing 
novel insight into the link between UVR and melanocytic naevi formation and how in 
the presence of genetic susceptibility (i.e. BRAFV600E mutation), can lead to the 
induction of melanoma. 
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Genetic 
Strong family history (≥ 3 first degree relatives affected) 
Mutations in NRAS, BRAF, cKIT, cyclin-dependent kinase (CDK) and tumour suppressors such 
as CDKN2A and p53 [44-46] 
Naevi 
Multiple benign naevi (>100) 
Multiple atypical naevi 
Previous skin cancer 
Previous melanoma 
Previous non-melanoma skin cancer 
Immunosuppression 
Transplant recipients 
Patients with AIDS 
Surrogates of sun sensitivity 
Type 1 skin (burns without tanning) 
Freckling 
Blue eyes 
Red hair 
UV exposure 
History of blistering sunburn 
Use of artificial tanning devices [40] 
 
Table 1.1: Risk factors for melanoma. Adapted: Thomson et al, 2005 [47].  
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1.2.4 Oncogenic mutations in BRAF and NRAS 
Perhaps one of the greatest risk factors described for cutaneous melanoma is the 
presence of an oncogenic mutation in the BRAF protein kinase, resulting in constitutive 
activation of the growth mitogen-activated protein kinase (MAPK)/extracellular signal-
regulated kinase (ERK) pathway, essential in the regulation of cell proliferation, 
differentiation, senescence and cell survival. 
The MAPK pathway is activated in response to extra cellular signalling from hormones, 
cytokines and growth factors [48]. These extra cellular signals activate the small GTP-
proteins of the RAS family, which in turn recruit RAF protein kinases to the cell 
membrane, leading to activation of MEK1/2 and ERK1/2 and their downstream 
effectors which regulate gene expression via a variety of nuclear and cytoplasmic 
targets [49] (Figure 1.5). 
 
 
 
Figure 1.5: Schematic representation of the MAPK signalling cascade. RAS is activated to its GTP-
bound form by extracellular signals from hormones, cytokines and growth factors. This in turn recruits 
RAF protein kinases leading to activation of MEK 1/2 and ERK 1/2 and their downstream effectors which 
regulate gene expression controlling cellular proliferation, differentiation and cell survival.
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BRAF, as a member of the RAF family of serine/threonine protein kinases is the most 
potent activator of MEK in the MAPK/ERK pathway, initiating a kinase cascade that 
acts through ERK1/2 (Figure 1.5) [48]. Constitutively activating BRAF mutations may 
occur in approximately 40% of all primary cutaneous melanomas which lead to the 
hyper activation of MAPK signalling, promoting tumour proliferation, survival and 
resistance to apoptosis (Figure 1.6). The most common mutation in BRAF involves a 
thymidine to adenosine transversion at nucleotide 1799 in exon 15 of the gene, causing 
a V600E valine with glutamic acid substitution at amino acid 600 (BRAFV600E mutation) 
which accounts for up to 90% of all BRAF mutations [50].  
RAS proteins cycle between an inactive GDP-bound form and an active GTP-bound 
form, thus functioning as a molecular switch for transmission of regulatory signals [51]. 
Approximately 20% of human cancers bear an activating RAS point mutation, mainly 
in codons 12,13 or 61 [52] which like mutations in BRAF, also result in MAPK hyper 
activation (Figure 1.6). In the context of melanoma, although 15-20% of tumours are 
reported to bear NRAS mutations, these are mutually exclusive and rarely is a primary 
NRAS and BRAF mutation observed within the same tumour [53-57]. 
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Figure 1.6: Mutations in BRAF or NRAS lead to constitutive activation of the MAPK signalling 
pathway. BRAF and NRAS mutations are mutually exclusive and rarely occur within the same tumour. 
BRAFV600E and NRAS mutations constitutively activate MEK and ERK in the absence of extracellular 
signalling, leading to hyper activation of MAPK signalling promoting tumour proliferation, survival and 
resistance to apoptosis. While BRAF relies on the MEK/ERK pathway for signalling, mutant NRAS can 
also act through other pathways. 
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1.3 Melanoma Disease Staging, Biomarkers and Targeted therapies 
 
1.3.1 The American Joint Committee on Cancer (AJCC) 7th edition melanoma 
staging criteria 
The 2009 AJCC melanoma 7th edition melanoma staging criteria is the most 
comprehensive staging system to date and remains the international standard for 
melanoma disease staging. It is the most widely used staging system to stratify patients 
diagnosed with melanoma according to prognosis and to guide management.  
AJCC staging combines several prognostic factors known in melanoma, including the 
depth of invasion of tumour, rate of mitoses, presence of ulceration, evidence of 
metastatic spread and changes in serum lactate dehydrogenase (LDH) to allow risk 
stratification of morbidity and mortality at initial diagnosis. 
 
Breslow Depth and TNM Staging Classification 
In 1970, the pathologist Alexander Breslow reported that the depth of invasion was a 
prognostic factor in melanoma associated with disease progression in a cohort of 98 
patients [58]. This has been reinforced by several studies, including a study cohort by 
the AJCC of 38,900 patients of varying melanoma disease stage showing that 
increasing Breslow depth was significantly associated with a decreased 10 year 
survival, re-enforcing its use as a principle tool to stratify disease risk [37]. The eponym 
‘Breslow depth” has since been formalised to describe the measurement of melanoma 
tumour thickness from the top of the epidermal granular layer to the deepest point of 
invasion [59]. This has been further refined to allow classification under (T) of the TNM 
system of cancer staging (Table 1.2).
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(T) Classification Tumour thickness (mm) 10-year survival (%) 
Tis (in situ) Confined to epidermis 100 
T1 ≤1.00 92 
T2 1.01 – 2.00 80 
T3 2.01 – 4.00 63 
T4 >4.00 50 
 
Table 1.2: Tumour thickness (T) classification in TNM staging with associated 10-year survival. 
Adapted: Balch et al., 2009 [37]. 
 
The TNM Staging System was developed and is maintained by the AJCC to facilitate 
an international standardised system amongst different cancer types and was 
incorporated into the AJCC 7th edition staging system for melanoma. Alongside tumour 
thickness (T), TNM describes the extent of spread to the lymph nodes (N) and the 
presence of metastasis (M) [60].  
 
Mitotic count and tumour ulceration 
The presence of mitotic activity and tumour ulceration has been used to further 
subdivide the (T) staging into Ta and Tb. Increased mitotic rate constitutes the second 
strongest predictor of survival after tumour thickness, with the most significant 
threshold being 1-mitosis per mm2 [37]. In the AJCC 7th edition staging system, the 
presence of ≥1 per mm2 of mitoses increases the staging of tumours ≤1 mm thick from 
T1a to T1b. 
The presence of loss of epidermal integrity overlying resected melanoma tumours 
(ulceration) has been shown to adversely affect outcome [37] with the 5-year survival 
of patients with melanoma deposits in >4 regional lymph nodes disease but with no  
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ulceration of the primary tumour dropping from 45.4% to 29.2% if ulceration is present. 
[61]. Its significance is highlighted in AJCC staging whereby in defining (T) stage, the 
presence of ulceration increases (T) staging from Ta to Tb, resulting in an increase of 
overall AJCC clinical stage to a  category with poorer prognosis compared to a non-
ulcerated tumour of same thickness [37] (Table 1.3). 
 
AJCC Stage TNM Stage 5-year survival rate (%) 
0 Tis 100 
IA T1a 95 
IB T1b – T2a 89 – 91 
IIA T2b – T3a 77 – 79 
IIB T3b – T4a 63 – 67 
IIC T4b 45 
 
Table 1.3: AJCC 2009 Melanoma Staging and 5-year overall survival for stage I-II disease. 
Adapted: Balch et al., 2009 [37]. 
 
Regional and distant metastases 
While early stage localised melanoma is largely curative with surgical excision, the 
presence of any regional or distant site metastases (AJCC Stage III and IV) results in 
a significant drop in survival rates (Table 1.4). The (N) category of TNM reflects the 
presence of regional nodal metastases where the number of lymph node involves 
determines the stage. The presence of ‘micrometastases’ (detected using 
immunohistochemistry after sentinel lymph node biopsy) confers a slightly better  
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outcome than ‘macrometastases’, which are clinically detectable and confirmed 
histologically. Distant metastases are categorised as M1a – distant skin, 
subcutaneous, or nodal metastases, M1b – lung metastases and M1c – all other 
visceral metastases. Elevation of serum LDH in any metastatic disease confers a 
worse prognosis and automatically elevates any distant metastases regardless of site 
into category M1c. 
 
 
AJCC Stage TNM Stage 5-year survival rate (%) 
IIIA T1 – 4a N1a / 2a M0 63 – 69 
IIIB 
T1 – 4b N1a / 2a M0 
T1 – 4a N1b / 2b / 2c M0 
30 – 53 
IIIC 
T1 – 4a / b N1b / 2b / 2c / 3 
M0 
27 – 29 
IV T – Any N-Any M1a/1b/1c 9 – 19 
 
Table 1.4: AJCC 2009 Melanoma Staging and 5-year overall survival for stage III-IV disease. 
Adapted: Balch et al., 2009 [37].
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1.3.2 The American Joint Committee on Cancer (AJCC) 8th edition staging 
criteria 
The AJCC 8th edition staging manual was published at the end of 2016, heralding 
changes in staging criteria for cutaneous melanoma of the skin which will formally 
come into effect at the beginning of 2018. A significant change in melanoma staging in 
the 8th edition manual is the classification of a melanoma as T1a if non-ulcerated and 
<0.8 mm in thickness and T1b if it is 0.8-1.0 mm thick or <0.8 mm with ulceration, with 
tumour mitotic rate being dropped completely as a staging criterion for T1 tumours [62, 
63]. In addition, tumour thickness measurements will be rounded to the closest 0.1 mm 
as opposed to the closest 0.01 mm as in the 7th edition guidelines to accommodate the 
inherent lack of precision in measuring melanoma tumours. There has also been 
expansion of the N and M categorization of TNM with changes in N categorization 
leading to 4 pathological AJCC stage III subgroups (AJCC stage III A – D) rather than 
3 (AJCC stage III A – C) as previously [62, 63]. With regards to N staging as well, the 
term micrometastasis has been dropped and replaced by “clinically occult disease as 
detected by sentinel lymph node biopsy (SLNB)” [62]. To date however, there is 
conflicting evidence on the mortality benefit of SLNB and its impact on overall survival 
is yet to be determined [64, 65]. 
Despite the impending changes in melanoma tumour staging brought about by the 
updated 8th edition AJCC staging criteria, data from biomarker studies presented in the 
result chapters will be based on the 2009 7th edition AJCC staging criteria unless 
indicated otherwise.
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1.3.3 Epidermal differentiation and tumour ulceration 
Epidermal differentiation, associated markers and role in tumour ulceration 
The epidermis is the outermost functional barrier of the skin and is formed from tightly 
packed layers of stratified squamous epithelium, consisting predominantly of 
keratinocytes that make up 90% of epidermal cells, melanocytes and Langerhans cells. 
Keratinocytes undergo an ordered process of cornification, beginning with proliferation 
and differentiation of epidermal stem cells located in the stratum basale (the innermost 
layer of the epidermis) [66]. A process of graduated differentiation continues as these 
cells migrate supra-basally to become part of stratum spinosum, granulosum and 
finally, fully-differentiated corneocytes that are eventually shed through desquamation 
[67]. This process of keratinocyte renewal can be mapped through the epidermis via 
expression of proteins synthesised by keratinocytes at each level of differentiation, 
which form epidermal differentiation markers. These include Cytokeratins 1, 5, 10 and 
14, keratinocyte transglutaminases 1 and 5 and terminal differentiation markers 
Involucrin and Loricrin [68, 69] (Figure 1.7). Deregulation of the sequential process of 
differentiation can lead to barrier dysfunction contributing to skin disease such as 
psoriasis and eczema, or in the case of skin neoplasms: tumour ulceration. 
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Figure 1.7: Epidermal differentiation markers expression at different layers of the epidermis. 
Keratinocytes undergo a graduated process of differentiation, moving up the epidermis towards the 
stratum corneum where they become terminally differentiated corneocytes which are eventually shed. 
This process can be mapped by the expression of proteins synthesised by keratinocytes at each level: 
Cytokeratin 5 and 14 in the stratum basale, transglutaminases 1 and 5 in the stratum spinosum, 
Cytokeratin 1 and 10 in the stratum granulosum, Loricrin and Involucrin in the stratum corneum. 
 
Tumour Ulceration 
Ulceration of a primary melanoma has been defined as an absence of an intact 
epidermis with reactive changes in the skin [70]. It is an independent histological 
prognostic marker associated with thicker melanomas and poor survival where 5 year 
survival rate is reduced from 80% to 55% in ulcerated stage I melanomas and from 
53% to 12% for stage II melanomas [71]. The importance of tumour ulceration as a 
prognosticator for melanoma is reflected by its incorporation in the AJCC 2009 7th 
edition staging criteria and maintenance in the impending AJCC 8th edition guidelines 
when categorising patients into TNM stage [37, 62]. 
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It is still unclear however, if the enigma of tumour ulceration represents the effect of an 
innately more aggressive and metastatic tumour phenotype expanding and breaching 
the top layers of the epidermis causing ulceration or if ulcerated tumours results in an 
increased likelihood of spread. 
Paradoxically, the European Organisation for Research and Treatment of Cancer 
(EORTC) 18991 and 18952 trials demonstrated that patients with ulcerated primary 
melanomas had greater benefit with an increase in recurrence-free survival following 
adjuvant treatment with PEGylated interferon α-2b compared to non-ulcerated 
matched controls [72, 73]. This preferential benefit of treatment seen in ulcerated 
tumours suggests an underlying tumour secretory process leading to direct effects on 
the surrounding epithelium contributing to ulceration that is modified in some way by 
interferon-α.
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1.3.4 Biomarkers in melanoma 
With the emergence of novel targeted and immunotherapies for malignant melanoma, 
current interest is focused on the discovery of prognostic and predictive biomarkers. A 
biomarker refers to “any measurable diagnostic indicator that is used to assess the risk 
or presence of disease” [74]. 
Predictive biomarkers are able to indicate which patient subgroups are likely to benefit 
from certain treatments [75]. The best example of this in melanoma is the BRAF 
mutational status of a tumour where the presence of a BV600E or BV600K mutation acts 
as a biomarker in predicting responsiveness to BRAF or MEK inhibition to stratify 
patients for treatment with such inhibitors. BRAF status however, is neither diagnostic 
nor prognostic as the mutation is also present in benign naevi and there is no evidence 
that it has any effect on overall survival [55]. 
Prognostic markers are able to stratify patients at initial diagnosis according to eventual 
outcome and can be used clinically to guide management including earlier initiation of 
adjuvant therapies in patients at high risk of disease progression, potentially preventing 
the development of untreatable metastatic disease [76].  
In melanoma, some of the best established prognostic biomarkers seen in solid 
tumours have been incorporated in the AJCC 2009 staging criteria. These include 
Breslow depth, presence of mitoses and tumour ulceration. A systemic review and 
meta-analysis performed by Gould Rothberg and his colleagues identified 101 
immunohistochemistry-based proteins with prognostic biomarker potential in 
melanoma. Unfortunately, many of these tumour marker studies lacked sufficient 
information for adequate assessment of quality and applicability [76].  
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Serological biomarkers 
In the recent years, there has been much focus on serum Vitamin D levels as a 
prognosticator in melanoma leading to its recent incorporation into the 2015 NICE 
guidelines on assessment and management of melanoma [77]. Low levels of serum 
25-hydroxyvitamin D at primary melanoma diagnosis has been associated with high 
risk melanomas with thicker primaries, tumour ulceration and poorer melanoma 
specific survival despite conflicting evidence on overall survival and insufficient 
evidence to establish cause-effect [78-82]. To date, serum LDH is still the only 
established serological prognostic biomarker routinely used in clinical practice and 
incorporated into AJCC staging [83].  
A systemic review on emerging biomarkers in melanoma describes other serological 
biomarkers including S100, Melanoma Inhibitory Activity (MIA) protein, vascular 
endothelial growth factor (VEGF) and microRNAs [84]. However to date, there is still 
no substantial evidence to validate their prognostic use in melanoma. Other prognostic 
biomarkers reported include the detection of circulating cancer cells (CTC) and cancer 
stem cell (melanoma initiating cells) markers, metallothionein (MT) expression in 
tumour cells and tumour lymph angiogenesis [84]. Although promising with many 
showing significant survival differences, to date none have undergone large rigorous 
prospective trials with multivariate analysis for full validation for clinical application. 
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Molecular predictors  
More recently, there has been emergence of molecular predictors utilising melanoma 
gene expression profiling with evidence that gene expression phenotypes hold 
prognostic information and predict survival outcome in metastatic melanoma [85-87]. 
DecisionDX by Castle Biosciences determines metastatic risk of AJCC stage I and II 
cutaneous melanomas by measuring gene signatures of 31 genes on FFPE melanoma 
tissue with validation based on an original data set of 164 patients and a further cohort 
of 101 patients with 5 years follow up on outcome [88-90]. The clinical utility of 
DecisionDx and many other molecular predictors however, remain uncertain given they 
do not form companion biomarkers i.e. there is lack of a therapeutic target for 
intervention.  
 
Autophagy biomarkers  
Autophagy is a hot topic in cancer medicine and observations of deregulation in 
melanoma as well as novel therapeutic approaches through which to harness its 
modulation for therapeutic benefit have brought its potential as a biomarker for 
melanoma to the forefront of current research. Key regulatory proteins, including 
Atg8/microtubule-associated light chain 3 (LC3) and BECN1 (Beclin 1) have been 
proposed as potential prognostic biomarkers [91, 92]. However, given the dynamic 
nature of autophagy, their expression in vitro does not translate to their use as a 
prognostic biomarker for melanoma in vivo [93]. More recently, the expression of the 
autophagy shuttled protein Sequestosome1/SQSTM1 (p62) has been defined as an 
independent prognostic biomarker for AJCC stage II melanoma, where its biphasic 
expression reflects the paradoxical role of autophagy in melanoma [94]. 
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In addition, expression of p62 may represent a companion biomarker of response to 
autophagy modulation in vivo, an important concept in view of emerging autophagy 
modulator therapies [95] and their potential to improve overall clinical outcome for 
patients with metastatic melanoma. 
Current practice of malignant melanoma is to treat all patients with surgical excision 
and surveillance until metastasis ensues. However, with still no consistently beneficial 
treatments for metastatic melanoma, there is a push towards informing the clinical 
decisions, at the outset. Despite its comprehensiveness, the role of AJCC staging as 
a prognostic biomarker is still limited by the fact that it is unable to identify tumours that 
will go on to progress and metastasise, especially seemingly ‘low risk’ tumours of stage 
I disease. This emphasises the acute need for novel companion biomarkers to more 
accurately stratify this subset of patients at risk of disease progression for potential 
early targeted therapeutic intervention, preferably prior to the development of 
metastasis.
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1.3.5 Current Pathway Targeted therapies 
The discovery of activating mutations in the MAPK pathway has undoubtedly 
revolutionised therapy for melanoma, leading to the development of new generation 
BRAF and MEK inhibitors, that for patients stratified by the presence of a BRAF 
mutation now form main line therapy for metastatic disease for which the BRAF 
mutational status of an individual tumour is perhaps the best example of a companion 
biomarker [96].  
Initial therapy with BRAF inhibitors Vemurafenib (Zelboraf®, Roche, Basel, 
Switzerland) and Dabrafenib (Tafinlar®, GlaxoSmithKline, Brentford, UK) results in 
dramatic antitumor activity [97-99], increasing progression free survival by up to 6 
months. However, the beneficial effects of BRAF inhibition are short lived, and after a 
matter of months, the development of acquired resistance is inevitable in most patients 
[96, 100]. Re-activation of the MAP kinase pathway is thought to be mediated by the 
acquisition of an additional NRASQ61 mutation or several MEK1 mutations [101], 
providing the rationale for the clinical use of MEK inhibitors.  
More recently, two different combinations of BRAF inhibitors plus MEK inhibitors 
(Dabrafenib plus Trametinib (Mekinist®, GlaxoSmithKline) and Vemurafenib plus 
Cobimetinib (COTELLIC®, Roche) have shown higher response rate, longer 
progression-free survival and overall survival compared with BRAF inhibition alone in 
phase III clinical trials [102-105]. Treatment with combined BRAF plus MEK inhibitors 
however was associated with a higher toxicity profile and increased incidence of 
adverse events compared to monotherapy of either drug alone [104]. Due to 
significantly better survival outcomes, combination therapy remains mainstay therapy 
for BRAF V600 melanoma however, clinician awareness of the specific set of associated 
adverse events ultimately determines the use of combination therapy over 
monotherapy [104].  
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Overall however, growing concerns over drug resistance to molecular targeted 
therapies still exists and the optimal treatment approach for management of patients 
with disease progression while on treatment with BRAF/MEK inhibitors remains under 
active investigation [106]. In addition, not all melanomas harbour a BRAF mutation and 
equally not all BRAF mutant melanomas response to targeted therapies with 
BRAF/MEK inhibition. The rational combination of BRAF/MEK targeted therapies to 
address resistance or combining BRAF inhibition with other effective therapies such 
as immunotherapy may therefore improve overall outcome [107]. 
The introduction of immune modulating antibodies has further improved the outlook for 
patients with metastatic melanoma. Ipilimumab (Yervoy®, Bristol-Myers Squibb, NY, 
USA) a cytotoxic T-lymphocyte antigen (CTLA4) blocking antibody, was the first 
checkpoint inhibitor to be approved by the FDA in 2011 for the treatment of metastatic 
melanoma following significantly improved median overall survival  compared to the 
control arms in randomised clinical trials [108, 109]. In 2014, Pembrolizumab 
(Keytruda®, Merck, NJ, USA) a programmed death-1 (PD-1) checkpoint inhibitor was 
approved for the treatment of BRAF mutated metastatic melanoma that has 
progressed on treatment with Ipilimumab and BRAF inhibitors, following results of a 
randomised clinical trial demonstrating increased overall response rates with tumour 
shrinkage following treatment with Pembrolizumab [110]. Another PD-1 inhibitor, 
Nivolumab (Opdivo®, Bristol-Myers Squibb) demonstrated improved overall survival, 
progression free survival and a comparable side effect profile in comparison with 
Dacarbazine for the treatment of previously untreated melanomas without a BRAF 
mutation, leading to FDA approval in 2014 [111]. 
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The emergence of BRAF/MEK targeted therapies and immunotherapies have 
undeniably revolutionised treatment of metastatic melanoma, particularly in the last 
decade. The impressive initial responses seen following treatment with BRAF inhibitors 
coupled with prolonged duration of response seen with immunotherapy has driven a 
move towards combination therapy to further improve outcome with several clinical 
trials (NCT02130466 and NCT02027961) currently evaluating PDL1/PD1 antibodies 
combined with BRAF and/or MEK inhibitors [112].  
Despite significant breakthroughs in the treatment of metastatic melanoma, there is as 
of yet still no consistently effective method to determine metastatic risk in early AJCC 
stage melanomas at time of primary diagnosis, nor any method of adjuvant therapy to 
prevent disease progression of high risk tumours. Moreover, with increasing focus on 
personalised medicine and targeted therapy, there is an urgent need for companion 
biomarkers to enable stratification of high risk patients for early adjuvant therapies to 
prevent the development of metastasis.
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1.4 Pilot data leading to present study: Down regulation of epidermal 
AMBRA1 and relationship with TGF-β signalling 
 
1.4.1 Role of AMBRA1 in cellular differentiation and proliferation 
The process of cellular differentiation is an energy consuming process with oxidative 
mitochondrial metabolism shown to regulate keratinocyte differentiation [113, 114]. 
Autophagy, as the principle catabolic process for lysosomal mediated degradation and 
recycling of damaged organelles and excess proteins has energy providing capacity, 
supporting its role in differentiation. Activating molecule in Beclin 1 regulated protein 1 
(AMBRA1) is a component of the Beclin 1/VPS34 complex and involved in the 
formation of PI3K rich membranes during the nucleation phase of autophagy [115]. As 
a key autophagy initiating regulatory protein, AMBRA1 represents a potential marker 
of autophagy induction as well as a possible therapeutic target for autophagy inhibition. 
However, in addition to its functional role in autophagy, a growing body of evidence 
supports a role for AMBRA1 in cellular differentiation [113, 114], with evidence that the 
protein plays a role in early neuronal differentiation of stem cells which activate 
autophagy to fulfil their high energy demands [116]. AMBRA1 has also been shown to 
regulate cell proliferation with Ambra1+/gt heterozygous mice having a three-fold 
increase in cancer susceptibility and AMBRA1 deficient tumour cells having increased 
growth capability [117]. This highlights the role of AMBRA1 in cellular differentiation 
and proliferation, where when dysregulated is pro-tumorigenic and in the context of 
epidermal differentiation, may promote tumour ulceration. 
In line with these findings, pilot data leading up to the present study has demonstrated 
the role of AMBRA1 in epidermal differentiation with expression in vivo increasing in 
line with keratinocyte differentiation from the basal layer of the epidermis to the 
uppermost layer, the stratum corneum (Figure 1.8) [118].  
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In addition, knockdown of ATG7 (an alternative autophagy regulatory protein) in 
calcium-induced differentiated primary keratinocytes in vitro demonstrated impaired 
autophagy with no effect on Loricrin upregulation. In contrast, in addition to impairment 
of LC3-II induction, siRNA mediated knockdown of AMBRA1 resulted in the significant 
down regulation of Loricrin suggesting that the role of AMBRA1 in keratinocyte 
differentiation is independent of its pro-autophagy role, or at least independent of Atg7 
(Ellis and Lovat, unpublished data).  
 
 
 
Figure 1.8: Epidermal differentiation is associated with increased expression of AMBRA1.                 
A Expression of AMBRA1 increases in line with keratinocyte differentiation from the basal layer of the 
epidermis to the stratum corneum. B Representative western blot for the expression of AMBRA1 (132 
kDA), Loricrin (26-30 kDA) and β-Actin (45 kDA) depicting concurrent increase in the expression of 
terminal differentiation marker Loricrin, with increased AMBRA1 expression when primary keratinocytes 
were cultured in high calcium conditions to induce differentiation (Ellis & Lovat, unpublished data). 
 
More strikingly, AMBRA1 expression was observed to be lost in the epidermis overlying 
many cutaneous melanomas (Figure 1.9 A) which did not correlate with the degree of 
epidermal invasion (Figure 1.9 B) and was not observed in benign nevi (Ellis and Lovat, 
unpublished data). These data suggest that the expression of AMBRA1 in the 
melanoma microenvironment may have prognostic potential. In addition, there was no 
correlation with Breslow depth, suggesting that epidermal AMBRA1 expression may 
represent a biologically distinct biomarker (Ellis and Lovat, unpublished data). 
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Figure 1.9: Epidermal AMBRA1 loss is not associated with the degree of tumour invasion. A 
Representative IHC images of AMBRA1 expression revealed by VIP counterstaining (pink) depicting (i) 
maintained and (ii) loss of epidermal AMBRA1 expression overlying 2 separate melanoma tumours 
compared with that of the normal adjacent epidermis. Scale bar =100 μm. B Representative IHC images 
of Cytokeratin 5/6 expression in epidermis with melanoma tumour invasion present revealed by DAB 
counterstaining (brown). Cytokeratin 5/6 expression levels shown are associated with correlating 
epidermal AMBRA1 expression levels: (i) no AMBRA1 loss, (ii) some AMBRA1 loss or (iii & iv) complete 
AMBRA1 loss, depicting no correlation between epidermal invasion and epidermal AMBRA1 
expression. Scale bar =50 μm (Ellis and Lovat, unpublished data). 
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The presence of epidermal hyperplasia and hyperkeratosis observed in melanoma 
tumours that have lost epidermal AMBRA1 expression (Ellis and Lovat, unpublished 
data), coupled with the lack of association between AMBRA1 expression and 
epidermal tumour invasion suggests that these morphological changes are due to a 
chronic, tumour secretory process, rather than direct tumour invasion of the basal cell 
layer, a process subsequently shown to be significantly associated with increased 
tumour expression of transforming growth factor (TGF)-β2 (TGF-β2) (Ellis and Lovat, 
unpublished data). 
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1.4.2 TGF-β signalling cascade and implications in melanoma 
The secretory polypeptide TGF-β, represented by three isoforms, TGF-β2, TGF-β2 
and TGF-β3, signals via receptor serine/threonine kinases and intracellular Smad 
effectors, exerting multiple effects on numerous biological functions including cellular 
proliferation, differentiation and apoptosis. TGF-β is initially synthesised in an inactive 
form, associated with latency associated proteins (LAPs) in a large latent complex 
(LLC) [119]. Latent TGF-β can be activated in several ways including conformational 
change of LAPs induced by thrombospondin-1 (TSP-1), upregulation of alpha v beta 6 
(αvβ6) integrin, mechanical contraction of stromal myofibroblasts and also in response 
to low pH levels in the environment or the production of irradiation-induced reactive 
oxygen species (ROS) [120]. These result in proteolytic cleavage of the latent complex 
and the release of active TGF-β, which binds to TGF-β receptors, propagating 
downstream signalling. 
Active TGFβ ligands transduce signalling via three types of TGF-β receptors (TGF-
βR), TGF-βRI (also known as activin receptor-like kinase 1-7 (ALK1-7), TGF-βRII, and 
TGFβRIII (betaglycan, endoglin in endothelial cells) [121]. In most tissues, TGF-β 
ligands form heterotetrameric TGF-βRII/ALK5 complexes between two TGF-βRIs and 
two TGF-βRIIs where TGFβ-RII phosphorylates and activates TGF-βRI, which then 
interacts with R-Smads, resulting in their phosphorylation [122]. Phosphorylated 
Smads form heterotrimeric complexes with co-Smads: coactivators (Smad4) or co-
repressors (C-SKI, SNON) which translocate into nuclei of cells to modulate gene 
expression (Figure 1.10) [123].  
TGF-β signalling is balanced by a negative feedback loop mediated by the inhibitory 
Smad7, which can bind to TGF-βRI to prevent Smad activation as well as recruit 
protein phosphatase PP1/GADD34 which dephosphorylates TGF-β receptors or E3 
ubiquitin ligases SMURF1 and 2 which induces proteosomal degradation of the 
receptors (Figure 1.10) [124-127]. 
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Figure 1.10: The canonical TGF-β/Smad signalling pathway. Activated TGF-β ligands bind to TGF-
βRII, which recruits, phosphorylates and activates TGF-βRI (ALK5), forming heterotetrameric TGF-
βRII/ALK5 complexes. TGF-βRI interacts and phosphorylates R-Smads (Smad2/3) which associate with 
co-Smads (Smad4) to form complexes that are translocated into cell nuclei to regulate target gene 
transcription. Inhibitory Smad7 binds to TGF-βRI to prevent Smad activation or recruit PP1/GADD34 
and E3 ubiquitin ligases (SMURF1/2) to degrade or dephosphorylate the TGF-β receptor. C-SKI and 
SNON function as transcriptional co-repressors to repress TGF-β/Smad driven transcription. Adapted: 
Perrot et al, 2013 [127]. 
 
TGF-βII/ALK5 is the predominant receptor complex responsible for signal transduction 
in most cell types. It activates Smad2 and 3 as part of the canonical TGF-β/Smad-
dependent signalling pathway whereas ALK1, with predominant expression in 
endothelial cells and sites of epithelial-mesenchymal interactions, activates Smad1 
and Smad5 [128-131]. In endothelial cells, TGF-β can transduce signals via ALK1 and 
5 with both pathways having opposing effects. ALK5 inhibits endothelial cell migration 
and proliferation whereas ALK1 stimulates both these processes [129, 132] (Figure 
1.11). However, it is important to note that TGF-β signalling can also be transduced  
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through activation of other non-Smad pathways such as PI3 K/Akt, RhoGTPase, 
Mek/Erk and p38/MAPK pathways [120].  
 
 
 
 
 
Figure 1.11: Schematic model for activation of TGF-β mediated ALK 1 and 5 signalling in 
endothelial cells. Active TGF-β binds to TGF-βRII which recruits, phosphorylates and activates ALK5 
and signalling down the canonical pathway. TGF-β can also signal down the non-canonical pathway 
through ALK1 which also can be recruited by ALK5 into the complex. Activated ALK1 and 5 
phosphorylates Smad 1/5 and 2/3 respectively with opposing effects in endothelial cells. ALK5 inhibits 
endothelial cell migration and proliferation whereas ALK1 stimulates both these processes. The 
preferential activation of either canonical or non-canonical TGF-β signalling determines if TGF-β 
functions as a tumour suppressor or promoter of tumour progression. Adapted: Goumans et al, 2003 
[129].
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TGF-β2 signalling in melanoma 
The role of TGF-β in carcinogenesis and tumour progression is complex with its effects 
known to be highly cell-type specific and context dependent. For instance, TGF-β is 
known to act as a tumour suppressor in early tumorigenesis however may promote 
tumour invasiveness and metastasis in later stage disease [127, 133].  
In melanoma, autonomous activation of the TGF-β/Smad pathway has been well 
documented [134, 135] with TGF-β secretion by melanoma cells exerting both 
autocrine and paracrine effects that are cytostatic in early stages but coupled with its 
effect on the tumour microenvironment, promote tumour invasion and progression in 
advanced stages (Figure 1.12) [127]. The TGF-β pathway has also been shown to 
promote an epithelial to mesenchymal transition (EMT), allowing cancer cells to 
become metastatic and this is believed to be similar to the process melanoma cells 
undergo during transition from radial to vertical growth phases [136, 137].  
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Figure 1.12: Effects of TGF-β on melanoma cells and the tumour microenvironment. High levels 
of TGF-β expressed and secreted by melanoma cells exert cytostatic effects on early stage tumours 
however, switches to a tumour promoter role in advanced melanoma. TGF-β secreted also affects 
stromal fibroblasts, endothelial cells and immune cells in the tumour microenvironment, acting to 
promote tumour growth, invasion and angiogenesis with reduced immune surveillance. Adapted: Perrot 
et al, 2013 [127]. 
 
In addition, studies have demonstrated that TGF-β induces the expression of 
interleukin-8, a factor well documented to be involved in angiogenesis, growth and 
melanoma metastasis [138, 139] and that stable overexpression of inhibitory Smad7 
in human melanoma cells inhibits tumourigenesis both in vitro and in vivo in mice 
models [140], reinforcing the importance of TGF-β signalling in melanoma metastasis.  
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Despite high levels of nuclear phosphorylated Smad2 found in benign melanocytic 
naevi, melanomas in situ and primary invasive melanomas (confirming hyperactivation 
of the TGF-β/Smad pathway in melanocytic tumours), phospho-Smad2 positivity was 
associated with low tumour thickness and did not correlate with survival or metastases 
[141]. This is in keeping with the observation that melanoma cells exhibit a variable 
degree of resistance to the anti-proliferative action of TGF-β and that this may be 
further attenuated in advanced disease, the mechanisms of which still remain elusive 
[142] ).  A review of proposed mechanisms for the resistance of melanomas to TGF-β-
mediated tumour suppression included deregulation of transcription factors-coactivator 
repressors (Ski/SnoN upregulation, c-myc upregulation, Smad 2/3 linker 
phosphorylation), cell cycle G1 – S effectors (Cyclin D1 overexpression, activating 
mutations in CDK4 or downregulation of p15, p21 or p27), upregulation of MIA or loss 
of Filamin expression, and suggested that different mechanisms or a combination of 
these different mechanism may propagate resistance, specific to different melanoma 
tumours and their unique tumour microenvironment [142]. This suggests that an 
‘invasive switch’ that may be responsible for the critical switch from RGP to VGP and 
subsequent progression may be via a non-canonical Smad signalling pathway (Figure 
1.11). 
In vitro studies on melanoma cell lines have shown that there is increased expression 
of TGF-β2 and 3 isoforms with little or no expression in normal melanocytes [143]. 
While the TGF-β1 isoform is primarily associated with tumour progression in human 
cancers, increased levels of TGF-β2 have been measured in the plasma of patients 
with metastatic melanoma with in vivo studies demonstrating that increased secretion 
of TGF-β2 and 3 in particular, is associated with melanoma progression and 
metastases [144-147] and that TGF-β2 expression also correlates with tumour 
thickness and invasiveness [148]. 
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In addition, melanoma cells have been shown to switch between high and low melanin 
pigment states during metastasis where microarray analysis  demonstrated 
upregulation of TGF-β2 in a subpopulation of poorly pigmented cells within a 
melanoma tumour, with in vitro studies confirming that TGF-β2 signalling induced 
hypopigmentation and hypermotility in these cells, enabling entry into blood vessels 
[149].  
In line with this, preliminary results leading up to the present study has demonstrated 
a significant association between increased isoform specific tumoural TGF-β2 and not 
TGF-β3 expression with loss of epidermal AMBRA1 in all AJCC stage melanomas 
(Ellis and Lovat, unpublished data, Figure 1.13). Moreover, highest expression of 
tumoural TGF-β2 was observed in ulcerated melanoma tumours known to be 
associated with a worse prognosis. Collectively, these data suggest that the specific 
expression or enhanced secretion of TGF-β2 by primary melanomas may lead to down 
regulation of epidermal AMBRA1 and in turn, loss of epidermal integrity with potentially 
a similar process leading to endothelial breach, paving a route for melanoma ulceration 
and metastasis. The targeting of TGF-β2 signalling may therefore prove a viable 
therapeutic strategy to prevent the development of melanoma metastasis, for which 
the epidermal loss of AMBRA1 may be a companion biomarker. 
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Figure 1.13: Loss of Epidermal AMBRA1 overlying primary cutaneous melanomas correlates 
with increased tumoural secretion of TGF-β2. A Representative IHC photomicrographs depicting no 
loss, some loss or complete loss of epidermal AMBRA1 expression overlying the tumour or in the 
adjacent epidermis of ulcerated melanomas of varying AJCC disease stage in association with tumoural 
expression of TGF-β2. Scale bar =50 μm. B Scatter graph depicting mean % tumoural TGF-β2 
expression levels in 109 melanomas of varying AJCC stages where there was no, some or complete 
loss of epidermal AMBRA1 expression or where the epidermis was ulcerated. Each point represents % 
tumoural TGF-β2 expression levels derived from analysis of 10 representative 200x magnification 
microscope fields of vision using Leica QWin image analysis software. Horizontal line represents mean 
% tumoural TGFβ2 expression levels. One-way ANOVA with Tukey’s post hoc correction, * P <0.05, **P 
<0.01, ****P <0.0001 (Ellis and Lovat, unpublished data). 
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1.4.3 Current strategies to target TGF-β2 signalling in tumourigenesis 
Several TGF-β inhibitors have been developed for cancer therapy and demonstrated 
efficacy in preclinical trials but none have been approved for clinical use to date. 
Generally, these agents target TGF-β signalling at three levels: the ligand, the 
receptors or down-stream signal transduction and include ligand traps (monoclonal 
neutralizing antibodies against TGF-β, soluble TGF-β receptors and TGF-β receptor 
antibodies), antisense oligonucleotides blocking TGF-β ligand production and receptor 
kinase inhibitors [150].  
In the context of pan-TGF-β inhibition, Fresolimumab (GC1008), a monoclonal 
antibody that neutralizes all isoforms of TGF-β, has been evaluated in advanced 
melanoma patients with phase I/II trials demonstrating evidence of anti-tumour activity 
[151]. Its use however, was associated with the development of eruptive 
keratoacanthomas/SCCs, possibly due to its non-specific pan-inhibitory effects on 
TGF-β signalling [152].  
With regards to specific targeting of TGF-β2 signalling, LucanixTM 
(Belangenpumatucel-L, NovaRx, San Diego, CA, USA), a TGF-β2 antisense vaccine 
has reached phase III trials in advanced stage non-small cell lung cancer with 
suggested survival benefits [153].  Trabedersen (AP12009, Antisense Pharma, 
Munich, Germany), an antisense oligonucleotide targeting TGF-β2 has shown 
encouraging survival results in phase I/II clinical trials for advanced pancreatic cancer, 
metastatic melanoma and glioblastoma [154, 155]. Its use however, was limited by off-
target toxicity and challenges faced in achieving direct delivery of the drug to tumours 
to avoid this [156, 157]. The FANG™ vaccine (rhGMCSF/shRNAFurin, Gradalis, Tx, 
USA), an autologous tumor-based product incorporating a plasmid encoding 
granulocyte-macrophage colony-stimulating factor (GMCSF) and a novel bi-functional 
short hairpin RNAi (bi-shRNAi) targeting furin convertase, targets TGF-β1 and 2 and 
has entered phase II clinical trials for treatment of advanced melanoma 
(NCT01453361), colorectal carcinoma (NCT01505166) and ovarian cancer  
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(NCT01309230) following initial trial results demonstrating prolonged survival in 
advanced solid tumours [158]. 
Alternatively, specific targeting of the TGF-β receptor complex (i.e. targeting ALK5 or 
ALK1) may prove to be a more efficacious approach to minimise off target effects seen 
in pan-TGF-β2 inhibition. In addition, despite ligand inhibitors limiting the bioavailability 
of active TGF-β ligands, they may fail to effectively block downstream receptor 
signalling. Given this, small molecule inhibition of receptor kinases has been an 
emerging area of experimental cancer drug development in the recent years as these 
agents are easy and economical to produce as well as practical as they are stable 
when delivered orally [159]. 
To date, Galunisertib (LY2157299, Eli Lilly, Indianapolis, USA), a small molecule 
inhibitor of TGF-βRI (ALK5), is the most advanced TGF-β signalling inhibitor in clinical 
which in phase II clinical trials has shown improvement in overall survival in advanced 
hepatocellular carcinoma patients with normal alpha-fetoprotein (AFP) and reduced 
serum TGF-β1 following treatment [160]. Galunisertib has also entered/is emerging 
from phase II clinical trials for treatment of pancreatic cancer, glioma and glioblastoma 
[161]. Similarly, TEW-7917 (MedPacto, Suwon, South Korea), another small moledule 
inhibitor of ALK5 has entered phase I clinical trials for the treatment of advance stage 
solid tumours (NCT02160106) [161]. 
More recently, specific receptor targeting of the TGF-β/ALK complex with ALK1 
inhibitors has emerged as a target for antiangiogenic cancer therapy and is currently 
evaluated in various malignancies (advanced solid tumours and refractory multiple 
myeloma)[162]. Dalantercept (Acceleron Pharma, MA, USA) an ALK1 ligand trap that 
inhibits activation of endogenous ALK1 by binding with high affinity to the ligands bone 
morphogenetic proteins (BMP 9 and 10), was initially evaluated for clinical use in head 
and neck and renal carcinomas but failed to progress through phase II clinical trials 
due to lack of efficacy [163-165]. 
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PF03446962 (Pfizer, NY, USA) a monoclonal antibody targeting ALK1 has emerged 
from phase I clinical trials with encouraging results observed in solid tumours and 
hepatocellular carcinoma with good side effect profile and tolerability [166, 167] 
however, to date the therapeutic use of ALK1 inhibitors has not been evaluated in 
malignant melanoma [162].      
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1.5 Hypothesis, Aims and Objectives 
While novel targeted and immunotherapies have revolutionised therapeutic 
approaches in malignant melanoma, unfortunately there is still lack of consistently 
beneficial treatments and moreover, no credible biomarkers able to predict disease 
progression of high risk tumours. 
Despite its comprehensiveness, the role of AJCC staging as a prognostic biomarker is 
still limited by the fact that it is unable to identify tumours that will go on to progress 
and metastasise, especially seemingly ‘low risk’ tumours of stage I disease. This 
emphasises the acute need for novel companion biomarkers to more accurately stratify 
this subset of patients at risk of disease progression for potentially earlier and more 
efficacious precision based therapies. 
Work leading up to this study suggests that the combined loss of epidermal AMBRA1 
and Loricrin overlying AJCC stage I melanoma tumours defines a high risk subgroup 
for which a patent has been filed (UK Patent 2014: 1419976.4.4, Inventors RE Ellis, 
M Labus and PE Lovat). The primary aim of this study is therefore to refine and validate 
the prognostic potential of epidermal AMBRA1 and Loricrin expression in an 
independent powered cohort of AJCC stage I melanomas. 
Key pilot data (as described in section 1.4) demonstrated that treatment of primary 
keratinocytes cultured in high calcium medium to induce differentiation,  with 
recombinant TGF-β2 results in the down regulation of AMBRA1 and Loricrin, 
suggesting that TGF-β2-mediated de-regulated epidermal differentiation may be a 
pivotal process in melanoma ulceration (Ellis and Lovat, unpublished data). As well as 
further exploring the signalling mechanisms (specifically the contribution of canonical 
or non-canonical TGF-β2 signalling) by which melanoma specific secretion of TGF-β2 
mediates loss of epidermal integrity, this study additionally aimed to test the hypothesis 
that a similar mechanism mediates the loss of endothelial integrity whereby the down 
regulation of endothelial AMBRA1 and cell junctional protein expression leads to 
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endothelial breach and metastatic spread (Figure 1.14), for which combined epidermal 
AMBRA1 and Loricrin expression may represent a companion biomarker to stratify 
patients for potential novel adjuvant TGF-β targeted therapy at the time of primary 
excision. 
 
 
 
 
Figure 1.14: Hypothesis for TGF-β2 mediated AMBRA1 down regulation, loss of epidermal and 
endothelial integrity, tumour ulceration and metastasis. TGF-β2 secretion by some melanomas 
results in down regulation of AMBRA1 leading to deregulated epidermal differentiation, marked by loss 
of Loricrin expression. A similar mechanism may exist in the endothelium by which TGF-β2 signalling 
via ALK1-Smad1/5 mediates down regulation of AMBRA1 which results in endothelial breach, enabling 
tumour entry and metastatic spread. 
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To test these hypotheses, the specific objectives of this research project were to: 
1. Refine and validate the combined epidermal expression of AMBRA1 and 
Loricrin as prognostic biomarkers for AJCC stage I melanomas. 
2. Confirm the association of increased TGF-β2 expression with loss of epidermal 
Loricrin and epidermal/endothelial AMBRA1 expression in an independent 
cohort of AJCC stage I melanomas. 
3. Define the mechanisms mediating TGF-β2-induced loss of epidermal and 
endothelial integrity. 
4. Inform the development of novel stratified TGF-β2 targeted adjuvant therapies 
to prevent melanoma metastasis at the time of primary excision with the use of 
combined epidermal AMBRA1/Loricrin expression as a companion biomarker 
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2.1 Growth and maintenance of primary human keratinocytes, 
endothelial cells, human endothelial and melanoma cell line 
 
2.1.1 Human Umbilical Vein Endothelial Cells (HUVEC) 
The endothelial cell line HUVEC (ATCC, Middlesex, UK) was cultured in  T75 tissue 
culture flasks (Corning, Flintshire, UK) pre-coated with 0.2% gelatin (Sigma-Aldrich; 
Poole, UK) and maintained at 37°C in 10ml of Endothelial Cell Basal Medium (Lonza, 
Walkersville, USA) supplemented with Endothelial Growth Medium Bullet Supplement 
(Lonza, USA; comprising bovine brain extract (BBE), human epidermal growth factor 
(HEGF), hydrocortisone, ascorbic acid, Gentamicin, Amphotericin B and foetal bovine 
serum), 5x10-5 M N-6,2’-O-dibutyryl-adenosine 3’, 5’-cyclic monophosphate (Sigma-
Aldrich), 1 µg/ml hydrocortisone acetate (Sigma-Aldrich), 5% Penicillin-Streptomycin 
(10,000 U/ml Penicillin, 10mg/ml Streptomycin (PS); Sigma-Aldrich) and 10% foetal 
calf serum (FCS; Sigma-Aldrich) (complete ECCM), in a humidified atmosphere of 5% 
CO2 in air. Cells were passaged every 2 – 3 days at approximately 70% confluency by 
detaching with Trypsin EDTA (TE; Sigma-Aldrich) as previously described [168] and 
cultured for up to a maximum of 50 passages at which point fresh cells were taken 
from frozen stocks, with a change in culture flask every 3 passages.  
 
2.1.2 Primary Human Dermal Lymphatic Endothelial Cells (HDLEC) 
Primary HDLECs (Promocell, Heidelberg, Germany) were cultured in T75 tissue 
culture flasks pre-coated with 0.2% gelatin and maintained in 10ml of complete ECCM, 
at 37°C in a humidified atmosphere of 5% CO2 in air. Cells were passaged every 5 
days at approximately 80 – 90% confluency by detaching with TE as previously 
described [168] and cultured for up to a maximum passage number of 5, with a change 
of culture flask at every passage. 
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2.1.3 CCD1106 Keratinocytes 
The retrovirus vector transformed human keratinocyte cell line CCD1106 (ATCC) was 
cultured in 10 ml of Epilife Medium (ThermoFisher Scientific, Loughborough, UK) 
supplemented with 5ml of Human Keratinocyte Growth Supplement (HKGS; 
ThermoFisher Scientific) and 1% PS (complete Epilife) in T75 tissue culture flasks and 
maintained at 37°C in a humidified atmosphere of 5% CO2 in air. Cells were passaged 
every 2 – 3 days at 70 – 80% confluency and cultured for up to a maximum passage 
number of 8 at which point fresh cells were taken from frozen stocks, with a change of 
culture flask every 3 passages. 
 
2.1.4 Human A375 melanoma cells pre subjected to stable knockdown of  
TGF-β2  
Stable knockdown of TGF-β2 using short hairpin RNA (shRNA or using a control short 
hairpin RNA) was performed in human cutaneous A375 melanoma cells by Dr Marco 
Corazzari, University of Tor Vergata Rome, Italy. TGF-β2 knockdown in A375 cells 
was confirmed by Real Time Reverse Transcriptase Polymerase Chain Reaction 
(qPCR) and control (A375 shControl) or A375 cells in which TGF-β2 expression had 
been depleted (A375 shTGF-β2) were cultured and maintained in T75 tissue culture 
flasks in 10 ml of Dulbecco’s Modified Eagle Medium (DMEM; Lonza, Slough, UK) 
supplemented with 10% FCS and 1% PS (complete DMEM) at 37°C in a humidified 
atmosphere of 5% CO2 in air and passaged every 2 – 3 days at 80% confluency. To 
prevent genetic drifts and other morphological changes in cells, all modified A375 
melanoma cell lines were not passaged beyond 10 passages before replacing with 
frozen stocks.  
 
 
 
Chapter 2: Materials and Methods 
 55  
 
 
 Isolation, growth and calcium induced differentiation of primary 
human keratinocytes 
  
Primary human keratinocytes were isolated from human foreskin samples obtained 
from routine circumcision with informed patient consent. Ethical approval was granted 
by Newcastle and North Tyneside Research Ethics Committee (Ref: 
08/H0906/95+5_Lovat) and sponsored by The Newcastle Upon Tyne NHS Foundation 
Trust (Ref 4775).  
Foreskin samples were rinsed with phosphate buffered saline (PBS; Sigma-Aldrich) 
containing  5% Penicillin-Streptomycin-Amphotericin (10,000 U/ml Penicillin, 10 μg/ml 
Streptomycin and 25 μg/ml Amphotericin B (PSA; Lonza, UK) in 10 cm petri dishes 
(Corning). Following removal and disposal of subcutaneous tissue, the epidermis of 
the remaining sample was scored using a blade prior to overnight incubation in PBS 
with 10% Dispase II (Sigma-Aldrich) and 10% PSA at 4°C to facilitate epidermal-
dermal separation. The epidermis was then peeled off, incubated in TE at 37°C for 5 
minutes, neutralised in DMEM with 10% FCS, and centrifuged at 330 g for 5 minutes. 
The keratinocyte cell pellet derived from this was re-suspended and cultured in 20 ml 
of Complete Epilife, in T150 – T175 tissue culture flasks, maintained at 37°C in a 
humidified atmosphere of 5% CO2 in air.  
Primary keratinocytes were passaged at approximately 80% confluency by detaching 
with TE as previously described [168] and used for subsequent experiments between 
passages 1 – 5 in the presence or absence of differentiation which was induced by 
switching culture medium to Epilife medium containing 1.3 mM of Calcium Chloride 
(CaCl2; Sigma-Aldrich) for 5 days. 
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 Isolation of primary human dermal endothelial (HDEC) cells    
 
2.3.1 Isolation of HDEC using endothelial cell-specific antibody EN4 coated 
wells 
Human dermal endothelial cells (HDEC) were isolated from the remaining dermis of 
human foreskin samples, following processing and peeling of the epidermal layer as 
described in 1.2. After removal of the epidermis, a cell scraper (Corning) was used to 
remove cells from the top layer of the dermis into complete ECCM. This dermal cell 
suspension was then filtered through a sterile 100 μm cell strainer (Corning), 
centrifuged at 330 g for 5 minutes and the cell pellet re-suspended in 4 – 6 ml of 
complete ECCM, prior to seeding 2 x 104 cells/cm2 in a volume of 2 ml of complete 
ECCM per well of a 6 well tissue culture plate (Corning) pre-coated with 0.2% gelatin. 
Cells were cultured at 37°C in a humidified atmosphere of 5% CO2 in air, with media 
changes every 2 – 3 days and upon reaching 70% confluency, detached with TE as 
previously described [168]. 
To eliminate contaminating cells such as dermal fibroblasts, detached cells at passage 
0 were incubated overnight at 37°C in 0.5 ml of complete ECCM in endothelial cell-
specific antibody EN4 (Monosan, Newmarket, UK) coated 24 well tissue culture wells 
(Corning) as previously described [169]. Briefly, EN4 antibody coated wells were pre-
prepared by incubating 200 μl of EN4 antibody diluted 1:6 in Hanks’ balanced salt 
solution (HBSS; Sigma-Aldrich) with 1 mM CaCl2 in each well of a 24 well tissue culture 
plate for 3 hours at 37°C, followed by blocking of non-specific antibody binding with 
1% Bovine Serum Albumin (BSA; Bioscience, Nottingham, UK) for 1 hour at 37°C. 
Following overnight incubation of detached passage 0 cells as described above, non-
adherent cells were removed with x3 PBS washes. Adherent isolated endothelial cells 
were then detached using TE, pooled together and cultured in 3 ml of complete ECCM 
in a T25 0.2% gelatin coated tissue culture flask with culture medium changes every 2 
– 3 days. 
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2.3.2 Isolation of HDEC using PE anti human CD31 antibody and Miltenyi 
Biotech Magnetic Columns 
To eliminate contaminating cells such as dermal fibroblasts, HDEC cell selection was 
also attempted using a human Phycoerythrin (PE) anti CD31 antibody (CD31-PE; 
Miltenyi Biotec, Surrey UK) with Miltenyi Biotech Magnetic Columns (Miltenyi Biotec). 
Following initial isolation and culture as described in 1.3.1, passage 0 primary 
endothelial cells with fibroblast contamination were detached with TE at 80% 
confluency [168]. 5 x 106 cells were suspended in 2 ml of complete ECCM and 
centrifuged 330 g for 5 minutes, after which the supernatant was discarded, the cell 
pellet re-suspended in 5 ml of PBS and passed through a 30 μm CellTrics mesh filter 
(Sysmex, Milton-Keynes, UK) to form a single cell suspension which was then 
centrifuged again for 5 minutes at 330 g. The cell pellet obtained was re-suspended in 
40 μl of buffer solution (BS) consisting of PBS with 0.5% BSA and 2 mM 
Ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich) followed by addition of 5 μl of 
FcR blocking reagent (Miltenyi Biotec) and 5 μl of CD31-PE antibody with gentle mixing 
every 2 – 3 minutes for 10 minutes at 4°C. After x2 washes with 0.5 ml of BS and 
centrifugation for 5 minutes at 330 g, the cell pellet derived was re-suspended in 35 μl 
of BS with addition of 5 μl of FcR blocking reagent and 10 μl of anti-PE microbeads 
(Miltenyi Biotec) and gently mixed for 15 minutes at 4°C. Following x2 washes in 500 
μl BS and centrifugation at 330 g, the resulting cell pellet was then resuspended in 500 
μl of BS and passed through an MS MACS column (Miltenyi Biotec) with an attached 
MiniMACS Separator magnet (Miltenyi Biotec). The collected eluate was labelled as 
the negative population. The MS column was then washed a further x3 with 500 μl BS 
and the negative population effluent discarded. Finally, the MS column was detached 
from the magnet, 1 ml of BS added and a plunger firmly applied to expel CD31 positive 
endothelial cells into a new collection tube. Collected cells were suspended in 5 ml of 
complete ECCM and cultured in T25 cell culture flasks pre-coated with 0.2% gelatin at 
37°C in a humidified atmosphere of 5% CO2 in air, with media changes every 2 – 3 
days.  
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 Treatment of HUVEC, HDLEC cells and CCD1106 keratinocytes with 
human recombinant TGF-β2 in the presence or absence of an ALK5 
inhibitor 
 
Human recombinant TGF-β2 (Sigma-Aldrich) was reconstituted with sterile 4 nM 
Hydrochloric Acid (VWR, Lutterworth, UK) containing 0.1% BSA to produce a stock 
concentration of 1 μg/ml and stored in working aliquots of 6 μl or 20 μl at -20°C. At 90 
– 100% confluency, HUVEC or HDLEC cells were detached with TE as previously 
described [168], seeded onto 0.2% gelatin coated 60 mm cell culture dishes at a 
density of 2 x 105 cells/dish in 3 ml of complete ECCM and left overnight to attach at 
37°C in a humidified atmosphere of 5% CO2 in air before subsequent treatment and 
continued incubation with 10 ng/ml human recombinant TGF-β2 (diluted in complete 
culture medium) for 24, 48 or 72 hours or an equal volume of vehicle (complete culture 
medium) control prior to processing for Western Blot analysis 
Primary keratinocytes were seeded at 2.4 x 104 cells/well in 6 well tissue culture plates 
and maintained until 100% confluency in 2 ml/well of Complete Epilife, then switched 
to culture in Complete Epilife with high CaCl2 (1.3 nM) for 5 days to induce 
differentiation prior to the addition of 10 ng/ml human recombinant TGF-β2 for the final 
24 – 48  hours of incubation. 
5 mg ALK5 inhibitor II (Santa Cruz Biotechnology, Heidelberg, Germany) was 
reconstituted with 5 ml of 100% Dimethyl Sulfoxide (DMSO; Fisher Scientific, 
Loughborough, UK) and 12.4 ml of sterile H20 to produce a stock concentration of 1 
mM and stored in working aliquots of 30 μl at -20°C. HUVEC cells were seeded onto 
0.2% gelatin coated 60 mm cell culture dishes at a density of 2 x 105 cells/dish in 3 ml 
of complete ECCM, co-treated with 10 ng/ml of human recombinant TGF-β2 in the 
presence or absence of 10 μM ALK5 inhibitor II (again further diluted in complete 
culture medium) or an equal volume of culture medium vehicle control for 24 hours 
prior to processing for Western blot analysis or RNA extraction. 
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 Treatment of HUVECs and HDLECs with TGF-β2 rich melanoma 
supernatants or supernatants derived from melanoma cells in which 
TGF-β2 has been stably knocked down 
 
At 80% confluency, high TGF-β2 secreting A375 melanoma cells (A375 shControl) and 
melanoma cells in which TGF-β2 has been stably knocked down (A375 shTGF-β2) 
were detached with TE as previously described [168], seeded at 2.4 x 104 cells/well in 
6 well tissue culture plates and cultured in either 2 ml/well of complete DMEM or 
complete ECCM for 72 hours. The effect of culture in complete DMEM or ECCM on 
cell proliferation was then assessed by manual cell counting using a haemocytometer. 
Supernatants derived from A375 shControl and A375 shTGF-β2 melanoma cell lines 
pre-cultured to confluency in complete ECCM for 72 hours were then collected and 
used as the culture medium for HUVEC or HDLEC cells for 72 hours in replacement of 
complete ECCM and with daily changes with fresh supernatants to account for nutrient 
depletion.  
The effects on AMBRA1 and Claudin-5 expression in HUVEC and HDLEC cells treated 
with either supernatants or complete ECCM (negative control) or ECCM containing 10 
ng/ml of recombinant TGF-β2 was evaluated by western blotting or a commercial cell 
viability assay as described in 1.6. 
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 CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay 
(MTS) 
 
HUVECs or primary HDLECs were seeded at a density of 0.5 x 105 cells/well in 0.2% 
pre-coated gelatin 96 flat well tissue culture plates (Corning) with 4 replicates per 
treatment condition, in a volume of 200 µl/well of complete ECCM and allowed to attach 
overnight at 37ºC in a humidified atmosphere of 5% CO2 in air. The following day, 
medium from each well was replaced with fresh complete ECCM, complete ECCM 
medium containing 10.0 ng/ml and 20.0 ng/ml human recombinant TGF-β2 or A375 
shControl or shTGF-β2 cell supernatants for 24, 48 or 72 hours. Additionally, the effect 
on HUVEC cell proliferation in the presence of an ALK5 inhibitor was assessed by the 
concurrent addition of 10 μM ALK5 inhibitor II and 10.0 ng/ml of human recombinant 
TGF-β2 or an equal volume of vehicle control added to control for 72 hours.  
Cell viability was assessed by the addition of 20 µl of CellTiter 96 Aqueous Assay 
Reagent (Promega, Southampton, UK) for 3 hours at 37ºC and measuring the 
absorbance at 490 nm with a SpectraMAX 250 plate reader (Molecules Devices Ltd, 
Wokingham, UK). 
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 siRNA-mediated knockdown of ALK1 in HUVEC cells 
 
To transiently knock down the expression of ALK1 in HUVEC endothelial cells, 3 
different siRNAs oligoribonucleotides targeting human ALK1 (Invitrogen, Carlsbad, 
CA, USA, Table 2.1) were evaluated against a non-targeting scrambled siRNA control 
(Invitrogen).  
 
ALK1 siRNA Sequence 
ACVRL1HSS100150 
1 5’ – UCAAGAGCCGCAAUGUGCUGGUCAA – 3’ 
2 5’ – UUGACCAGCACAUUGCGGCUCUUGA – 3’  
ACVRL1HSS100151 
1 5’ – GGAGGACUAUAGACCACCCUUCUAU – 3’  
2 5’ – AUAGAAGGGUGGUCUAUAGUCCUCC – 3’ 
ACVRL1HSS100152 
1 5’ – CCAGAGAAGCCUAAAGUGAUUCAAU – 3’  
2 5’ – AUUGAAUCACUUUAGGCUUCUCUGG – 3’  
 
Table 2.1: Duplex siRNA oligoribonucleotides targeting human ALK1. 
 
6 x 105 HUVEC cells were seeded into 60 mm tissue culture petri dishes pre-coated 
with 0.2% gelatin, in a volume of 3 ml of complete ECCM and allowed to attach 
overnight. The following day, a pre-transfection mix consisting of 20 μM of each pool 
siRNA and 8 µl of Lipofectamine RNAi Max (Invitrogen), was prepared in 3 ml/dish of 
complete ECCM in absence of PSA and Gentamicin, per transfection condition with 30 
minutes incubation at room temperature. In the meantime, adhered HUVEC cells were 
rinsed in PBS prior to addition of 3 ml of the siRNA/lipofectamine mix and continued  
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incubation for 24 hours at 37°C in a humidified atmosphere of 5% C02. Each 
transfection was then repeated for a further 24 hours to increase efficacy. 
Cells were then trypsinised, resuspended in 3 ml of complete ECCM, and seeded at 3 
x 105 cells/well in 6 well flat bottom cell culture plates pre-coated with 0.2% gelatin in 
a volume of 2 ml of complete ECCM and incubated overnight at 37°C to allow 
attachment. The following day, cells were treated with human recombinant TGF-β2 
(Sigma-Aldrich) at 10 ng/ml for 2 or 24 hours with an equal volume of vehicle control 
added to no treatment control cultures. Cells were then harvested and processed for 
western blot analysis as previously described [170] or for RNA extraction as described 
in section 2.8 with lysates/RNA additionally derived from cells in absence of TGF-β2 
treatment as a control.
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 Real Time Reverse Transcriptase Polymerase Chain Reaction 
(qPCR) 
 
Real Time Reverse Transcriptase Polymerase Chain Reaction (qPCR) was used to 
quantify AMBRA1, ALK1 and ALK5 mRNA expression in HUVEC cells and CCD1106 
keratinocyte cells as well as verify siRNA-mediated knockdown of ALK1 in HUVEC 
cells.  
All cell lines were seeded at 3  x  105 cells/well in a volume of 3 ml/well of their 
respective cell culture medium, in 6 well flat bottom cell culture plates pre-coated with 
0.2% gelatin for 24 hours prior to RNA extraction. Extraction of RNA was performed 
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer 
specifications. Total RNA for each sample was quantified using a NanoDrop 2000 
Spectrophotometer and its accompanying software (Thermo Scientific, Waltham, 
Massachusetts, USA). RNA was then stored at -80°C prior to conversion to single 
stranded cDNA using a Reverse Transcription Kit (Promega, Madison, Wisconsin, 
USA) as per manufacturer’s recommendations. 20 µl of PCR reverse transcription 
reactions (first-strand cDNA synthesis) were prepared for each sample as detailed in 
Table 2.2. cDNA from the first-strand reverse transcription reaction was then diluted to 
100 μl with Nuclease-Free water for PCR amplification.  
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Reverse Transcription Reaction (Promega) 
Component Amount 
Magnesium Chloride 25mM 4µl 
10X Reverse Transcription Buffer 2μl 
dNTP Mix (10mM) 2µl 
Recombinant RNAsin Ribonuclease Inhibitor 0.5μl 
AMV Reverse Transcriptase HC (25u/µl) 0.6μl 
RT Random Primers (0.5μg/µl) 1µl 
Total RNA  2µg 
Nuclease-Free Water to 20μl 
Total volume 20μl 
 
Table 2.2: Constituents of a single Reverse Transcription Reaction. 
 
PCR reactions for cDNA amplification were then performed using a Veriti 96-well 
Thermal Cycler (Applied Biosystems, Foster City, CA, USA) at conditions of 10 minutes 
at 70°C, 45 minutes at 45°C, 5 minutes at 95°C prior to a cooling cycle at 4°C. cDNA 
was stored short term at 4°C or -20°C long term.  
The expression levels of AMBRA1, ALK1 and ALK5 mRNA relative to the 
housekeeping control of L34 mRNA were subsequently measured using qPCR. A 
Maxima SYBR Green Master Mix (Thermo Scientific) was used to produce 
fluorescently labelled PCR products during repetitive cycling of the amplification  
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reaction with the melting curve protocol adopted to verify probe specificity as described 
previously [170]. Primer sets for all amplicons were designed using the Primer Express 
1.0 software system (Roche, Basel, Switzerland) as detailed in Table 2.3. Master 
reaction mixes were prepared for each gene sequence of interest to a volume of 25 
μl/well in a 96-well PCR plate (Thermo Scientific) according to the manufacturer’s 
recommendations, and as detailed in Table 2.4. Each qPCR reaction was prepared in 
replicates of three. qPCR was performed using a Rotor-Gene 6000 Real-Time PCR 
Machine (Corbett Research Ltd, Cambridgeshire, UK). The thermocycling program 
consisted of one cycle at 50°C for 2 minutes (pre-treatment) followed by 95°C for 10 
minutes (initial denaturation) and 40 cycles at 95°C for 15 seconds (denaturation) and 
60°C for 1 min (annealing/extension).  
 
Amplicon Primer sequence 
L34 
Forward 5’-GTCCCGAACCCCTGGTAATAGA-3’ 
Reverse 5’-GGCCCTGCTGACATGTTTCTT-3’ 
ALK1 
Forward 5’-CATCGTGAATGGCATCGT-3’ 
Reverse 5’-CACACACACCACCTTCTTC-3’ 
ALK5 
Forward 5’-GCCTTGAGAGTAATGGCTAAA-3’ 
Reverse 5’-CCTTCCTGTTGACTGAGTTG-3’ 
AMBRA1 
Forward 5’-AACCCTCCACTGCGAGTTGA-3’ 
Reverse 5’-TCTACCTGTTCCGTGGTTCTCC-3’ 
 
Table 2.3: Primer sets for amplification of L34, ALK1, ALK5 and AMBRA1 gene sequences.
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Maxima SYBR Green Master Mix 
Component Amount 
Maxima SYBR Green Master Mix for qPCR 12.5μl 
Forward Primer 0.2 μl 
Reverse Primer 0.2μl 
cDNA 5μl 
Nuclease-Free Water 7.1μl 
Total volume 25μl 
 
Table 2.4: Constituents of a single qPCR reaction using the Maxima SYBR Green Assay. 
 
 
Real time mRNA expression was analysed using the accompanying Rotor-Gene 6000 
software (Corbett Research Ltd). The result of the fluorescent PCR was expressed as 
the threshold cycle (CT). CT values for each sample was normalized to the reference 
mRNA, L34 to obtain a ΔCT value which is the difference between the CT for the 
specific mRNA and the CT for L34. The fold change in ALK1 and ALK5 gene 
expression was calculated using the comparative 2-ΔΔCT method where 2 was raised 
to the power of ΔΔCT (the difference between the ΔCT from treated cells and the CT 
from untreated cells) [170].
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 Western blotting 
 
Total protein was extracted from cells at the end of experimental treatment by direct 
lysis of cell pellets, derived from initial seeding of 6 x 105 cells in 60 mm cell culture 
plates per treatment condition, in 150 µl of cell lysis buffer (0.1 M Tris-Hcl pH 7.4, 25 
mM NaF, 1 mM benzamidine, 2 mM EDTA, 0.1 mM sodium orthovanadate, 0.1% Triton 
X-100) containing 150 µl/ml of protease inhibitor cocktail (Promega, Southampton, 
UK). Cell lysates were incubated on ice for 20 minutes prior to sonication with a probe 
sonicator, using 3 pulses of 5 seconds each, at an amplitude of 7 microns (Soniprep 
150, MSE, UK). 
Protein concentration was quantified using a commercial Bradford assay (Pierce 
Biotech, Rockford, USA) following the manufacturers specification and protein 
absorbance was measured at a wavelength of 595 nm using a SpectraMAX 250 plate 
reader (Molecular Devices Ltd, Wokingham, UK). Protein lysates were then diluted 1:3 
in 4x sample buffer (0.25 M Tris-HCL (pH 8.0), 8% sodium dodecyl sulphate (SDS), 
40% glycerol, 10% β-mercaptoethanol and bromophenol blue) and denatured by 
heating to 95°C for 5 minutes. Proteins were separated by gel electrophoresis through 
Bio-Rad 4 – 20% tris-glycine gels (Bio-Rad Laboratories Inc., CA, USA) with running 
buffer (Tris-Base 250 nM, Glycine 1.9 M, 1% SDS; pH 8.5) using a XCell Surelock 
apparatus (Novel Experimental Tech; San Diego, CA, USA). Transfer of separated 
proteins to PVDF membranes was performed using a Trans-Blot TurboTM Transfer 
System (1.3 A, 25 V, Bio-Rad, California, USA) with Bio-Rad Trans-Blot TurboTM 
Transfer Packs (Bio-Rad,) for 15 minutes. Membranes were then washed briefly in 1x 
Tris-buffered saline (TBS; 10x stock 200mM Tris-Base, 1.37M Sodium Chloride; pH 
7.6) containing 0.1% Tween 20 (ThermoFisher Scientific) (TBS/T) and incubated for 1 
hour in TBS containing 5% non-fat milk (Oxoid Ltd, Basingstoke, UK) to block non-
specific antibody binding prior to overnight incubation with primary antibodies at 4°C 
as detailed in Table 2.5. 
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 Membranes were then given 3 x 15 minute washes in TBS/T prior to incubation for 1 
hour at room temperature with horseradish peroxidase-conjugated secondary 
antibodies as detailed in Table 2.5. Finally, following 3 x 15 minute washes in PBS/T, 
protein expression was revealed using ClarityTM Western ECL Substrate (Bio-Rad, 
California) for 5 minutes according to the manufacturers specifications followed by 
visualisation with a LI-COR Odyssey Fc Imager and its accompanying Image Studio 
Software (LI-COR Biosciences, Cambridge, UK) and quantification by densitometry.  
  
1° Antibody 
(Supplier) 
Species 
(Molecular 
Weight) 
1° Antibody Dilution 2° Antibody Dilution 
AMBRA1 
(Novus Biologics, 
Abingdon, UK) 
Rabbit 
Polyclonal 
(132 kDA) 
1:1000 
5% non-fat milk TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Claudin-5 
(Abcam, 
Cambridge, UK) 
Rabbit 
Monoclonal 
(24 kDA) 
1:2000 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
VE-Cadherin 
(Cell Signalling, 
Leiden, The 
Netherlands) 
Rabbit 
Monoclonal 
(130-140 kDA) 
1:1000 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Phospho-Smad 
1/5/9 
(Cell Signalling) 
Rabbit 
Monoclonal 
(60 kDA) 
1:1000 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Phospho-Smad 3 
(Cell Signalling) 
Rabbit 
Monoclonal 
(52-60 kDA) 
1:500 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Phospho-Smad 2 
(Cell Signalling) 
Rabbit 
Polyclonal 
(60 kDA) 
1:500 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Total Smad 1 
(Cell Signalling) 
Rabbit 
Polyclonal 
(58-60 kDA) 
1:500 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
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Total Smad 5 
(Cell Signalling) 
Rabbit 
Monoclonal 
(60 kDA) 
1:500 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Total Smad 3 
(Cell Signalling) 
Rabbit 
Monoclonal 
(52 kDA) 
1:500 
5% non-fat milk in TBS/T 
Anti-rabbit 1:2500 
5% non-fat milk in 
TBS/T 
Loricrin 
(Biolegend, 
London, UK) 
Rabbit 
Polyclonal 
(26-30 kDA) 
1:10,000 
5% BSA in TBS/T 
Anti-rabbit 
1:20,000 in 5% BSA in 
TBS/T 
β-Actin 
(Sigma-Aldrich) 
Mouse 
Monoclonal 
(45 kDA) 
1:40,000 
5% non-fat milk in TBS/T 
Anti-mouse 1:2500 
5% non-fat milk in 
TBS/T 
GAPDH 
(Cell Signalling) 
Rabbit 
Monoclonal 
(37 kDA) 
1:5000 
5% BSA in TBS/T 
Anti-rabbit 1:2500 
5% BSA in TBS/T 
 
Table 2.5: Optimal primary and secondary antibody conditions for respective western blot 
analysis.
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 Immunohistochemistry for formalin fixed paraffin embedded (FFPE) 
tissue 
 
2.10.1 Immunohistochemistry for AMBRA1, Loricrin, CD31 and TGF-β2 using 
DAB counterstaining 
5 µm FFPE tissue sections were derived from an independent cohort of AJCC stage I 
melanomas from the James Cook University Hospital (JCUH), Middlesbrough with 
ethical permission (Ref 08/H0906/95+5_Lovat).  
Antigen retrieval conditions and antibody dilutions for the automated 
immunohistochemical (IHC) detection of AMBRA, Loricrin and TGF-β2 was optimised 
using a Ventana Benchmark XT automated IHC staining instrument (Ventana Medical 
Systems Inc., Tucson, AZ, USA) with antibody binding visualised either with an 
Optiview DAB Detection Kit (Ventana Medical Systems Inc., Tucson, AZ, USA) or an 
ultraView Universal DAB Detection Kit (Ventana Medical Systems Inc., Tucson, AZ, 
USA), according to the manufacturers specifications. All antibodies were optimised by 
Miss Alison Greenwood at the JCUH pathology lab using control human tissue sample 
sections known to positively express each antibody. 
Following validation of consistent AMBRA1, Loricrin, CD31 and TGF-β2 expression 
using the Ventana automated system, the following conditions were used to detect 
these antibodies in tissue cohort samples in the Pathology department of JCUH (Table 
2.6) with final counterstaining in haematoxylin for 8 minutes at room temperature. All 
IHC stained sections were digitally imaged using automated scanning of slides on a 
digital slide scanner (see section 2.13) for subsequent visual and semi-quantitative 
analysis. 
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1° 
Antibody 
(Supplier) 
Species 
Antigen 
retrieval 
1° 
Antibody 
dilution 
1° Antibody 
incubation 
time 
Automated 
DAB 
detection kit 
AMBRA1 
(Abcam) 
Rabbit 
Polyclonal 
Cell 
Conditioning 1 
(CC1) Solution  
(Ventana) 
1:300 16 minutes 
Optiview 
(Ventana) 
Loricrin 
(Abcam) 
Rabbit 
Polyclonal 
EZprep 
Solution (950-
102, Ventana) 
1:1000 32 minutes 
ultraView 
Universal 
(Ventana) 
CD31 
(Abcam) 
Mouse 
Monoclonal 
CC1 Solution 
(Ventana) 
1:200 32 minutes 
Optiview 
(Ventana) 
TGF-β2 
(R&D 
Systems, 
Minneapolis
, USA) 
Mouse 
Monoclonal 
CC1 Solution 
(Ventana) 
1:200 32 minutes 
ultraView 
Universal 
(Ventana) 
 
Table 2.6: Optimal conditions for AMBRA1, Loricrin, CD31 and TGF-β2 detection using the 
Ventana Benchmark XT automated IHC system. 
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2.10.2 Bleaching of FFPE melanoma tissue prior to analysis of TGF-β2 using 
DAB counterstaining 
To eliminate error in quantifying staining intensity for TGF-β2 expression with DAB 
counterstaining where there was difficulty in discriminating between melanin staining 
with that of true TGF-β2 staining, melanoma tumour sections were bleached prior to 
the automated IHC detection of TGF-β2 as described in 2.10.1. 5 µm FFPE melanoma 
tissue sections were incubated for 10 minutes in 30% H202 diluted in PBS followed by 
x3 washes with tap water prior to being loaded onto the Ventana Benchmark XT 
automated IHC staining instrument. 
 
2.10.3 Immunohistochemistry for AMBRA1 and TGF-β2 using VIP 
counterstaining 
5 µm sections of FFPE tissue samples of melanoma tumours were cut onto X-tra 
microscope slides (Leica Microsystems, Milton Keynes, UK) prior to incubation in 
Histoclear (Sigma) for 20 minutes, followed by rehydration of tissue sections through 
graded ethanol solutions (100%, 75%, 50%) and a wash in distilled water for 5 seconds 
each. Antigen retrieval was undertaken by microwave heating of slides, incubated in 
preheated 10 mM Tris-Hcl (pH 9.0) (TGF-β2) or 10 mM Tris-Hcl (pH 7.6)(AMBRA1), 
for 16 minutes with buffer top up at 8 minutes, followed by cooling at room temperature 
for 20 minutes. An area of staining for each tissue section was marked using an 
ImmEdge hydrophobic pen (Vector Laboratories Inc., Burlingame, USA) followed by 3 
minute rehydration in PBS containing 0.05% Tween 20 (ThermoFisher Scientific) 
(PBS/T). Sections were then permeabilised by 10 minute incubation in 0.2% Triton X-
100 (Sigma-Aldrich), briefly washed in PBS/T then incubated in 3% H202 (Sigma-
Aldrich) in water for 10 minutes at room temperature to block endogenous peroxidase. 
After another brief wash with PBS/T, endogenous Avidin was blocked with the Avidin 
solution from an Avidin/Biotin Blocking kit (Vector Laboratories) for 15 minutes,  
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followed by another brief PBS/T wash and incubation with the Biotin solution from the 
same kit for a further 15 minutes; again all steps were performed at room temperature. 
Protein blocking was performed by incubating the sections in 2% blocking serum from 
an animal specific Vectastain Elite (Vector Laboratories) for 20 minutes, followed by a 
brief wash in PBS/T. Sections were then incubated for 1 hour at room temperature with 
a pre-validated TGF-β2 purified mouse monoclonal antibody (R&D Systems; diluted 
1:40 in PBS + 2% BSA) or AMBRA1 rabbit polyclonal  antibody (Abcam; diluted 1:200 
in PBS + 2% BSA) before washing x3 in PBS/T, followed by incubation in biotinylated 
animal specific secondary antibody from the same Vectastain Elite kit (Vector 
Laboratories; diluted 1:200 in 2% blocking serum + PBS/T) for 30 minutes. Staining 
was revealed by incubating sections for 30 minutes in ABC reagent from the Vectastain 
Elite kit (Vector Laboratories), premixed according to the manufacturers’ specifications 
and left at room temperature for 30 minutes prior to use. Following 3 further washes in 
PBS/T, sections were next incubated for 10 minutes at room temperature in VIP 
solution (Vector Laboratories), followed by immersion in tap water for 5 minutes to stop 
the peroxidase reaction and prior to counter staining with haemotoxylin (Sigma) for 2 
minutes. Following several rinses with tap water over 10 minutes, sections were then 
dehydrated through 75% and 100% ethanol for 5 seconds each, cleared for 2 minutes 
in Histoclear (Sigma) and finally left to dry at room temperature before mounting with 
a glass coverslip with DPX mounting medium (VWR International Ltd., Poole, UK).  
 
 
 
 
 
 
 
Chapter 2: Materials and Methods 
 74  
 
 
 Immunofluorescence for AMBRA1 and CD31 expression in FFPE 
HUVEC cell pellets and melanoma tissue  
 
5 μm sections of HUVEC FFPE cell pellets or FFPE sections derived from the JCUH 
cohort of AJCC stage I melanomas were incubated in Histoclear for 20 minutes, 
followed by rehydration of tissue sections through graded ethanol solutions (100%, 
75%, 50%) and a wash in distilled water for 5 seconds each. Antigen retrieval was 
undertaken by microwave heating of slides in preheated 10 mM Tris-Hcl (pH 9.0) for 
16 minutes with buffer top up after 8 minutes, followed by cooling at room temperature 
for 20 minutes. An area of staining for each tissue section was marked using an 
ImmEdge hydrophobic pen (Vector Laboratories), followed by 3 minute rehydration in 
PBS/T. Sections were then permeabilised by incubation in 0.2% Triton X-100 (Sigma-
Aldrich) for 10 minutes, briefly washed in PBS/T, then incubated for 20 minutes at room 
temperature in 2% horse serum in PBS/2% BSA for protein blocking. Following a brief 
wash in PBS/T, sections were then incubated for 1 hour at room temperature with 
primary AMBRA1, CD31 (alone or together) or null primary antibody control (PBS/2% 
BSA) in optimal conditions as detailed in Table 2.7. Sections were then given x3 PBS/T 
washes and incubated in secondary fluorescent antibodies detailed in Table 2.7 for 1 
hour in the dark at room temperature, with 4’6-Diamidino-2-Phenylindole dye (DAPI; 
Thermo Fisher Scientific) diluted 1:1000 in 2% horse serum in PBS/2% BSA to detect 
nuclear staining. Following x3 further washes in PBS/T, sections were dehydrated 
through 75% and 100% ethanol for 5 seconds each, cleaned for 2 minutes in Histoclear 
(Sigma Aldrich) and finally left to dry at room temperature before mounting with a glass 
coverslip using Vectashield hard set mountant (Vector Laboratories). Slides were 
finally visualised and images captured using a Leica TC2 SP2 UV AOBS MP Upright 
Confocal Microscope (Leica Microsystems, Milton Keynes, UK) and analysed using 
Volocity imaging software (PerkinElmer, Wokingham, UK).
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1° Antibody Species 
Antigen 
Retrieval 
1° Antibody 
dilution 
2° Antibody 
2° Antibody 
dilution 
AMBRA1 
(Abcam) 
Rabbit 
Polyclonal 
Tris Hcl (pH 9) 
1:200 
PBS/2% 
BSA 
Alexa Fluor 
568 anti-
rabbit 
1:250 
2% horse 
serum in 
PBS/2% 
BSA 
CD31 
(Abcam) 
Mouse 
Monoclonal 
Tris Hcl (pH 9) 
1:25 
PBS/2% 
BSA 
Alexa Flour 
488 anti-
mouse 
1:250 
2% horse 
serum in 
PBS/2% 
BSA 
 
Table 2.7: Optimal primary and secondary antibody conditions for immunofluorescence 
detection of AMBRA1 and CD31 expression.
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 Patient Cohort Selection and Database development 
Ethical permission was obtained from the Newcastle and North Tyneside research 
ethics committee (REF 08/H0906/95+5) with associated material transfer agreements 
to enable the collation of patient tissue from JCUH into the Newcastle University 
Dermatology Biobank.   
Suitable tissue was identified from the Department of Plastic & Reconstructive 
Surgery’s melanoma skin cancer database at the JCUH. All melanomas with Breslow 
depth ≤2 mm diagnosed pre September 2006 were included in the search criteria to 
allow a minimum of 8 year follow up on outcome. Information obtained from this 
database included age of patient at diagnosis, date of initial diagnosis, subtype of 
melanoma, Breslow depth of tumours at diagnosis, occurrence of nodal or metastatic 
spread to date, patient’s co-morbidities including details of other cancers and date and 
cause of patient’s death where applicable (Table 2.8).  
The stage of disease at diagnosis (to include only AJCC stage I melanomas) was re-
confirmed from initial pathology reports, accessed via the JCUH’s results 
administration systems - APEX and WINPATH. Further searches of the pathology and 
radiology results reporting system were also conducted to extrapolate any extra 
information regarding nodal or metastatic spread. Given that our melanoma cohort was 
derived pre-2006 when mitotic rate was often not reported as it was not a factor 
discerning TNM stage T1a (AJCC stage IA) and T1b (AJCC stage IB), we did not 
further stratify our AJCC stage I melanoma cohort into stage IA or IB in our biomarker 
validation. Exclusion criteria for our study cohort included: unavailable or damaged 
FFPE tissue blocks from JCUH pathology stores, tumour samples where the epidermis 
was lost/ulcerated or where there was no melanoma tumour tissue visible (Figure 2.1). 
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Figure 2.1: Graphical illustration of exclusion of samples from initial identification of potential 
samples using the JCUH Department of Plastic and Reconstructive surgery melanoma database, 
to inclusion in the final biomarker validation study cohort. 
 
All information obtained was amalgamated into a Microsoft Access template, creating 
a bio-bank database for this JCUH melanoma cohort within the central Dermatology 
Biobank database. The template allows simplified storage and analysis of patient 
demographics and disease characteristics.  All data was link anonymised and stored 
on a secure University computer, backed up every 24 hours. 
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Relevant FFPE tissue blocks of identified melanoma tumours were retrieved by Ms 
Alison Greenwood, a biomedical scientist based at the JCUH pathology laboratory, 
who performed IHC staining for AMBRA1, Loricrin, CD31, TGF-β2 using their Ventana 
Benchmark XT automated IHC staining system (Ventana) described in section 2.10.1. 
In addition, 20 additional 5 μm tissue sections were cut onto X-tra microscope slides 
(Leica) for additional manual staining for other biomarkers. These were then logged 
into the above database and transferred to the Newcastle University laboratory bio-
bank.
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JCUH Cohort of AJCC Stage I Melanomas 
Number of patients 236 
Male: Female 83:153 
Median age at diagnosis (range) 55 (13-94) 
Eventual AJCC Stage (8 year follow up) 
I/II 223 
III 6 
IV 7 
Total number of metastases 13 
Melanoma subtype 
Superficial Spreading 139 
Nodular 12 
Other (lentigo maligna melanoma, naevoid, etc.) 85 
Median Breslow depth (range) 0.8 (0.1-2) mm 
 
Table 2.8: Study cohort patient demographics.
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 Analysis of Immunohistochemistry by Slide Scanner 
 
All IHC stained sections were digitally imaged using automated scanning of slides on 
a Leica SCN400 digital slide scanner (Leica Biosystems, Milton Keynes, UK) within the 
Newcastle University Biobank. These were then visualised using Leica Biosystems 
Digital Image Hub software (Leica Biosystems), allowing visual analysis of biomarker 
expression as well as the semi quantitative calculation of percentage staining intensity. 
 
2.13.1 Analysis and scoring of epidermal and endothelial AMBRA1 expression 
IHC staining of epidermal AMBRA1 expression was analysed visually using the Leica 
Digital Image Hub software (Leica Biosystems) by two independent dermatologists. 
Each tumour was assigned a score (Table 2.9) based on the perceived degree of loss 
of epidermal AMBRA1 expression overlying it compared to normal epidermis within the 
same tumour section (Figure 2.2, depicting example of intensity staining).  
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Figure 2.2: AMBRA1 expression in normal epidermis and the epidermis overlying primary AJCC 
stage I melanomas. Photomicrographs depicting expression of AMBRA1 with DAB (brown) 
counterstain in A normal epidermis, or in the epidermis overlying a stage 1 melanoma (B – D) in which 
epidermal AMBRA1 expression was either maintained (A, B) decreased (C) or completely lost (D). Scale 
bar = 100 µm. 
 
 
 
 Score 
No loss 0 
Some loss 1 
Complete loss 2 
 
Table 2.9: Visual scores of epidermal AMBRA1 expression/staining intensity overlying primary 
melanomas.
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As it was potentially difficult to clearly discriminate between expression levels of 
epidermal AMBRA1 by eye, the robustness of visual scoring was next assessed by 
comparing expression levels scored qualitatively “by eye” with those derived from 
semi-quantitative analysis of epidermal AMBRA1 staining intensity using the previously 
validated Leica Biosystems Digital Image Hub software (Leica Biosystems). 5 
representative areas of normal epidermis were selected at 200x magnification and the 
mean percentage of DAB positive pixels were obtained for each tumour. This was 
compared to the mean percentage of DAB positive pixels in a minimum of 5 
representative areas of epidermis overlying each tumour at  
200x magnification. The overall percentage decrease in AMBRA1 expression/staining 
intensity between the epidermis overlying each tumour and that of the corresponding 
normal epidermis was then calculated and compared with visual scores. 
IHC expression of peri-tumoural endothelial AMBRA1 was analysed qualitatively using 
the Leica Digital Image Hub software (Leica Biosystems) in conjunction with 
endothelial cell marker CD31 expression in the same field of vision to highlight 
endothelial cells, both revealed by DAB counterstaining pre-optimised on the Ventana 
automated platform as described in 2.10.1. Loss of endothelial AMBRA1 expression 
was depicted by the absence of brown DAB staining whereas maintained endothelial 
AMBRA1 expression was depicted by the presence of brown DAB staining in the peri-
tumoural endothelium, in the same field of vision where brown staining for CD31 
expression highlighting endothelial cells was present (Figure 2.3). 
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Figure 2.3: Peri-tumoural AMBRA1 and CD31 expression in primary AJCC stage I melanomas. 
Photomicrographs depicting expression of A – B (i) CD31 highlighting the endothelium, in an AJCC 
stage I melanoma with A (ii) maintained AMBRA1 expression or an AJCC stage I melanoma with B (ii) 
loss of AMBRA1 expression in the peri-tumoural endothelium, revealed by DAB counterstaining (brown). 
Red arrows indicate the endothelium in matched fields of vision. Scale bar = 100 μm.
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2.13.2 Analysis and scoring of epidermal Loricrin expression 
IHC staining of epidermal Loricrin expression was also visually assessed by two 
independent dermatologists, using the Leica Digital Image Hub software (Leica 
Biosystems). Any break in the continuity of Loricrin staining in the epidermis overlying 
the tumour that was not due to direct tumour invasion of the upper epidermis was 
scored as Loricrin loss. Unlike AMBRA1, semi-quantitative analysis of Loricrin 
expression was not deemed necessary as in this case the visual analysis assessment 
was clear-cut, i.e. it was either expressed continuously or not in the epidermis overlying 
any evaluated melanoma (Figure 2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Loricrin expression in normal epidermis and the epidermis overlying primary 
melanomas. Photomicrographs of Loricrin expression with DAB counterstain in A normal epidermis, or 
B & C in the epidermis overlying two differing AJCC stage I melanomas, depicting maintained 
expression in image B and complete loss of expression in image C. Scale bar = 100 µm.
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2.13.3 Analysis of tumoural TGF-β2 expression 
IHC staining of tumoural TGF-β2 expression (revealed with both DAB and VIP 
counterstaining) was visually analysed and staining intensity was measured semi 
quantitatively using the Leica Digital Image Hub software (Leica). 5 representative 
areas of normal epidermis were selected at 200x magnification and the mean 
percentage of DAB positive pixels were obtained for each tumour for correlation 
analyses.
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 Statistics and Bioinformatics Analysis 
 
GraphPad Prism 6 (GraphPad Software Inc; San Diego, USA) statistical analysis 
software was used for all statistical analysis and the generation of graphical images 
unless otherwise stated.  
Quantification of protein expression in vitro via Western blotting was derived from 
densitometry analysis of at least 3 replicate experiments with absolute expression 
levels acquired using LI-COR Image Studio Software. Western blot band intensity of 
respective protein expression was normalised to corresponding β-actin or GAPDH 
housekeeping gene expression and expressed relative to the mean protein/β-Actin 
value for each experiment. Data presented are the mean ± SD from 3 independent 
biological replicates unless otherwise stated In the text. Statistical variation in protein 
expression levels between two groups were compared using the unpaired t Test 
whereas variation between more than two groups was compared using one way 
ANOVA with Dunnett’s multiple comparison test (when comparing differences in 
protein expression against a control) or one way ANOVA with Tukey’s multiple 
comparisons test (when comparing differences between all treatment groups). P 
values of <0.05 were considered as significant. 
Quantification of cell viability was derived from the readings of a SpectraMAX 250 plate 
reader (Molecules Devices Ltd) at 490 nm and expressed as the mean of 3 replicate 
experiments ± SD and normalised to respective vehicle control. Statistical variation in 
cell viability was derived using One-way ANOVA with Dunn’s multiple comparisons 
test. P values of <0.05 were considered as significant. 
To test the robustness of visual scoring in evaluating epidermal AMBRA1 expression, 
qualitative visual scores of epidermal AMBRA1 expression (no loss, some loss or 
complete loss) were compared to semi-quantitative calculation of the percentage 
decrease in staining intensity overlying each tumour with that of adjacent normal 
epidermis. D’Agostino and Pearson omnibus normality test revealed all groups had a 
Gaussian distribution; one-way analysis of variance (ANOVA) testing was undertaken  
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to determine statistical variance between the means of all groups, as well as Dunn’s 
multiple comparison test to calculate differences between the means of each individual 
pair within the group.  
Power calculations to determine sample size were undertaken with the assumptions of 
an Alpha score (probability of a type 1 (false positive) error) of 0.05, and a power (ability 
to detect a difference between groups) of 90% and performed in collaboration with Mr 
Stuart Horswell, Senior biostatistician, The CRICK Institute, UK. The anticipated 
incidence of metastases was based on the rate of metastases seen in AJCC stage I 
disease in the general population as described in the 2009 AJCC staging criteria [37]. 
Based on hazard ratios derived from survival curve analysis of AMLo expression in the 
pilot Newcastle Hospitals NHS Trust cohort, this gave a minimum sample size of 133, 
with at least 8 metastatic samples to be included in subsequent biomarker validation 
studies. 
To assess the validity of combined epidermal AMBRA1 and Loricrin expression as a 
prognostic biomarker, tumours were stratified into “high risk” and “low risk” groups. A 
‘high risk’ tumour was defined as one in which AMBRA1 expression in the overlying 
tumour epidermis was completely lost AND with any break in the continuity of overlying 
epidermal Loricrin expression. Any other combination of variables e.g. where 
epidermal AMBRA1 expression was completely lost but where Loricrin expression was 
maintained, or where epidermal AMBRA1 expression was maintained with only 
expression of Loricrin lost, were stratified as ‘low risk’. 
All univariate (analysis of data based on the biomarker expression as the only variable) 
and multivariate analysis (when pre-stratified by AJCC stage of disease) of study 
variables for disease free survival (DFS) were undertaken using Kaplan-Meier curve 
constructions against 10 year follow up, as well as log-rank (Mantel-Cox) analysis of 
the comparative data. The Mantel-Cox log-rank test is a non-parametric hypothesis 
test to compare survival distributions of two samples. 
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Positive predictive values (PPV) are the proportion of true positives within all positive 
results whereas negative predictive values (NPV) are the proportion of true negative 
results within all negative results. PPVs and NPVs describe the accuracy of a 
diagnostic test or statistical measure [171]. These were calculated as follows: 
 
𝑃𝑃𝑉 =
No.of high risk tumours that metastasised
No.of high risk tumours that metastasised+No.of high risk tumours that did not metastasise
  
 
𝑁𝑃𝑉 =
No.of low risk tumours that did not metastasise
No.of low risk tumours that did not metastasise+No.of low risk tumours that metastasised
  
 
Sensitivity is defined as the proportion of true positives that are correctly identified by 
a test, where a negative result in a test with high sensitivity is useful for ruling out 
disease. A positive result however, is not necessarily significant and would need to be 
looked at in the context of how specific a test is [172]. Specificity is the proportion of 
true negatives that are correctly identified by a test where a positive result in a test with 
high specificity signifies a high probability of the presence of disease but a negative 
test does necessarily rule this out [172]. Sensitivity and specificity were calculated as 
follows: 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
No.of high risk tumours that metastasised
No.of high risk of tumours that metastasised+No.of low risk tumours that metastasised
  
 
 
Chapter 2: Materials and Methods 
 89  
 
 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
No.of low risk tumours that did not metastasise
No.of low risk tumours that did not metastasise+No.of high risk tumours that did not metastasise
  
 
 
Bioinformatics analysis of the upstream AMBRA1 promoter (Figure 2.5) was 
undertaken in collaboration with Dr Marco Corazzari, University of Rome ‘Tor Vergata’  
in which the MatInspector (Genomatix, Munich, Germany) matrix library tool was used 
to identify putative TGF-β2 related transcription factor binding sites/responsive 
elements by locating matches in DNA sequences. Confidence matrix simetry values of 
>0.8 were considered significant.   
 
TGAGTAGTGGGGAAGGGTGTAAACCTCCCTAGGAGCAGGTAAGGTAGACTATGATTGCTCACAATTGGTA
ACCATACTTGCAGTGATCTTTGTGATTTATTGAATCACATCTAGGATGTACATATTAATCCATATTTGTGCTG
AGCATATTCATTTATCAACTAAGAGACTACAGAAAAAAGCCATTGTTGTGGTGATGAAAATGTCAACACTTT
ATCAGGTTCTGAACCCAAAGAGACTTTTGCTTATTATGTAAGAAGCACACCTGTGGCTCTAGGCCTTTGGA
AGAAAATAAAAGAGAAAAGCAATCCGTGTGCTTTTTTTCCCCCTGCCTTAAGGTCAGGCTACATAATTCTG
GGTTTTCCCAGCTTCTCTTGGTCATGCTTTGTGGGGACTAAACTGGAGCTTTTACGTAGACTGTTCATTTTGT
TCCTCAGCTTGAATTCTCTCTCGTTTTCTGTCTCTATGATTTTTAATTCCCCTCACTGCTCTGTTAGGAAACTA
AGGGTCAAATGAGGTTAACTAATTTGCTCAATTGGGATAAAGAGTGTTGGGAGTCCATAGAACAGTTGGG
GGACTATAGTTACACAACAAGTGTTATTGCGCTATGATTTGATCTTCAACACATTCACGAGAAACTCCAGTT
CTCTAAAGAACTTTAACAGCCGGCGACCCACAGAAAATGGCAGAAGTGCAGGCTCTTTTTTAACCCGTGG
CTTATGATCTGGGTTTGTTTATTTACGCCTCAGACAGGAGCCGGACCTTGAGTAGGAGTTGAGCTGTTTTTC
GGCGCTCGGCTGTGGTTCCTTGAACGATTGCTTGGGCGTTCCTCCTTTGATGTCTGGGGCGTTCTTGTATTC
GGTGATCTTTTGCGCCGTCTTCTTGCTTGATGTCTCCTGAGCGGCGGCGGCGCCGGGTCGAGGGCTGAGT
TGTCCGCGAGGCCCCGCGCTCAAGCCGCCTTCTCCTGCCGGTCGGTAGAACGGACCCCTTCCTTTA 
Figure 2.5: AMBRA1 upstream promoter sequence. 
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3.1 Introduction 
 
Activating molecule in Beclin 1 regulated protein 1 (AMBRA1) is a component of the 
Beclin 1/VPS34 complex and involved in the formation of PI3K rich membranes during 
the nucleation phase of autophagy [115]. As a key autophagy initiating regulatory 
protein, AMBRA1 represents a potential marker of autophagy induction as well as a 
possible therapeutic target for autophagy inhibition. In addition to its functional role in 
autophagy, a growing body of evidence however, supports the role of AMBRA1 as an 
important regulator of cellular differentiation [113, 114] including in the early stages of 
differentiation in neuronal stem cells, during which autophagy is activated to fulfil the 
high energy demands of this process [115, 116]. Furthermore, functional inactivation 
of AMBRA1 results in epithelial hyper-proliferation, as well as dysregulated 
differentiation [173] however, the precise role autophagy plays within the differentiation 
process is yet to be fully elucidated [174].  
Preliminary observations leading up to the present study support the role of AMBRA1 
in epidermal differentiation with an observed increase in AMBRA1 expression in the 
epidermis of normal skin in vivo in line with keratinocyte differentiation [118]. However, 
knockdown of ATG7 (an alternative autophagy regulatory protein) in calcium-induced 
differentiated primary keratinocytes in vitro demonstrated impaired autophagy with no 
effect on Loricrin upregulation. In contrast, in addition to impairment of LC3-II induction, 
siRNA mediated knockdown of AMBRA1 resulted in the significant down regulation of 
Loricrin suggesting that the role of AMBRA1 in keratinocyte differentiation is 
independent of its pro-autophagy role, or at least independent of Atg7 (Ellis & Lovat, 
unpublished data).  
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The observed decrease, or even complete loss of AMBRA1 expression in the 
epidermis overlying numerous cutaneous melanomas revealed by IHC [118], further 
suggested that the expression of AMBRA1 in the melanoma microenvironment may 
have prognostic potential. Preliminary analysis of the IHC expression of epidermal 
AMBRA1 overlying 111 all AJCC stage primary melanomas derived retrospectively 
from the Newcastle Hospitals NHS Trust demonstrated that decreased or complete 
loss of epidermal AMBRA1 expression was indeed associated with significantly 
decreased disease free survival (DFS) which when stratified by AJCC stage, was also 
significant for AJCC stage I disease (Ellis & Lovat, unpublished data). However, 
although AMBRA1 expression alone was able to detect all primary melanomas that 
went on to develop metastases, the specificity of AMBRA1 alone as a prognostic 
biomarker, required further improvement to be clinically relevant. Specificity in this 
context is defined as the proportion of truly low risk tumours without subsequent 
metastases that were correctly identified by epidermal AMBRA1 expression; a high 
degree of test specificity in this context signifies a high probability of eventual 
metastases when epidermal AMBRA1 expression is decreased or completely lost. 
Consequently these studies led to the investigation of other markers of epidermal 
differentiation to aid the improved specificity of epidermal AMBRA1 expression as a 
single prognostic biomarker. 
Expression of Loricrin in the stratum corneum of the epidermis represents a marker of 
keratinocyte terminal differentiation and in normal skin is revealed by IHC staining as 
a clear-cut “line” of expression in contrast to other potential IHC markers of 
differentiation with less clear cut pan-epidermal IHC staining (involucrin), or where 
genetic variability in expression exists across patients i.e. filaggrin [175]. Preliminary 
analysis of the epidermal IHC expression of Loricrin overlying a small cohort of 14 
AJCC Stage I melanoma tumours derived from the Newcastle Hospitals demonstrated 
that loss of epidermal Loricrin was indeed associated with decreased disease free 
survival. 
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However in contrast to AMBRA1 expression, epidermal Loricin alone was associated 
with poor sensitivity i.e. the proportion of high risk tumours with eventual metastases 
that were correctly identified by epidermal Loricrin loss (Ellis, Tang and Lovat, 
unpublished data) was relatively insensitive.  
However, when loss of epidermal Loricrin overlying primary AJCC stage I melanomas 
was combined with the analysis of epidermal AMBRA1 loss, this resulted in the 
significant enhancement of prognostic potential and the prediction of disease free 
survival for AJCC stage I melanomas, with an assay specificity and sensitivity of 100% 
(Ellis and Lovat, unpublished data), and leading to the current studies and primary aim 
of the current chapter, to validate combined loss of AMBRA1 and Loricin (AMLo) as a 
prognostic biomarker for AJCC stage I melanoma.
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3.2 Results 
 
Data presented in this chapter was derived from an extension of the initial Newcastle 
Hospitals NHS Trust melanoma cohort (up to 129 patients) and validation of both 
biomarkers in a further independent retrospective cohort of AJCC stage I melanomas 
derived from the James Cook University Hospital NHS Trust with 8 year follow up on 
outcome. All biomarker studies and data presented within this chapter were performed 
in line the “Reporting Recommendations for Tumour Marker Prognostic Studies” 
(REMARK) guidelines released on behalf of the National Cancer Institute – European 
Organisation for Research and Treatment of Cancer (NCI-EORTC) that gives guidance 
on preferred methods on biomarker data analysis and presentation (Appendix 1) [75]. 
 
3.2.1 Loss of AMBRA1 in the overlying AJCC stage I melanomas is a putative 
prognostic biomarker 
To determine the potential role of AMBRA1 expression as an independent biomarker 
for melanoma progression, qualitative visual analysis of its expression was performed 
in an initial retrospective cohort of 129 all AJCC stage melanomas derived from 
Newcastle Hospitals NHS Trust with at least 8 years follow up data. Following 
optimised IHC detection of epidermal AMBRA1 (see section 2.10.1), each slide was 
imaged using a Leica SCN400 digital slide scanner software (Leica Biosystems). 
Analysis of peri-tumoural epidermal AMBRA1 expression was scored qualitatively “by 
eye” as being ‘maintained’, ‘decreased’, ‘completely lost’ or ‘ulcerated’ when compared 
to the normal epidermis adjacent to the tumour which acted as an internal control. 
Three independent observers; two dermatologists and a histopathologist undertook 
independent analysis. Univariate analysis comparing epidermal AMBRA1 expression 
scores with time to metastases development (disease free survival (DFS)) over an 8  
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year follow up period was performed using Kaplan-Meier survival analysis. This 
revealed a significant step-wise reduction in DFS from 100% survival in tumours with 
maintained epidermal AMBRA1 expression, to 72.2% survival for patients in which 
AMBRA1 expression in the overlying epidermis was ‘decreased’ or ‘completely lost’, to 
only 35.7% in frankly ulcerated tumours (where the epidermis overlying the tumour had 
been lost or breached by the tumour; Log-Rank (Mantel-Cox) Test P < 0.0001, Figure 
3.1). Of note, ulcerated tumours are unable to be analysed via AMBRA1 expression 
as, by definition, the epidermis is not present in the sample and so cannot be assessed. 
 
 
Figure 3.1: Loss of epidermal AMBRA1 expression overlying tumours correlates with decreased 
disease free survival in all AJCC stage melanomas. Kaplan-Meier curve showing a 27.8% decrease 
in 8 year DFS (months until metastases first detected) in 79 primary AJCC stage I melanomas with 
decreased or completely lost epidermal AMBRA1 expression (red line, DFS 72.2%) and a 64.3% 
decrease in DFS in 28 tumours with epidermal ulceration (grey line, DFS 35.7%) compared to 22 primary 
tumours in which epidermal AMBRA1 expression was maintained (black line, DFS 100%). Log-Rank 
(Mantel-Cox) Test P <0.0001. 
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To further test the utility of AMBRA1 as a prognostic biomarker in early stage disease, 
sub-cohort multivariate analysis of this initial retrospective cohort was undertaken to 
assess epidermal AMBRA1 expression levels overlying the tumours, pre-stratified by 
AJCC stage of disease at diagnosis. Results highlighted a significant association 
between decreased DFS and decreased/lost epidermal AMBRA1 in AJCC stage I 
melanomas, with a DFS of 100% associated with no loss of epidermal AMBRA1 
expression, compared to a DFS of 80.8% in the decreased/lost AMBRA1 sub-group 
(Log-Rank (Mantel-Cox) Test P <0.03, HR 4.3 (95% CI 1.14 – 16.51), Figure 3.2), 
suggesting that loss of epidermal AMBRA1 expression overlying stage I melanomas 
may represent a putative biomarker of disease progression.  
However, although loss of epidermal AMBRA1 expression overlying tumours was 
associated with the development of metastasis with 100% sensitivity in this cohort i.e. 
all tumours that metastasised were correctly identified, the specificity was not 
particularly high at 34.3%. This translates to 65.7% of melanoma tumours identified as 
high risk by epidermal AMBRA1 loss not actually developing metastasis (Figure 3.2). 
To improve assay specificity, we hypothesised that expression of the terminal 
differentiation marker Loricrin is altered overlying high risk melanoma tumours in line 
with the down regulation of epidermal AMBRA1 expression, which could then be used 
in conjunction with epidermal AMBRA1 expression to increase assay validity. 
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Figure 3.2: Loss of AMBRA1 expression in the epidermis overlying AJCC stage I melanomas 
correlates with decreased disease free survival. Kaplan-Meier curve showing a 19.2% decrease in 
8 year DFS in 52 AJCC stage I melanomas in which epidermal AMBRA1 expression was decreased or 
lost (red line, DFS 80.8%) as compared with 22 tumours in which epidermal AMBRA1 overlying tumours 
was maintained (black line, DFS 100%). Log-Rank (Mantel-Cox) Test P <0.03, HR 4.3 (95% CI 1.14 – 
16.51). AMBRA1 as a prognostic biomarker in this Newcastle Hospitals derived cohort demonstrates 
100% sensitivity and NPV; however is only 34.3% specific with a PPV of 19.2%.
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3.2.2 Loss of Loricrin in the epidermis overlying AJCC stage I melanomas is a 
putative prognostic biomarker 
Epidermal expression of Loricrin overlying 20 all AJCC stage melanomas derived from 
the Newcastle Hospitals NHS Trust retrospective cohort was analysed using an 
optimised IHC assay (section 2.10.1). Sections were visualised and scored as having 
either maintained or lost epidermal Loricrin expression using Leica Digital Image Hub 
software (Leica) as previously described in section 2.13.2.  
Univariate analysis comparing peri-tumoural epidermal Loricrin expression scores with 
DFS over a 8 year follow up period was performed using Kaplan-Meier survival 
analysis, revealing a significant reduction in DFS from 69.2% in tumours with 
maintained epidermal Loricrin expression to 0% in tumours with any break in 
continuous expression (Log-Rank (Mantel-Cox) Test P =0.0006, HR 18.40 (95% CI 
3.52 – 96.21), Figure 3.3). Loss of Loricrin in the overlying tumour epidermis was also 
associated with the development of metastasis with 100% specificity in this cohort 
however; sensitivity was only 63.6% with a NPV of 69.2%.
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Figure 3.3: Loss of Loricrin expression overlying primary melanomas of differing AJCC stage 
correlates with decreased disease free survival. Kaplan-Meier curve showing a 69.2% decrease in 
8 year DFS in 7differing AJCC stage primary melanomas (derived from the Newcastle Hospitals cohort) 
with loss of epidermal Loricrin expression (red line, DFS 0%) compared to 7 tumours in which expression 
was maintained (black line, DFS 69.2%). Log-Rank (Mantel-Cox) Test P =0.0006, HR 18.4 (95% CI 3.52 
– 96.21). Loricrin as a prognostic biomarker in this Newcastle Hospitals derived cohort is highly specific 
(specificity of 100%) but lacks sensitivity at 63.6%. PPV and NPV were 100% and 69.2% respectively. 
 
When stratifying for AJCC stage I disease in 14 primary melanoma from this initial 
cohort, multivariate analysis demonstrated a significant reduction in DFS which 
dropped from 90% in tumours where epidermal Loricrin expression was maintained to 
0% in tumours with loss of expression (Log-Rank (Mantel-Cox) Test P <0.0001, HR 
210.3 (95% CI 16.86 – 2624), Figure 3.4). In this context, the assay sensitivity for the  
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IHC analysis of epidermal Loricrin improved to 80% with a maintained specificity of 
100% (Figure 3.4), collectively suggesting that similarly to AMBRA1 expression, the 
loss of Loricrin expression in the epidermis overlying AJCC stage I primary melanomas 
is also associated with an increased risk of metastasis in AJCC stage I melanomas.  
 
 
 
Figure 3.4: Loss of Loricrin expression in the epidermis overlying primary AJCC stage I 
melanomas correlates with decreased disease free survival. Kaplan-Meier curve showing a 90% 
decrease in 8 year DFS in 4 primary AJCC stage I melanomas (Newcastle Hospitals Cohort) in which 
epidermal Loricrin was lost (red line, DFS 0%) compared to 10 primary tumours in which epidermal 
Loricrin was maintained (black line, DFS 90%). Log-Rank (Mantel-Cox) Test P <0.0001, HR 210.3 (95% 
CI 16.86 – 2624). Table indicating 100% assay specificity and PPV for the IHC detection of epidermal 
Loricrin with 80% sensitivity and a 90% NPV.
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Given the high assay sensitivity for the detection of epidermal AMBRA1 and high 
specificity for the detection of epidermal Loricrin at predicting DFS in AJCC stage I 
melanomas, subsequent studies explored the potential for the combined expression 
as a means to improve both assay sensitivity and specificity and the utility of combined 
epidermal AMBRA1 and Loricrin as an independent prognostic biomarker for AJCC 
stage I melanomas. 
Multivariate analysis comparing combined AMBRA1 and Loricrin expression scores 
with DFS in a sub-cohort of 12 AJCC stage I melanomas derived from the Newcastle 
Hospitals cohort revealed a highly significant decrease in DFS from 100% in tumours 
where expression of both proteins in the overlying epidermis was maintained to 0% in 
tumours in which both epidermal AMBRA1 and Loricrin expression were lost. (Log-
Rank (Mantel-Cox) Test P =0.0002, HR 93.5 (95% CI 8.67 – 1008), Figure 3.5).  
Furthermore using combined analysis of epidermal AMBRA1 and Loricrin in these 
studies resulted in the improvement of both assay sensitivity and specificity to 100%, 
thereby underpinning the utility of combined expression as a prognostic biomarker, 
over and above the expression of either epidermal AMBRA1 or Loricrin alone.  
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Figure 3.5: Combined loss of AMBRA1 and Loricrin expression overlying primary melanomas is 
a highly sensitive and specific prognostic biomarker for the prediction of disease free survival 
in AJCC stage I melanomas. Kaplan-Meier curve showing % decrease in DFS of 12 patients diagnosed 
with AJCC stage I melanomas (Newcastle Hospitals Cohort) over 8 years according to the loss (red line) 
or maintenance (black line) of epidermal  AMBRA1 and Loricrin expression and indicating the significant 
correlation of reduced DFS from 100% to 0% in patients with tumours in which the expression of 
AMBRA1 and Loricin overlying the primary tumour was lost. Log-Rank (Mantel-Cox) Test P =0.0002, 
HR 93.5 (95% CI 8.67 – 1008). Table indicating the 100% assay specificity and sensitivity and, NPV 
and PPV values of 90 and 100% respectively. 
 
 
To further validate the prognostic value of combined epidermal expression of AMBRA1 
and Loricrin, expression levels subsequent studies were undertaken in an independent 
powered, retrospective cohort of AJCC stage I melanomas derived from the James 
Cook University Hospital (JCUH), Middlesbrough 8 year follow up on outcome. 
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Power calculations to determine sample size were undertaken with the assumptions of 
an Alpha score (probability of a type 1 (false positive) error) of 0.05, and a power 
(ability) to detect a difference between groups) of 90%. The anticipated incidence of 
metastases was based on the rate of metastases seen in AJCC stage I disease in the 
general population as described in the 2009 AJCC staging criteria [37]. Based on 
hazard ratios derived from survival curve analysis of AMLo expression in the pilot 
Newcastle Hospitals NHS Trust cohort, this gave a minimum sample size of 133, with 
at least 8 metastatic samples to be included. In line with this, 460 potential AJCC stage 
I melanomas including 20 metastatic samples were initially identified from the JCUH 
Plastic Surgery Department melanoma database of which 224 were excluded as 
detailed in section 2.12, leaving 236 including 13 metastatic samples (5.5% prevalence 
of metastases) making up the final cohort.  
Prior to further biomarker validation work, initial studies were undertaken to validate 
qualitative visual analysis of epidermal AMBRA1 expression as a robust mean of 
identifying ‘loss of AMBRA1 expression’ in AJCC stage I melanomas for subsequent 
scoring of melanoma tumours as high risk or low risk based on the combined loss of 
epidermal AMBRA1 and Loricrin expression.
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3.2.3 Validation of visual analysis of epidermal AMBRA1 expression as a robust 
mean of identifying ‘loss of AMBRA1 expression’ in AJCC stage I 
melanomas 
While visual assessment of the maintenance or loss of epidermal Loricrin was clear 
cut, i.e. expression was continuous throughout the epidermis over lying primary AJCC 
stage I melanomas or not, this was less apparent with AMBRA1 expression where 
more subtle differences in epidermal expression were apparent and as such, making 
it potentially more difficult to visually discriminate between relatively small differences 
in staining intensity. Prior to further combined analysis of AMBRA1 and Loricrin in the 
independent retrospective JCUH melanoma cohort of AJCC stage I melanomas, the 
optimal means of scoring epidermal AMBRA1 expression and the robustness of 
scoring this by eye was thus evaluated.  
Qualitative visual assessment of staining intensity (scored as no loss, some or 
complete loss of staining intensity) was compared with semi-quantitative expression 
analysis using the Leica SCN400 digital slide scanner software (Leica) in order to 
calculate the overall percentage decrease between the staining intensity for AMBRA1 
in the epidermis overlying a melanoma with that in the normal adjacent epidermis. 
Analysis of 101 AJCC stage I melanomas from the JCUH cohort demonstrated that “by 
eye” scoring of epidermal AMBRA1 staining revealed a significant step wise correlation 
with semi-quantitative scoring (D’Agostino-Pearson omnibus normality test revealed 
normal distribution of the data, thereby enabling the application of  One Way ANOVA 
with Dunn’s multiple post hoc correction for statistical comparison between groups). 
This confirmed a highly significant difference in percentage decrease of epidermal 
AMBRA1 staining intensity derived semi-quantitatively between tumours scored 
visually as having ‘no loss’, ‘some loss’ and ‘complete loss’ of epidermal AMBRA1 
expression (*** P =0.0001(no loss vs. some loss), **** P <0.0002 (no and some loss 
vs. complete loss), Figure 3.6).  
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However, despite a stepwise correlation, there was broad crossover between the 
percentage decrease of epidermal AMBRA1 staining intensity derived semi-
quantitatively falling within the ‘no loss’ and ‘some loss’ groups (‘no loss’ median 
percentage quantitative expression loss 12.43 (25th percentile 2.19, 75th percentile 
30.88), and ‘some loss’ median quantitative expression loss 37.41 (25th percentile 
25.84, 75th percentile 52.02) which reduced the sensitivity of visual scoring between 
these groups. Visual scoring of ‘complete loss’ however, was highly statistically 
separate with a median percentage quantitative score of 89.10 (25th percentile 58.52, 
75th percentile 95.76) (Figure 3.6).  
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Figure 3.6:  Correlation of qualitative visual scoring of epidermal AMBRA1 expression with semi-
quantitative scoring. Scatter graph representing the mean % decrease of epidermal AMBRA1 staining 
intensity in the epidermis overlying 101 primary AJCC stage I melanomas (JCUH cohort, semi-
quantitative analysis) compared with qualitative visual assessment in the same tumour group scored as 
‘no loss’ (n=34), ‘some loss’ (n=33) or ‘complete loss’ (n=34). Each point is the mean % decrease in 
AMBRA1 staining intensity from 10 fields of vision compared with staining intensity in the normal 
adjacent epidermis. Horizontal bars represent the mean % decrease in AMBRA1 staining intensity for 
each group ± SEM. One Way ANOVA with Dunn’s multiple post hoc correction *** P =0.0001, **** P 
<0.0002. 
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The statistical difference of ‘complete loss’ to ‘no loss’ and ‘some loss’ of epidermal 
AMBRA1 overlying primary AJCC stage I melanomas as determined by visual analysis 
was further assessed by comparing ‘complete loss’ with a combination of ‘no or some 
loss’. Direct comparison of the combination of ‘no or some loss’, with ‘complete loss’ 
visual loss of AMBRA1 epidermal expression overlying tumours revealed a highly 
significant difference in percentage quantitative scoring values, as well as minimal 
overlap of percentiles (‘no/some’ loss median percentage quantitative staining 28.38, 
25th percentile 9.52, 75th percentile 44.24 versus ‘complete loss’ median percentage 
quantitative staining 68.85, 25th percentile 58.25, 75th percentile 89.10) (Mann-Whitney 
P <0.0001, Figure 3.7). The clear-cut difference between visual staining assessment 
of ‘no or some loss’ versus ‘complete loss’ of AMBRA1 expression suggested that only 
tumours in which there is complete loss of epidermal AMBRA1 expression can be 
defined ‘high risk’ and hence this scoring was applied to all subsequent analysis.  
Collectively these data thus validated visual scoring as a robust and reliable method 
for analysing IHC epidermal AMBRA1 expression levels, also providing a simple and 
cheap as well as a favourable method for pathologists over complex scoring algorithms 
used in other biomarker studies.
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Figure 3.7: Comparison of ‘complete loss’ with a combination of ‘no or some loss’ of AMBRA1 
expression in the epidermis overlying AJCC stage I melanomas with semi-quantitative analysis. 
Scatter graph representing the mean % decrease of epidermal AMBRA1 staining intensity in the 
epidermis overlying 101 primary AJCC stage I melanomas (JCUH cohort, semi-quantitative analysis) 
compared with qualitative visual assessment in the same tumour group scored as ‘no or some loss’ 
(n=67) or ‘complete loss’ (n=34). Each point is the mean % decrease in AMBRA1 staining intensity from 
10 fields of vision compared with staining intensity in the normal adjacent epidermis. Horizontal bars 
represent the mean % decrease in AMBRA1 staining intensity for each group ± SEM. Mann-Whitney P 
<0.0001. 
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3.2.4 Combined loss of epidermal AMBRA1 and Loricrin (AmLo) identifies a 
high risk AJCC stage I melanoma subgroup 
To validate the prognostic value of combined epidermal AMBRA1 and Loricrin 
expression for AJCC stage I melanomas, analysis of the expression of each protein 
individually was initially performed in a further retrospective cohort of 236 stage I 
melanomas derived from the JCUH NHS Foundation Trust with at least 8 years follow 
up data and for which all analysis was performed by visual assessment. Power 
calculations were performed in conjunction with the study biostatistician Mr Stuart 
Horswell (Cancer Research UK, London) to determine how many AJCC stage I 
tumours would be required in a valid independent retrospective cohort. The anticipated 
incidence of metastases was based on the rate of melanoma metastases seen in AJCC 
stage I disease in the general population as described in the 2009 AJCC staging 
criteria [37] and power calculations were based on hazard ratios derived from survival 
curve analysis of AMLo expression in the pilot Newcastle Hospitals NHS Trust cohort, 
which revealed a minimum sample size of 133, with at least 8 metastatic samples to 
be included, as described above.  
Multivariate analysis comparing epidermal AMBRA1 expression scores with time to 
metastatic development over an 8 year follow up period was performed using Kaplan-
Meier survival analysis. In line with the results from the Newcastle Hospitals cohort, 
analysis of 236 stage I melanoma tumours revealed a significant step-wise reduction 
in DFS from 98.1% survival in AJCC stage I melanoma tumours with maintained or 
decreased epidermal AMBRA1 expression to 87.8% in tumours with complete loss of 
epidermal AMBRA1 expression in the overlying epidermis (Log-Rank (Mantel-Cox) 
Test P ≤0.001, HR 6.9 (95% CI 2.17 – 21.62), Figure 3.8), thus suggesting AMBRA1 
as an independent putative biomarker for AJCC stage I melanoma. However once 
again, although loss of epidermal AMBRA1 expression overlying tumours associated 
with the development of metastasis with 76.9% sensitivity, the specificity for predicting 
metastasis was only 63.2% with a positive predictive value of 10.9% (Figure 3.8).
Chapter 3: Combined loss of epidermal AMBRA1 and Loricrin (AMLo): A novel 
prognostic biomarker for AJCC stage I melanomas 
111 
 
 
 
 
Figure 3.8: Loss of AMBRA1 expression in the epidermis overlying AJCC stage I melanomas is 
associated with decreased disease free survival. Kaplan-Meier curve showing a 10.3% decrease in 
DFS over 8 years of 236 patients diagnosed with AJCC Stage I melanomas (JCUH cohort) in which 
epidermal AMBRA1 was completely lost overlying 92 tumours (red line) as compared with 144 tumours 
(black line) in which epidermal AMBRA1 overlying tumours was partially lost or maintained. Log-Rank 
(Mantel-Cox) Test P ≤0.001, HR 6.9 (95% CI 2.17 – 21.62). AMBRA1 as a prognostic biomarker in these 
studies revealed an assay sensitivity of 76.9% sensitivity, 63.2% specificity and PPV and NPV values 
of 10.0% and 97.9% respectively.   
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Validation of the prognostic potential of Loricrin as an independent biomarker for AJCC 
stage I melanoma was also undertaken in the JCUH melanoma cohort. IHC epidermal 
expression of Loricrin overlying 236 stage I melanoma tumours was analysed and 
scored as described previously. Multivariate analysis comparing Loricrin expression 
scores with DFS using Kaplan-Meier survival analysis in this cohort also demonstrated 
a significant reduction in DFS, which dropped from 99.1% in tumours in which 
epidermal Loricrin expression was maintained to 90.2% in tumours with loss of 
expression (Log-Rank (Mantel-Cox) Test P ≤0.002, HR 5.3 (95% CI 1.79 – 15.77), 
Figure 3.9). Loricrin as a biomarker to detect metastasis in these studies was thus 
more sensitive than AMBRA1 (92.3% sensitive) but the IHC assay in this context 
lacked specificity (50.7% specific). Nevertheless, these results again show the loss of 
Loricrin expression in the epidermis overlying primary AJCC stage I melanomas is 
associated with increased risk of metastasis and further guided the evaluation in 
combination with the loss of epidermal AMBRA1 expression to test the prognostic 
value of both biomarkers.
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Figure 3.9: Loss of Loricrin expression in the overlying AJCC stage I melanomas is associated 
with decreased disease free survival. Kaplan-Meier curve showing an 8.2% decrease in DFS of 236 
patients diagnosed with AJCC stage I melanomas (JCUH cohort) over 8 years in 122 tumours in which 
the expression of epidermal Loricrin was lost (red line, DFS 90.2%) compared to 114 tumours in which 
expression was maintained (black line, DFS 99.1%). Log-Rank (Mantel-Cox) Test P ≤0.002, HR 5.3 
(95% CI 1.79 – 15.77). Loricrin as a prognostic biomarker in these studies was 92.3% sensitive, with an 
assay specificity of 50.7% and PPV and NPV values of 9.8% and 99.1% respectively. 
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To validate the prognostic value of combined epidermal Loricrin and AMBRA1 
expression for AJCC stage I melanomas, 236 stage I tumours from the JCUH cohort 
were pre-stratified into ‘high risk’ and ‘low risk subgroups’. A ‘high risk’ tumour was 
defined as one in which AMBRA1 expression in the overlying tumour epidermis was 
completely lost AND with any break in the continuity of overlying Loricrin expression. 
Any other combination of variables e.g. where epidermal AMBRA1 expression was 
completely lost but where Loricrin expression was maintained, or where epidermal 
AMBRA1 expression was maintained with only expression of Loricrin lost, were 
stratified as ‘low risk’.  
Multivariate analysis of 236 tumours comparing high risk and low risk tumour 
subgroups with DFS using Kaplan-Meier survival analysis revealed a significant 
decrease in DFS in high risk tumours (DFS of 85.1%) as compared to 98.2% DFS in 
tumours where expression of both epidermal AMBRA1 and Loricrin were maintained 
(Log-Rank (Mantel-Cox) Test P <0.0001, HR 12.2 (95% CI 3.59 – 41.18), Figure 3.10). 
The use of this combined assay as a prognostic biomarker results in improved overall 
sensitivity of 76.9%, specificity of 74.4%, NPV of 98.2% and PPV of 14.9%, collectively 
validating loss of epidermal AMBRA1 and Loricrin (AMLo) as a novel independent 
prognostic biomarker for AJCC stage I melanomas. 
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Figure 3.10: Combined loss of epidermal AMBRA1 and Loricrin (AMLo) expression in the 
epidermis overlying AJCC stage I melanomas identifies a high risk sub group. Kaplan-Meier curve 
showing a 13.1% decrease in DFS of 236 patients diagnosed with AJCC stage I melanomas over 8 
years stratified as high risk (red line, DFS 98.2%) or low risk (black line, DFS 85.1%). Log-Rank (Mantel-
Cox) Test P <0.0001, HR 12.2 (95% CI 3.59 – 41.18). Combined analysis of AMLo in these studies 
revealed an assay sensitivity of 76.9%, and a specificity of 74.4%, with PPV and NPV values of 14.9% 
and 98.2% respectively.
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3.2.5 Combined loss of epidermal AMBRA1 and Loricrin (AmLo) identifies a 
high risk AJCC stage IB (AJCC 8th edition) melanoma subgroup. 
With changes in classification of melanoma staging being brought in by the updated 
8th Edition of the AJCC Staging Manual, which comes into effect in January 2018, the 
implications on the prognostic effect of AMLo in accordance with the updated 
guidelines were additionally assessed. A significant change in melanoma staging in 
the 8th edition is the classification of a melanoma as T1a if non-ulcerated and <0.8 mm 
in thickness and T1b if it is 0.8-1.0 mm thick or <0.8 mm with ulceration, with tumour 
mitotic rate additionally being dropped completely as a staging criterion for T1 tumours 
[176]. The implications of this on the present study cohort of melanomas diagnosed as 
AJCC stage I on the basis of the 7th edition of AJCC staging criteria is that a significant 
proportion of tumours given a TNM score of T1a or T1b will fall into the T2a category 
based on the 8th edition guidelines. However, overall, these changes in AJCC staging 
criteria will have minimal impact on the validity of AMLo as a prognostic biomarker for 
AJCC stage I melanoma as the present cohort of T1 – T2a melanoma tumours will still 
fall within AJCC stage I criteria. Nevertheless, given that the JCUH AJCC stage I 
melanoma cohort was derived pre-2006 when mitotic rate was not a factor discerning 
TNM stage T1a (AJCC stage IA) and T1b (AJCC stage IB), adequate information for 
further stratification of tumours into stage IA or IB was lacking for the present study 
biomarker validation. As mitotic rate will no longer be taken into consideration in the 
8th edition AJCC staging criteria, the prognostic impact of AMLo in stage IA melanomas 
defined by the updated guidelines (i.e. melanoma tumours <0.8 mm in thickness) was 
therefore further assessed. 
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Multivariate analysis of 98 tumours with a Breslow thickness of <0.8mm, comparing 
AMLo high risk and low risk scores with DFS using Kaplain-Meier survival analysis, 
demonstrated a significant decrease in DFS between tumours that have been scored 
as AMLo high risk (DFS of 90%) compared to tumours scored as AMLo low risk (DFS 
of 100%). The combined assay of AMLo loss as a prognostic biomarker in AJCC stage 
IA within the JCUH cohort revealed extremely high sensitivity and a NPV of 100%, 
specificity of 90.72 and a PPV of 10% ( Log-Rank (Mantel-Cox) Test P =0.003, HR 
18034 (95% CI 27.8 – 11699018), Figure 3.11). 
Similarly, multivariate analysis of 138 AJCC stage I melanomas within the JCUH cohort 
reclassified as stage IB melanoma subgroup according to the AJCC (8th edition) 
staging criteria, comparing AMLo high risk and low risk scores with DFS, demonstrated 
a highly significant decrease in DFS in high risk tumours (DFS of 81.7%) as compared 
to 98.7% DFS in low risk tumours (Log-Rank (Mantel-Cox) Test P =0.0004, HR 7.981 
(95% CI 2.526 – 25.21), Figure 3.12). The use of combined AMLo analysis in this 
context was associated with an assay sensitivity of 91.7%, specificity of 56.5%, NPV 
of 98.7% and PPV of 15.5%. 
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Figure 3.11: Combined loss of epidermal AMLo expression is a prognostic biomarker in AJCC 
8th edition criteria stage IA melanomas. Kaplan-Meier curve showing % DFS over 8 years of 98 
patients diagnosed with AJCC stage I melanomas  reclassified as AJCC stage  IA according to the 8th 
edition AJCC staging criteria, revealing a significant decrease in DFS from 100% in AMLo low risk 
tumours (black line) to 90% DFS in AMLo high risk (red line) tumours. Use of the combined assay in this 
subgroup resulted in high sensitivity and NPV of 100% and was also highly specific as a prognostic 
biomarker with specificity of 90.72% and a PPV of 10%. Log-Rank (Mantel-Cox) Test P =0.003, HR 
18034 (95% CI 27.8 – 11699018). 
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Figure 3.12: Combined loss of epidermal AMBRA1 and Loricrin (AMLo) identifies a high risk 
AJCC stage IB (AJCC 8th edition) melanoma subgroup. Kaplan-Meier curve showing % DFS over 
8 years of 138 patients diagnosed with AJCC stage I melanomas (JCUH cohort) reclassified as AJCC 
stage IB melanoma, revealing a significant decrease in DFS from 98.7% in tumours scored as AMLo 
high risk  to 81.7% in tumours scored as AMLo low risk. Log-Rank (Mantel-Cox) Test P =0.0004, HR 
7.981 (95% CI 2.526 – 25.21). The combined loss of AMLo.as a prognostic biomarker results in overall 
improved sensitivity of 91.7%, NPV of 98.7% and PPV of 15.1% in AJCC stage IB melanomas. 
 
 
Collectively, these data underpin the prognostic impact of AMLo as a powerful 
prognostic biomarker for AJCC stage IA and IB melanomas classified by the AJCC 8th 
edition staging criteria.
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3.3 Discussion 
 
The current and universally adopted 7th edition AJCC staging system (AJCC 2009) [37] 
provides a relatively accurate means through which to stage melanomas and guide 
some treatment approaches, however, the criteria within this staging system are   
unable to specifically identify those seemingly ‘low risk’ early stage melanomas at the 
highest risk of disease progression. In this case, such tumours are identified after the 
onset of disease progression at which point systemic treatment is required, which 
although increasingly effective, still lacks consistent clinical benefit and is associated 
with high morbidity and mortality and thereby emphasising the acute need for novel 
credible biomarkers to identify high risk tumour subsets and enable earlier patient 
follow up and the implementation of more efficacious personalised treatment. 
The incidence of melanoma is increasing worldwide, which in the UK alone is predicted 
to increase overall by 7% by 2035 [32], with increasing rates of up to 5.5% per year in 
the 20 – 45 year old age group - the 3rd highest internationally [33]. In the UK, up to 
91% of all melanomas are diagnosed at an early stage (stage I or II), each requiring 
follow up between 1 – 5 years however, there is lack of consistent evidence for the 
effectiveness of surveillance in these groups and to date, no internationally accepted 
standardised model of patient follow up [177, 178]. This inadvertently puts an 
increasing burden on already increasing healthcare costs and underpins the demand 
for more accurate biomarkers of genuinely low risk tumours to enable earlier patient 
discharge. 
Prior to biomarker validation studies within the JCUH cohort, results derived from the 
comparison of qualitative visual assessment of AMBRA1 expression with semi-
quantitative staining intensities for expression, validated visual assessment as a robust 
and reliable method for IHC analysis of epidermal AMBRA1 expression levels and 
identified tumours with complete loss of epidermal AMBRA1 expression as a distinct 
high risk subgroup. Adoption of this simple method of visual analysis of epidermal  
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AMBRA1 expression will thus provide a simple and cheap as well as a favourable 
method for pathologists for future utility, over and above other currently used complex 
scoring algorithms in other biomarker studies. 
Confirming preliminary observations leading up to the present validation study of 
AMBRA1 and Loricrin as prognostic biomarkers in AJCC stage I melanoma, results 
derived from multivariate survival curve analysis comparing visual scores of epidermal 
AMBRA1 expression against DFS in the JCUH melanoma cohort, confirmed loss of 
AMBRA1 loss as an independent prognostic biomarker able to predict risk of 
metastasis with reasonable sensitivity and specificity. Similarly, results derived from 
multivariate survival curve analysis comparing visual scores of Loricrin expression 
against DFS also validated Loricrin as a highly sensitive putative prognostic biomarker, 
however its expression alone over lying AJCC stage I melanomas was not highly 
specific, thereby limiting its prognostic impact as a single biomarker. Importantly 
however, when epidermal Loricrin expression was evaluated in combination with loss 
of epidermal AMBRA1 expression (AMLo), the combined assay resulted in improved 
overall sensitivity, specificity and PPV, while retaining a high NPV above the utility of 
either biomarker alone, collectively validating the combined loss of epidermal AMBRA1 
and Loricrin (AMLo) as a novel independent prognostic biomarker for AJCC stage I 
melanomas.  
Despite impending changes in melanoma tumour staging brought about by the 
updated 8th edition AJCC staging criteria (due to be implemented in January 2018), 
overall this will have minimal impact on the results derived from biomarker validation 
studies of AMBRA1 and Loricrin to date, since the study cohorts (both Newcastle 
Hospitals & JCUH) would remain classified as AJCC stage I tumours. However, with 
mitotic rate being omitted completely as a factor discerning TNM stage T1a and T1b 
(T1a distinguishes AJCC stage IA from AJCC stage IB which includes T1b and T2a 
melanomas) in the AJCC 8th edition guidelines, it was possible to further stratify the 
current AJCC stage I melanoma cohort into stage IA and IB in order to evaluate the 
prognostic impact of epidermal AMLo loss in each subgroup. 
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Results derived from multivariate survival curve analysis comparing AMLo high risk 
and low risk scores with DFS in AJCC (8th edition) stage IA melanomas not only 
validated the significant prognostic utility of AMLo scoring in predicting DFS in this 
subgroup in line with the new staging guidelines, but also highlighted an extremely high 
NPV of 100% associated with high sensitivity. Similarly, multivariate survival curve 
analysis comparing AMLo high risk and low risk scores with DFS in AJCC (8th edition) 
stage IB melanomas, demonstrated that epidermal AMLo loss in this subgroup was a 
highly sensitive prognostic biomarker with improved sensitivity, specificity and PPV 
while maintaining a high NPV, compared to the initial analyses in all AJCC stage I 
melanomas without differentiation of stages IA and IB. 
AJCC stage IA and IB melanomas represent the thinnest tumours with the lowest 
associated mortality risk of ~ 14% over 10 years [37]. With low rates of metastases of 
tumours at an early physiological stage development, more stratified follow up 
strategies in these groups would potentially allow the greatest benefit for health 
economics, with some evidence suggesting that patients at the lowest risk of disease 
recurrence may not need intensive clinician follow-up as is generally recommended 
[179]. Currently in the UK, patients diagnosed with AJCC stage IA melanomas are 
followed-up at 3 – 4 monthly intervals for up to a year. However, as these tumours are 
regarded to be at the lowest risk of disease progression, the high NPV afforded by 
AMLo as a prognostic biomarker could translate to the future earlier discharge of 
patients diagnosed with AMLo low risk AJCC stage IA melanomas following surgical 
excision of the primary tumour. Patients diagnosed with stage IB melanomas on the 
other hand, are currently followed up at 3 – 6 monthly intervals for up to 5 years as 
they understandably make up a higher risk group compared to thinner stage IA 
tumours. Within this subgroup, AMLo as a prognostic biomarker may inform on the 
need for closer clinical or radiological surveillance and investigation following primary 
excision in melanomas scored as AMLo high risk and equally, reduce the need for 
frequent and prolonged follow up for melanomas stratified as AMLo low risk. 
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At present, there are no robust validated biomarkers in routine use to guide clinical 
management of AJCC stage I melanomas or predict risk of metastases. DecisionDX 
by Castle Biosciences measures gene signatures of 28 genes on FFPE melanoma 
tissue based on an original data set of 164 patients and validation in 101 with 5 years 
follow up on outcome [88, 89]. The test however, has a 2 – 3 week turnaround and is 
costly at up to $7,918 per test and as a prognostic biomarker only affords an NPV of 
89% [88, 89] compared to AMLo which has a 5 hour test turnaround with an NPV of 
98.7% and estimated cost of £150 pounds per test.  
Overall, results from our biomarker validation studies suggest that going forwards with 
the staging changes brought in by the new 8th edition AJCC guidelines, the combined 
loss of AMLo overlying melanoma tumours as a prognostic biomarker will in fact enable 
prognostic evaluation of both AJCC stage IA and IB melanomas, supporting future 
validation work in a further independent “prospective retrospective” cohort. Completion 
of these studies will hopefully support future adoption of AMLo as a prognostic 
biomarker into NICE guidelines and eventual incorporation as a prognosticator in 
AJCC staging criteria for melanoma, facilitating its use in a wider context. More detailed 
evaluation of the proposed changes however, will be required when the full and 
finalised AJCC 8th edition guidelines are implemented in 2018. 
Given that results from this chapter clearly identifies AMLo as a powerful prognostic 
biomarker enabling the identification of high risk tumour subsets, it is therefore 
important to consider the underlying mechanisms contributing to loss of either protein 
expression and to the loss of epidermal integrity as well as any impact on the loss of 
endothelial integrity, allowing for the identification of a drug-able target for which AMLo 
may serve as a companion biomarker to stratify patients for novel adjuvant therapy. 
These questions are addressed in the subsequent chapter.
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Summary 
 
 Loss of epidermal AMBRA1 expression overlying AJCC stage I melanomas is 
an independent prognostic biomarker identifying a high risk AJCC stage I 
melanoma subgroup; revealed by an assay with relatively high sensitivity but 
less specificity in predicting disease free survival. 
 Loss of epidermal Loricrin expression overlying AJCC stage I melanomas is a 
prognostic biomarker; revealed by an assay with high sensitivity but which lacks 
specificity in predicting disease free survival. 
 The combined loss of epidermal AMBRA1 and Loricrin (AMLo) expression 
overlying tumours is a novel prognostic biomarker for AJCC stage I melanomas 
allowing the identification of high risk tumour subgroups. 
 AMLo as a prognostic biomarker allows evaluation of AJCC stage IA 
melanomas with a very high NPV, which could translate to the future earlier 
discharge of stage IA melanomas scored as AMLo low risk following surgical 
excision of the primary tumour. 
 AMLo as a prognostic biomarker in AJCC stage IB melanomas may inform on 
the need for closer clinical or radiological surveillance and investigation 
following primary excision in tumours scored as AMLo high risk and equally, 
reduce the need for frequent and prolonged follow up for tumours stratified as 
AMLo low risk.
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4.1 Introduction 
Ulceration of a primary melanoma has been defined as an absence of an intact 
epidermis with reactive changes in the skin [70] and is an independent histological 
prognostic marker associated with poor survival [37]. However, the underlying biology 
of ulceration is still unclear and whether it represents the effect of an innately more 
aggressive and metastatic tumour phenotype expanding and breaching the top layers 
of the epidermis, or if ulcerated tumours result from a secretory factor mediating the 
loss of epidermal differentiation, leading to loss of integrity remains undefined.  
Pilot data demonstrating a lack of association between epidermal AMBRA1 levels and 
degree of epidermal tumour invasion raises the possibility of a localised, tumour 
derived secretory process, mediating the loss of epidermal differentiation leading to 
ulceration (Ellis and Lovat, unpublished data). The loss in expression of epidermal 
AMBRA1 or Loricrin overlying melanoma tumours may therefore be key factors leading 
to tumour ulceration and as such, may define a surrogate marker of incipient melanoma 
ulceration that identifies a ‘high risk’ subgroup of patients associated with poorer 
prognosis.  
The preferential benefit of treatment with interferon α-2b seen in ulcerated melanoma 
tumours (demonstrated by the EORTC 18991 and 18952 trials) further supports the 
existence of an underlying tumour secretory process leading to direct effects on the 
surrounding epithelium, contributing to ulceration [72] that is modified in some way by 
interferon-α. Interestingly, interferon α-2b has been shown to modulate TGF-β 
signalling where it enhances the secretion and pro-apoptotic effects of TGF-β1 in pre-
neoplastic liver cells, preventing hepatocellular carcinogenesis [180]. This suggests 
that the paradoxical benefit following treatment with interferon α-2b in ulcerated 
melanoma may also be linked to TGF-β signalling. 
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In melanoma, autonomous activation of the TGF-β pathway has been well documented 
[134, 135] with TGF-β secretion by melanoma cells exerting cytostatic effects in early 
stages but coupled with its effect on the tumour microenvironment, promote tumour 
invasion and progression in advanced stages [127]. These findings are further 
supported by in vitro observations of increased TGF-β2 expression by melanoma cell 
lines compared to normal melanocytes [143] and in vivo studies demonstrating 
increased TGF-β2 expression correlates with tumour thickness and invasiveness [148]  
and that an increase in the secretion of both TGF- β2 and TGF-β3 is associated with 
melanoma progression and metastasis [144-147].  
Preliminary results leading up to the present study demonstrated a significant 
association between increased secretion of isoform specific tumoural TGF-β2 and not 
TGF-β3 expression and the loss of epidermal AMBRA1 expression in all AJCC stage 
melanomas (Ellis and Lovat, unpublished data), suggesting that enhanced tumoural 
TGF-β2 secretion mediates loss of epidermal integrity leading to tumour ulceration. As 
the endothelium of blood and lymphatic vessels represent an epithelial structure like 
the epidermis, this also raises the possibility that enhanced or increased melanoma 
TGF-β2 secretion may mediate the loss of endothelial integrity and provide a route for 
tumour cell entry and subsequent metastasis. To test this hypothesis, the aim of the 
current chapter was to validate the correlation of increased tumoural TGF-β2 and 
decreased AMBRA1 expression in vivo specifically in AJCC stage I melanomas and 
any association with high risk tumours stratified as high or low risk by AMLo expression 
as well as evaluate the specific effect of TGF-β2 on endothelial AMBRA1 and 
endothelial cell junction proteins expression with the ultimate aim of defining a drug-
able novel target to prevent the metastasis of high risk tumour subsets for which AMLo 
may serve as a companion biomarker.
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4.2 Results 
4.2.1 Increased TGF-β2 by AJCC stage I melanomas correlates with the 
decreased expression of epidermal AMBRA1 
Pilot data leading to the present study demonstrated in a cohort of all AJCC stage 
melanomas that loss of epidermal AMBRA1 overlying primary tumours correlated with 
increased tumoural TGF-β2 expression (Ellis and Lovat, unpublished data). To 
evaluate this potential correlation in AJCC stage I melanomas alone, semi quantitative 
analysis of  tumoural TGF-β2 expression in 76 AJCC stage I melanomas derived from 
the present study JCUH cohort was undertaken by automated IHC analysis using DAB 
counterstaining and results compared with epidermal AMLo expression defined in 
chapter 2. 
Results revealed a trend for decreased epidermal AMBRA1 expression with the 
increased expression of tumoural TGF-β2 (Figure 4.1). However, semi-quantitative 
analysis of 76 AJCC stage I melanomas comparing mean percentage tumoural TGF-
β2 staining intensity of each tumour with percentage decrease in epidermal AMBRA1 
staining intensity overlying the same tumour compared with the normal adjacent 
epidermis, revealed no significant correlation between percentage decrease in 
epidermal AMBRA1 expression and increased tumoural TGF-β2 expression (Figure 
4.2).
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Figure 4.1: Visual analysis of the IHC expression of epidermal AMBRA1 and tumoural TGF-β2 in 
AJCC stage I melanomas revealed by DAB counterstaining suggests a potential association 
between loss of epidermal AMBRA1 and increased tumoural TGF-β2. Representative IHC 
photomicrographs of 3 AJCC stage I melanomas (A – C): depicting A (i) maintained, B (i) some loss or 
C (i) complete loss of epidermal AMBRA1 associated with A (ii) lack of, B (ii) some or C (ii) high 
tumoural TGF-β2 expression in the corresponding tumour, revealed by DAB counterstaining (brown). 
Scale bar = 100 μm.
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Figure 4.2: Loss of epidermal AMBRA1 overlying AJCC stage I melanomas does not correlate 
with increased tumoural TGF-β2 expression when compared by IHC using DAB counterstaining. 
Scatter graph of semi-quantitative IHC analyses in 76 AJCC stage I melanomas demonstrating no 
significant correlation between mean % tumoural TGF-β2 expression and mean % decrease in 
epidermal AMBRA1 expression revealed by DAB counter staining.  Each point represents the matched 
mean % positive TGF-β2 staining intensity (derived from 10 fields of vision) against the mean % 
decrease in epidermal AMBRA1 expression overlying the tumour compared with that of the adjacent 
epidermis (derived from 10 fields of vision). 
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Unlike AMBRA1 which is only expressed in the epidermis, one of the main issues faced 
with IHC analysis of tumoural TGF-β2 expression using DAB counterstaining was the 
difficulty in discriminating between melanin staining with that of true TGF-β2 protein 
expression, likely accounting for inconsistent data derived from the semi-quantitative 
analysis (Figure 4.2) and providing a possible explanation for the lack of association 
between increasing tumoural TGF-β2 expression with loss of epidermal AMBRA1 
overlying AJCC stage I melanomas that was observed by visual analysis. To eliminate 
this error, staining of tumoural TGF-β2 expression using VIP counterstaining was 
subsequently undertaken and semi-quantitative analyses repeated and correlated in 
the same way, with epidermal AMBRA1 expression in the same tumour revealed by 
DAB counterstaining. Using this method, both visual (Figure 4.3) and semi-quantitative 
analysis of tumoural TGF-β2  IHC expression revealed by VIP counterstaining in 21 
AJCC stage I melanomas revealed a significant correlation between the mean % 
increase in tumoural TGF-β2 expression and the mean % decrease in epidermal 
AMBRA1 expression (Spearman’s r= 0.711, 95% CI  0.412 – 0.872, P =0.0001, Figure 
4.4).
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Figure 4.3: IHC expression of tumoural TGF-β2 in AJCC stage I melanomas revealed by VIP 
counterstaining. Representative IHC photomicrographs of 3 AJCC stage I melanomas depicting A (i) 
maintained, B (i) partial loss or C (i) complete loss of epidermal AMBRA1 expression revealed by DAB 
counterstain (brown) and corresponding tumoural TGF-β2 basal expression levels showing A (iii) 
absent B (iii) some or C (iii) increased TGF-β2 positive staining revealed by VIP counterstaining (pink) 
compared with matched negative controls A – C (ii) in the absence of TGF- β2 primary antibody. Scale 
bar = 100 μm.
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Figure 4.4: Loss of epidermal AMBRA1 overlying AJCC stage I melanomas correlates with 
increased tumoural TGF-β2 expression revealed by VIP counterstaining. Scatter graph of semi-
quantitative IHC analyses in 21 AJCC stage I melanomas demonstrating a positive correlation between 
mean % tumoural TGF-β2 expression revealed by VIP counterstaining and mean % decrease in 
epidermal AMBRA1 expression revealed by DAB counterstaining.  Each point represents the matched 
mean positive TGF-β2 staining intensity (derived from 10 fields of vision) against the mean % decrease 
in epidermal AMBRA1 staining intensity overlying the tumour compared with that of the normal adjacent 
epidermis (derived from 10 fields of vision). Spearman’s r= 0.711, 95% CI 0.412 – 0.872, P =0.0001).
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4.2.2 High Risk AJCC stage I melanomas are associated with increased 
tumoural TGF-β2 
To test the hypothesis that high risk AJCC stage I melanomas at risk of developing 
metastases display increased expression of tumoural TGF-β2, correlation of the 
combined loss of epidermal AMBRA1 and Loricrin expression (AMLo) with tumoural 
TGF-β2 expression in AJCC stage I melanomas was assessed. Given that IHC 
staining for AMBRA1 and Loricrin in the JCUH study cohort was performed using DAB 
counterstaining on the Ventana automated platform, IHC staining for TGF-β2 
expression was once again performed using this method in attempt to standardise the 
semi-quantitative analysis and correlation of tumoural TGF-β2 with epidermal 
AMBRA1 and Loricrin loss. To eliminate the issue associated with difficulty in 
discerning between true TGF-β2 staining with that of melanin, FFPE melanoma tumour 
sections were bleached prior to IHC staining for TGF-β2 with DAB counterstaining on 
the Ventana platform as described in section 2.10.2. 
Qualitative visual analysis of 29 AJCC stage I melanomas using this methodology 
revealed a trend for increased tumoural TGF-β2 staining intensity in tumours that 
subsequently developed metastatic disease compared to tumours that remained 
localised (example indicated by Figure 4.5). This observation was further supported by 
semi-quantitative analysis of mean percentage tumoural TGF-β2 in 10 AJCC stage I 
melanomas that subsequently developed metastasis (Mean 63.8 ± 2.497 SEM) with 
mean percentage tumoural TGF-β2 expression in 19 tumours that remained localised, 
revealing significantly increased TGF-β2 expression by the high risk tumour subset 
(Mean 50.68 ± 2.943 SEM; Unpaired t test **P =0.007, 95% CI (3.959 – 22.27), Figure 
4.6).
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Figure 4.5: TGF-β2 expression (revealed following bleaching and automated IHC analysis with 
DAB counterstaining) is increased in high risk AJCC stage 1 melanomas. Representative IHC 
photomicrographs of tumoural TGF-β2 basal expression expression (revealed by DAB counterstaining) 
in bleached AJCC stage I melanoma tumour sections depicting A increased tumoural TGF-β2 
expression in a tumour that subsequently metastasised compared to B reduced tumoural TGF-β2 
expression in a tumour that remained localised. Upper margin of tumour bulk indicated by red arrows. 
Scale bar =100 μm. 
 
In addition, semi-quantitative analysis of the mean percentage tumoural TGF-β2 
expression levels in these 29 tumours AJCC stage I melanomas demonstrated a 
significant increase in the mean percentage tumoural expression of TGF-β2 by 
tumours stratified as high risk by AMLo analysis (Mean % 59.52 ± 2.44 SEM) compared 
with those stratified as AMLo low risk (Mean % 49.1 ± 4.14; Unpaired t test *P =0.02, 
95% CI (1.136-19.7), Figure 4.7). Collectively, these results suggest that high risk 
AJCC stage I melanoma tumours that go on to develop metastasis have increased 
basal expression levels of TGF-β2 for which the loss of epidermal AMLo is a predictive 
biomarker. 
 
Chapter 4: Melanoma secretion of TGF-β2 mediates the down regulation of 
epidermal and endothelial integrity 
 137  
 
 
 
 
 
 
 
 
Figure 4.6: Tumoural TGF-β2 
expression is increased in AJCC 
stage I melanomas that developed 
metastatic disease compared to 
localised tumours. Scatter graph 
representing the mean % tumoural 
TGF-β2 expression in 19 primary 
AJCC stage I melanomas that 
remained localised compared to 
expression in 10 melanomas that 
eventually developed metastases. 
Each point is the mean % tumoural 
TGF-β2 staining intensity from 5 fields 
of vision. Horizontal bars represent 
the mean % tumoural TGF-β2 staining 
intensity for each group ± SEM 
demonstrating significantly higher 
mean % tumoural TGF-β2 expression 
in AJCC stage I melanomas that 
develop metastases. Unpaired t test 
**P =0.007, 95% CI (3.959 – 22.27).
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Figure 4.7: High  risk AJCC stage I melanomas stratified by AMLo display significantly increased 
TGF-β2 expression compared to AMLo low risk tumours. Scatter graph representing the mean % 
tumoural TGF-β2 expression in 12 primary AJCC stage I melanomas stratified as AMLo low risk 
compared to expression in 17 AMLo high risk tumours. Each point is the mean % tumoural TGF-β2 
staining intensity derived from 5 fields of vision. Horizontal bars represent the mean % tumoural TGF-
β2 staining intensity for each group ± SEM demonstrating significantly higher mean % tumoural TGF-
β2 expression in AMLo high risk AJCC stage I melanomas. Unpaired t test *P =0.02, 95% CI (1.136 – 
19.7).
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4.2.3 TGF-β2 induces the down regulation of calcium-induced differentiation of 
primary keratinocytes 
Preliminary data leading up to the present study demonstrated the integral role of 
AMBRA1 in epidermal differentiation, with expression in vivo increasing in line with 
keratinocyte differentiation from the basal layer to the stratum corneum, and which in 
in vitro studies of calcium-induced differentiation of primary keratinocytes is reflected 
by a concurrent increase in the terminal differentiation marker Loricrin (Ellis and Lovat, 
unpublished data). In addition, the lack of association between AMBRA1 expression 
and epidermal tumour invasion in the presence of epidermal hyperplasia suggests the 
presence of an underlying chronic, tumour secretory process (Ellis and Lovat, 
unpublished data). These findings coupled with the preferential benefit of interferon-α 
treatment seen in ulcerated tumours [72, 73] and studies demonstrating that increased 
secretion of TGF-β2 is associated with melanoma progression and metastasis [144-
147] led to the hypothesis that melanoma secretion of TGF-β2 leads to epidermal 
AMBRA1 down regulation and in turn, loss of epidermal integrity and tumour ulceration, 
conferring a worse prognosis. 
To test this hypothesis, primary keratinocytes were subjected to calcium-induced 
differentiation by culture for 5 days in high calcium medium (1.3 mM Calcium Chloride) 
in the presence or absence of 0.3, 1 or 10 ng/ml recombinant TGF-β2 or an equal 
volume of vehicle control (4 mM Hcl + 0.1% BSA), prior to western blotting for the 
expression of AMBRA1, Loricrin and β-Actin as a loading control. Results 
demonstrated increased expression of both AMBRA1 and Loricrin following 5 days 
culture of primary keratinocytes in medium with high calcium (Figure 4.8). However, 
culture for 5 days in high calcium media in the presence of recombinant TGF-β2 
resulted in the dose dependent down regulation of both AMBRA1 and Loricin (Figure 
4.8), collectively suggesting TGF-β2 secretion by melanoma cells leads to 
dysregulated differentiation and epidermal ulceration in ‘high risk’ tumours,  associated 
with poorer prognosis.  
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Figure 4.8: TGF-β2 mediates the down regulation of AMBRA1 and Loricrin in calcium-induced 
differentiated primary keratinocytes. Representative western blot for the expression of AMBRA1 (132 
kDA), Loricrin (35 kDA) or β-Actin loading control (45 kDA) in primary keratinocytes in which 
differentiation was induced by culture in high calcium medium (1.3 mM Calcium Chloride) in the 
presence or absence of either 0.3, 1.0 or 10.0 ng/ml of human recombinant TGF-β2 or vehicle control 
over 5 days. 
 
 
In the management of malignant melanoma however, as the whole tumour along with 
the overlying epidermis is removed at the time of primary excision, the potential effects 
of tumoural secretion of TGF-β2 are more pertinent to endothelial and endo-lymphatic 
integrity, disruption of which provides a route for subsequent tumour invasion and 
metastasis. Subsequent studies were therefore focused towards evaluating the impact 
of TGF-β2 secretion by primary melanomas on endothelial integrity.
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4.2.4 TGF-β2 induces the down regulation of AMBRA1 and junctional proteins 
in endothelial cells 
Since the epidermis is an epithelial structure, the morphological changes that occur in 
the epidermis brought about by melanoma TGF-β2 secretion that lead to deregulated 
epidermal differentiation and ulceration are similarly, likely to occur in the surrounding 
endothelium. To test the hypothesis that TGF-β2 secretion by melanomas cells 
mediates down regulation of AMBRA1 and vascular endothelial integrity, model 
HUVEC endothelial cells were first cultured in the presence or absence of 10 ng/ml 
recombinant TGF-β2 for 24, 48 and 72 hours prior to the analysis of AMBRA1 and 
endothelial junctional proteins Claudin-5 and VE-Cadherin expression by western 
blotting. Results demonstrated the time dependent down regulation of AMBRA1 and 
Claudin-5 (Figure 4.9 A), with significant down regulation of AMBRA1 observed 
following 48 and 72 hours culture in the presence 10 ng/ml recombinant TGF-β2 
compared to expression in vehicle treated control HUVEC cells (One way ANOVA with 
Dunnett’s post-test correction *P <0.02, **P <0.001, Figure 4.9 B)  and significant down 
regulation of Claudin-5 observed after 48 and 72 hours culture in the presence of 
recombinant TGF-β2 (One way ANOVA with Dunnett’s post-test correction ***P 
<0.0001, Figure 4.9 D).  A similar trend for time-dependent TGF-β2-induced down 
regulation of VE Cadherin was also observed (Figure 4.9 A and C), however this effect 
across 3 independent experiments was not significant.
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Figure 4.9: TGF-β2 induces the down regulation of AMBRA1 and junctional protein expression 
in HUVEC endothelial cells. A Representative western blot for the expression of AMBRA1 (132 kDA), 
VE-Cadherin (115 kDA), Claudin-5 (24 kDA) and β-Actin (42 kDA) loading control in HUVEC cells 
following culture in the absence (Ctrl) or presence of 10 ng/ml recombinant TGF-β2 for 24, 48 and 72 
hours. B Relative protein expression (quantified by densitometry) of AMBRA1, C VE-Cadherin or D 
Claudin-5 normalised to β-Actin and expressed relative to the mean protein/β-Actin value for each 
experiment, following treatment of HUVECs for 24, 48 and 72 hours with 10 ng/ml recombinant TGF-
β2. Each bar represents the mean ± SD of 3 replicate experiments. One way ANOVA with Dunnett’s 
post-test correction *P <0.02, ***P <0.001. 
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To further evaluate the potential for TGF-β2-mediated down-regulation of endothelial 
AMBRA1 and junctional proteins and the impact of melanoma secretion of TGF-β2 on 
the endothelial integrity, identical experiments were performed in primary human 
dermal lympathic endothelial cells to more accurately represent an in vivo setting.  
Isolation of primary human dermal endothelial cells (HDEC) from the dermis of 
redundant adult foreskin samples was initially attempted using an endothelial cell 
specific EN4 antibody as described in section 2.3.1. However, use of this method 
resulted in very low endothelial cell yield in which selected cells failed to expand or 
achieve confluency despite 21 days of culture. Furthermore, analysis of selected 
endothelial cell populations following 21 days subsequent culture in endothelial specific 
culture media revealed significant fibroblast contamination (Figure 4.10). 
 
 
Figure 4.10: Isolation of human dermal endothelial cells from human foreskin samples using EN4 
antibody coated wells results in mixed dermal endothelial cell and fibroblast subpopulations. 
Representative photomicrographs of EN4 endothelial cell antibody selected primary dermal 
subpopulations following 21 days culture and depicting two distinct cell colonies of A dermal 
microvascular endothelial cells that grow in pebble-patterned circular colonies and B dermal fibroblasts 
that grow as spindle-shaped clusters. Scale bar =50 μm.
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Isolation of primary human HDECs was also attempted using human Phycoerythrin 
(PE) anti CD31 antibody with Miltenyi Biotech magnetic columns as described in 
section 2.3.2. Using this method of endothelial cell selection resulted in culture of 
relatively pure endothelial cell colonies at passage 1 that grew in circular clusters and 
expanded to achieve confluency after 21 days of culture. At day 14 of culture however, 
there was once again evidence of fibroblast contamination that rapidly expanded to 
form independent colonies at day 21 (Figure 4.11). 
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Figure 4.11: Isolation of human dermal endothelial cells from donor foreskin samples using 
human PE anti CD31 antibody with Miltenyi Biotech magnetic columns results in a mixed colony 
of dermal endothelial cells and fibroblasts. Representative photomicrographs of A an initial mixed 
colony of dermal endothelial cells and fibroblasts derived from a donor foreskin sample at passage 0, or 
dermal endothelial cells after anti CD31 cell selection (passage 1) following B 7 days, C 14 days or D 
21 days of culture and depicting the increasing presence of contaminating fibroblasts after E 14 days or 
F 21 days of maintained culture. Black arrows indicate fibroblasts. Scale bar =100 μm. 
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Due to the inability to isolate and culture pure populations of primary dermal endothelial 
cells, human dermal lymphatic endothelial cells (HDLEC) isolated from juvenile 
foreskin were subsequently obtained from PromoCell as detailed in section 2.1.2 in 
order to determine the impact of melanoma TGF-β2 secretion on primary endothelial 
AMBRA1 and endothelial junctional protein expression. Dermal lymphatic endothelial 
cells were chosen over dermal microvascular endothelial cells as in an in vivo setting, 
the lymphatics represent one of the earliest potential points for tumour cell entry with 
metastases from melanoma most commonly first presenting at regional lymph nodes 
[181].  
To test the hypothesis that TGF-β2 secretion by melanoma tumour cells mediates 
down regulation of AMBRA1 resulting in loss of lymphatic endothelium integrity, 
HDLECs were treated with 10 ng/ml recombinant TGF-β2 for 24, 48 and 72 hours prior 
to the analysis of AMBRA1 and Claudin-5 expression by western blotting. As with the 
observed results in studies in HUVEC cells, results demonstrated significant TGF-β2-
induced down regulation of AMBRA1 and Claudin-5 following 72 hours culture of 
HDLECs in the presence of 10 ng/ml recombinant TGF-β2 compared to expression in 
vehicle treated control HDLECs (Unpaired t Test *P <0.04 AMBRA1, **P <0.001 
Claudin-5, Figure 4.12). 
Collectively, these results suggest that melanoma secretion of TGF-β2 induces the 
down regulation of endothelial AMBRA1 and endothelial junctional protein expression 
thereby facilitating tumour metastasis by disrupting vascular and lymphatic 
endothelium integrity, leading to alterations in barrier function and the creation of an 
entry point for tumour cells into the wider circulation. 
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Figure 4.12: TGF-β2 induces the down regulation of AMBRA1 and Claudin-5 in primary HDLECs. 
Relative protein expression (quantified by densitometry) of A AMBRA1 and B Claudin-5 normalised to 
β-Actin and expressed relative to the mean protein/β-Actin value for each experiment, following 
treatment of HDLECs for 72 hours with 10 ng/ml recombinant TGF-β2. Each bar represents the mean 
± SD of 3 replicate experiments. Unpaired t Test  *P <0.04 (AMBRA1), ***P <0.001 (Claudin-5). C 
Representative western blot for the expression of AMBRA1 (132 kDA), Claudin-5 (24 kDA) and β-Actin 
(42 kDA) loading control in HDLECs following treatment with 10 ng/ml recombinant TGF-β2 for 72 hours 
or an equal volume of vehicle control for 72 hours in control no treatment cells.
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4.2.5 Knockdown of TGF-β2 in metastatic melanoma cell lines prevents TGF-
β2-induced down regulation of AMBRA1 and Claudin-5 in endothelial cells 
Preliminary data leading up to the present study also demonstrated the increased 
expression of TGF-β2 mRNA as well as increased secretion of TGF-β2 by metastatic 
melanoma cell lines SK-Mel-28, A375 and MeWo (Lovat et al, unpublished data). To 
test the hypothesis that metastatic melanoma secretion of TGF-β2 results in the down 
regulation of endothelial AMBRA1 and endothelial junctional proteins, HUVEC cells 
were subjected to culture with supernatants derived from A375 melanoma cells 
previously stably transfected with control (A375 shControl) or supernatants derived 
from A735 melanoma cells where TGF-β2 has been stably knocked down (A375 
shTGF-β2), prior to western blotting for AMBRA1 and Claudin-5. 
As HUVEC cells require culture only in complete ECCM whereas A375 melanoma cells 
are routinely maintained in DMEM, supernatants derived from A375 shControl and 
A375 shTGF-β2 melanoma cells used to treat HUVEC cells would need to consist of 
complete ECCM. As such, prior to the treatment of HUVECs with A375 melanoma cell 
supernatants subjected to TGF-β2 modulation, the cell viability of A375 shControl and 
shTGF-β2 melanoma cells cultured in complete ECCM was initially compared with the 
cell viability of cells cultured in complete DMEM, by manual cell counting following 
culture in either cell media for 72 hrs. 
Results confirmed no significant difference between the cell viability of either cell line 
cultured in either ECCM or DMEM (Figure 4.13) and hence for all subsequent 
experiments comparing the effect of A375 shControl or A375 shTGF-β2 melanoma 
supernatants on endothelial AMBRA1 or junctional protein expression, both melanoma 
cell lines were cultured in complete ECCM prior to collection and use of supernatants 
to treat HUVEC or HDLECs. 
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Figure 4.13: Culture of A375 cells subjected to TGFβ2 modulation in either complete ECCM or 
DMEM has no effect on cell viability. Cell viability of A A375 shControl or B shTGF-β2 melanoma 
cells following growth in ECCM or DMEM for 24, 48 and 72 hours. Each bar is the mean of 3 replicate 
experiments ± SD. 
 
 
To assess the effect of modulating TGFB 2 expression in melanoma cells on 
endothelial AMBRA1 and junctional protein expression, HUVEC cells were first 
subjected to culture for 72 hours in either complete ECCM or supernatants derived 
from A375 shControl or A375 shTGF-β2 melanoma cells prior to western blot analysis 
for the expression of AMBRA1and Claudin-5. Where control A375 melanoma cell 
supernatants were used as culture media, media changes were conducted daily to 
account for depleted nutrient content. Results demonstrated the significant down 
regulation of both AMBRA1 and Claudin-5, following culture in TGF-β2-rich A375 
melanoma supernatant (One way ANOVA with Dunnett’s post-test correction, ***P 
=0.001 for AMBRA1 (Figure 4.14 A and B), and  **P <0.01 for Claudin-5 (Figure 4.14 
A and C) and partial rescue of TGF-β2-induced AMBRA1 and Claudin-5 down 
regulation (Figure 4.14 B & C) in HUVEC cells subjected to culture in TGF-β2 depleted 
A375 melanoma supernatants. 
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Figure 4.14: Treatment of HUVEC cells with TGF-β2-depleted melanoma supernatants derived 
from A375 melanoma cells with stable TGF-β2 knockdown prevents TGF-β2 induced down 
regulation of AMBRA1 and Claudin-5. A Representative western blot for the expression of AMBRA1 
(132 kDA), Claudin-5 (24 kDA) or β-Actin (42 kDA) loading control in HUVECs cultured in ECCM vehicle 
control or HUVECs following culture for 72 hours in supernatants derived from A375 shControl (A375 
shCtrl sup) or A375 shTGF-β2 (A375 shTGF-β2 sup) melanoma cells. B Relative protein expression 
(quantified by densitometry) of AMBRA1 and C Claudin-5 normalised to β-Actin and expressed relative 
to the mean protein/β-Actin value for each experiment, following culture of HUVECs for 72 hours in 
ECCM (vehicle control) or supernatants derived from A375 shControl or A375 shTGF-β2 melanoma 
cells. Each bar represents the mean ± SD of 3 replicate experiments. One way ANOVA with Dunnett’s 
post-test correction ***P =0.001 (AMBRA1), **P <0.01 (Claudin-5).
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To test whether melanoma TGF-β2 mediated down regulation of AMBRA1 and 
junctional protein expression may also be prevented in primary human dermal 
lymphatic endothelial cells by modulation of TGF-β2 expression in melanoma cells, 
HDLECs were also subjected to culture for 72 hours in supernatants derived from A375 
shControl or shTGF-β2 melanoma cells, prior to western blot analysis of AMBRA1 and 
Claudin-5 expression. Results clearly demonstrated the significant down regulation of 
AMBRA1 in HDLECs following culture for 72 hours in TGF-β2-rich A375 shControl 
melanoma supernatant (One way ANOVA with Dunnett’s post-test correction **P 
<0.01, ***P <0.001, Figure 4.15 A and B), with partial rescue of TGF-β2-induced 
AMBRA1 down regulation also observed after 72 hrs culture TGF-β2-depleted A375 
shTGF-β2 melanoma supernatant (Figure 4.15 A & B). Similarly, results demonstrated 
a trend for the down regulation of Claudin-5 expression following culture of HDLECs 
for 72 hours in TGF-β2-rich A375 melanoma supernatant, with again an observed 
partial rescue of Claudin-5 expression in HDLECs cultured in supernatants derived 
from A375 melanoma cells previously subjected to stable knockdown of TGF-β2 
(Figure 4.15 A & C). 
Collectively, these data suggest that blockade of TGF-β2 secretion by melanoma cells 
may prevent the down regulation of AMBRA1 and Claudin-5 in both vascular and 
lymphatic endothelium. The partial rescue of AMBRA1 and Claudin-5 observed in 
HUVEC cells and HDLECs could be attributed to sub-complete TGF-β2 short hairpin 
RNA knockdown of the A375 melanoma cell clone used to derive the treatment 
supernatant (65-70% TGF-β2 knockdown confirmed by qPCR; Lovat et al, unpublished 
data), where the melanoma cells may still retain some residual TGF-β2 secreting 
function. 
 
 
 
 
  
Chapter 4: Melanoma secretion of TGF-β2 mediates the down regulation of 
epidermal and endothelial integrity 
 152  
 
 
 
 
Figure 4.15: Knockdown of TGF-β2 in melanoma cells inhibits TGF-β2 –mediated down 
regulation of AMBRA1 and Claudin-5 in primary HDLECs. A Representative western blot for 
expression of AMBRA1 (132 kDA), Claudin-5 (24 kDA) or β-Actin (42 kDA) loading control in control 
HDLECs (cultured for 72 hours in complete ECCM vehicle control) or HDLECs following culture for 72 
hours in supernatants derived from A375 shControl or A375 shTGF-β2 melanoma cells. B Relative 
protein expression of AMBRA1 and C Claudin-5 in HDLECs quantified by densitometry (normalised to 
β-Actin loading control and expressed relative to the mean protein/β-Actin value for each experiment), 
following culture for 72 hours in ECCM (vehicle control) or supernatants derived from A375 shControl 
or A375 shTGF-β2 melanoma cells. Each bar represents the mean ± SD of 3 replicate experiments. 
One way ANOVA with Dunnett’s post-test correction **P <0.01, ***P <0.001 (AMBRA1).
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4.2.6 Loss of endothelial AMBRA1 is associated with high risk AJCC stage I 
melanomas 
Data in this chapter so far has shown that AJCC stage I melanomas at high risk of 
metastases express or secrete higher levels of isoform specific TGF-β2 and that TGF-
β2 secretion by melanoma cells induces the down regulation of AMBRA1 and 
endothelial junctional protein expression in vitro; an effect that was partially rescued 
with by blockade of melanoma TGF-β2. 
To investigate if endothelial AMBRA1 is concurrently decreased in the melanoma 
microenvironment of tumours in which AMBRA1 expression in the overlying epidermis 
is lost, immunofluorescence (IF) analysis for the dual expression of endothelial 
AMBRA1 and CD31 (an endothelial cell marker expressed by both vascular and 
lymphatic endothelial cells) was undertaken in FFPE AJCC stage I tumour sections. 
Pre-assay optimisation was performed using FFPE sections of HUVEC cell pellets, 
where clear dual expression of AMBRA1 (red) and CD31 (green) was visualised, with 
DAPI as a stain for cell nuclei (blue) (Figure 4.16). 
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Figure 4.16: Dual immunofluorescence (IF) expression of AMBRA1 and CD31 in HUVEC 
endothelial cells. Representative images for the IF expression of DAPI (cell nuclei, blue) in the absence 
of CD31 or AMBRA1 primary antibody (A & B) and C dual expression of AMBRA1 (red) and CD31 
(green) with DAPI in HUVEC cells. Scale bar =23 μm. 
 
 
Subsequent dual IF analysis of AMBRA1 and CD31 expression in AJCC stage I 
melanomas with known maintained expression of epidermal AMBRA1, revealed partial 
maintenance of peri-tumoural endothelial AMBRA1 expression with maintained 
expression of epidermal AMBRA1 (Figure 4.17 A – B). Moreover, dual IF analysis in 
an AJCC stage I melanoma with known loss of epidermal AMBRA1 expression 
revealed concurrent loss of AMBRA1 expression in both the epidermis and 
endothelium (Figure 4.17 C – D). These preliminary findings thus support the 
hypothesis that melanoma TGF-β2-mediated down regulation of epidermal AMBRA1 
is associated with concurrent loss of endothelial AMBRA1 in the tumour 
microenvironment. 
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Figure 4.17: Loss of epidermal AMBRA1 overlying AJCC Stage I melanomas is associated with 
a concurrent loss in endothelial AMBRA1. Representative images for the IF expression of AMBRA1 
(red), CD31 (green) or DAPI (cell nuclei, blue) in the A endothelium or B epidermis of an AJCC stage I 
melanoma with known epidermal AMBRA1 loss; or in the C endothelium or D epidermis of an AJCC 
stage I melanoma with known maintained expression of epidermal AMBRA1. Scale bar =23μm. 
 
To further confirm these findings and test the hypothesis that loss of endothelial 
AMBRA1 expression is associated with high risk AJCC stage I melanomas, IHC 
analysis of peri-tumoural endothelial AMBRA1 and CD31 expression (revealed by DAB 
counterstaining on the Ventana automated platform) was undertaken in 15 primary 
AJCC stage I melanomas; 4 with known maintained epidermal AMBRA1 expression 
and 11 in which epidermal AMBRA1 expression was known to be completely lost. 
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Results revealed that peri-tumoural endothelial expression of AMBRA1 was 
maintained in all 4 melanomas in which epidermal AMBRA1 was maintained (Table 
4.1), suggesting a trend for maintenance of peri-tumoural endothelial AMBRA1 where 
epidermal AMBRA1 expression overlying the tumour is maintained (Figure 4.18 A – 
C). Conversely, in 11 melanomas with complete loss of epidermal AMBRA1 
expression, 7 had concurrent loss of peri-tumoural endothelial AMBRA1 expression 
(Figure 4.18 G – I) while peri-tumoural endothelial AMBRA1 expression was 
maintained in 4 (Figure 4.18 D – F), also suggesting a trend for loss of peri-tumoural 
endothelial AMBRA1 where epidermal AMBRA1 expression is completely lost (Table 
4.1). Interestingly, 6 of the 7 tumours with concurrent loss of epidermal and endothelial 
AMBRA1 expression eventually developed metastases, whereas all 8 tumours in 
which peri-tumoural endothelial AMBRA1 expression was maintained, regardless of 
epidermal AMBRA1 expression, did not metastasise (Table 4.1).  
When further stratifying these 15 AJCC stage I melanomas into high or low risk 
subgroups according to the combined epidermal expression of AMBRA1 and Loricrin 
(AMLo), all 4 tumours with concurrent maintenance of epidermal and endothelial 
AMBRA1 expression fell within the AMLo low risk category (Table 4.1). These data 
suggest that concurrent maintenance of epidermal AMBRA1 expression and 
endothelial AMBRA1 expression in the tumour microenvironment of AJCC stage I 
melanomas correlates with AMLo low risk scores and define a subgroup at low risk of 
developing metastases.  
Similarly, all 7 melanomas with concurrent complete loss of epidermal AMBRA1 and 
peri-tumoural endothelial AMBRA1 expression fell within the AMLo high risk category, 
of which 6 developed metastases (Table 4.1), suggesting that concurrent loss of 
epidermal and peri-tumoural endothelial AMBRA1 expression defines a subgroup at 
high risk of metastases for which AMLo is a biomarker. Interestingly, 4 melanomas with 
complete loss of epidermal AMBRA1 expression but maintained peri-tumoural 
endothelial AMBRA1 expression also fell within the AMLo high risk category despite 
not developing metastases, supporting the hypothesis that endothelial integrity is key  
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in preventing melanoma metastasis and may explain why not all tumours with complete 
loss of epidermal AMBRA1 or scored as AMLo high risk develop metastases.   
 
 
 
Table 4.1: Stratification of 15 AJCC stage I melanomas with known epidermal AMBRA1 status 
according to peri-tumoural endothelial AMBRA1 status, associated AMLo score and eventual 
outcome.
AJCC stage I 
melanomas 
Epidermal AMBRA1 
maintained (n=4) 
Epidermal AMBRA1 completely lost (n=11) 
AMLo Low Risk AMLo Low Risk AMLo High Risk 
Peri-tumoural 
endothelial 
AMBRA1 
Maintained Lost Maintained Lost Maintained Lost 
Non Metastatic 
tumours 
4 0 0 0 4 1 
Metastatic 
tumours 
0 0 0 0 0 6 
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Figure 4.18: Endothelial AMBRA1 expression is lost in metastatic AJCC stage I melanomas 
stratified as high risk by AMLo scoring. Representative photomicrographs of A – F (i) endothelial 
AMBRA1 expression (brown staining) with A – F (ii) corresponding CD31 expression (brown staining 
highlighting the endothelium) in 3 AMLo low risk AJCC stage I melanoma tumours with maintained 
epidermal AMBRA1 (A – C), 3 AMLo high risk tumours with complete loss of epidermal AMBRA1 that 
did not metastasise (D – F) and 3 AMLo high risk tumours with complete loss of epidermal AMBRA1 
that developed metastasis (G – I). Scale bar = 100 μm. 
 
Collectively, these results suggest that TGF-β2 secretion by high risk AJCC stage I 
melanomas leads to down regulation of epidermal AMBRA1 expression in the 
overlying tumour epidermis as well as a trend for concurrent down regulation of 
endothelial AMBRA1 and junctional proteins, leading to loss of endothelial integrity and 
a higher risk of tumour metastases. In addition results demonstrate AJCC stage I 
tumours that retain endothelial AMBRA1 expression, regardless whether epidermal 
AMBRA1 expression is lost or maintained, are associated with a low risk of 
metastases; suggesting the existence of idiosyncratic factors exhibited by such 
tumours that are protective against the pro-metastatic effect of TGF-β2 on the 
endothelium in the tumour microenvironment. 
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4.3 Discussion 
 
Presence of ulceration of a primary melanoma is an independent histological 
prognostic biomarker associated with poor survival [37]. Despite the poorly understood 
underlying biology of this association, the preferential benefit of treatment with 
interferon-α seen in ulcerated melanomas [72], support an underlying tumour secretory 
process having a direct effect on ulceration that is modified in some way by interferon-
α. Interestingly, crosstalk between interferon-α and TGF-β signalling has been 
described by studies showing that interferon-α antagonises TGF-β/Smad-dependent 
hepatic fibrosis in mice [182] as well as enhances the secretion and pro-apoptotic 
effects of TGF-β1 in pre-neoplastic liver cells, preventing hepatocellular 
carcinogenesis [180]. This raises the possibility that ulceration in melanoma may be 
linked to TGF-β signalling. 
Certainly in melanoma,  the dual role of TGF-β in tumorigenesis has been well 
documented with TGF-β secretion by melanoma cells exerting tumour suppressive 
effects in early stages but promoting tumour invasion and metastasis in advanced 
stages [127]. Moreover, the isoform specific increased secretion of TGF-β2 has been 
widely reported to be associated with melanoma progression and confers a worse 
prognosis [144, 145, 147, 148].  
Data from chapter 3 demonstrating the loss of AMBRA1 expression in the epidermis 
overlying primary AJCC stage I melanomas at high risk of metastases, taken together 
with preliminary data linking this association to an increase in melanoma secretion of 
isoform specific TGF-β2, raises the possibility that melanoma TGF-β2 secretion may 
contribute directly to the down regulation of epidermal AMBRA1, leading to loss of 
epidermal integrity and ulceration of a higher risk tumour.  
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Results from the present chapter incorporating analysis of an independent cohort of 
AJCC stage I melanomas derived from the James Cook University Hospital, 
Middlesbrough confirmed the correlation between loss of AMBRA1 expression 
overlying primary AJCC stage I melanomas with increased tumoural expression of 
TGF-β2. In addition, AJCC stage I melanomas with increased TGF-β2 expression 
correlated with high risk AMLo scores and were associated with a higher risk of 
metastases compared to tumours that remained localised. In addition, results 
demonstrating TGF-β2 mediated down-regulation of AMBRA1 and Loricrin in primary 
keratinocytes, further support the hypothesis that increased melanoma secretion of 
TGF-β2 leads to the disrupted epidermal differentiation leading to loss of epidermal 
integrity and tumour ulceration, conferring a worse prognosis, of which the combined 
loss of epidermal AMLo expression is a surrogate marker. 
As the epidermis is an epithelial structure, the morphological changes that occur in the 
epidermis brought about by tumoural TGF-β2 secretion leading to dysregulated 
epidermal differentiation and ulceration are also likely to occur in the endothelium. In 
addition, TGF-β2 has been also shown to modify the tumour microenvironment via 
endothelial-mesenchymal transition (EndoMT) in which endothelial cells lose 
expression of endothelial markers and acquire an invasive phenotype [183, 184]. 
Supporting the pro-tumorigenic role of TGF-β2 in melanoma progression and 
metastases, results from the present chapter demonstrated treatment of HUVEC 
endothelial cells or primary HDLECs with exogenous TGF-β2 induced the down 
regulation of AMBRA1 and junctional protein expression. To closer represent an in vivo 
setting and test the potential of metastatic melanoma TGF-β2 secretion in disrupting 
endothelial integrity, HUVEC cells and primary HDLECs were subjected to culture in 
supernatants derived from the metastatic melanoma cell line A375 known to secrete 
high levels of TGF-β2 or supernatants derived from A375 melanoma cells in which 
TGF-β2 had been stably knocked down. Results highlighted the significant down 
regulation of AMBRA1 and Claudin-5 in HUVECs, with significant down regulation of  
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AMBRA1 and a trend for down regulation of Claudin-5 in primary HDLECs cultured in 
TGF-β2 rich A375 melanoma cell supernatant; an effect that was partially reversed by 
culture in supernatant of A375 melanoma cells in which TGF-β2 has been knocked 
down. Collectively, these data suggest that melanoma secretion of TGF-β2 leads to 
loss of endothelial integrity by disrupting endothelial differentiation with down 
regulation of key cell junctional proteins, thereby facilitating a potential route for tumour 
cell entry and subsequent metastasis, a process that may be prevented by blockade 
of TGF-β2 signalling. 
Finally, analysis of AMBRA1 expression using CD31 as a marker of endothelial cells 
in the peri-tumoural endothelium of AJCC stage I melanomas revealed a trend for the 
concurrent loss of endothelial AMBRA1 where epidermal expression of AMBRA1 
overlying the primary tumour was lost, particularly in tumours scored as AMLo high risk 
that subsequently went on to metastasise. More interesting was the observation that 
some tumours with loss of epidermal AMBRA1 expression and scored as AMLo high 
risk, in fact maintained endothelial AMBRA1 expression and did not develop 
metastases. These findings further support the hypothesis that TGF-β2 secretion by 
high risk stage I melanoma tumours induce the down regulation of epidermal AMBRA1 
leading to epidermal ulceration and in the peri-tumoural endothelium of high risk 
melanomas, exert the same effect by disrupting endothelial integrity and facilitating 
melanoma metastases. The enigma remains however, as to how some melanoma 
tumours with loss of epidermal AMBRA1 expression appear to be protected from the 
pro-metastatic effects of TGF-β2 in the endothelium and which perhaps explains why 
some AJCC stage I melanomas defined as high risk by the combined loss of epidermal 
AMBRA1 and Loricrin expression do not in fact, develop metastases. 
In the recent years, Vitamin D in melanoma has received much attention as a key 
regulator of cell proliferation, differentiation and immunomodulation [185-187], with 
accumulating evidence that its deficiency may increase the risk of malignancy and 
cancer outcomes [188]. Vitamin D is primarily synthesised in the skin under the action 
of ultraviolet B (UVB) light from the sun as Cholecalciferol, which then undergoes  
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double hydroxylation; first in the liver to form 25-hydroxyvitamin D (25-
hydroxycholecalciferol) and finally in the kidneys to form the biologically active form 1-
25-dyhydroxycholecalciferol (Calcitriol) [189] which activates vitamin D receptors 
(VDR). To determine a person’s vitamin D status, 25-hydroxyvitamin D is the form 
measured in serum [190] . 
Certainly in melanoma, low levels of serum 25-hydroxyvitamin D at the point of primary 
melanoma diagnosis have been associated with high risk tumours with thicker 
primaries and a poorer prognosis, despite conflicting evidence on overall survival and 
insufficient evidence to establish cause-effect [78-82]. Lower Vitamin D levels have 
also been associated with ulceration of primary melanomas and poorer melanoma 
specific survival however, the underlying biology of this remains uncertain. 
Interestingly, Vitamin D is known to be a regulator of TGF-β signalling [191, 192] where 
impaired Vitamin D receptor signalling with reduced expression of VDR and decreased 
levels of its ligand may contribute to enhanced sensitivity to the effects of TGF-β and 
hyperactive TGF-β signalling [189]. In addition, calcitriol has been shown to inhibit both 
migration and invasion induced by TGF-β1 and TGF-β2 and regulates TGF-β induced 
epithelial-mesenchymal (EMT) transition in human airway epithelial cells [193]. 
In human skin, VDRs are found in the outer root sheath of hair follicles, the basal and 
upper layer of the epidermis where lack of its expression results in keratinocyte hyper 
proliferation and decreased epidermal differentiation [194, 195]. This interestingly ties 
in with the present observations of dysregulated epidermal differentiation with a hyper 
proliferative epidermis associated with loss epidermal AMBRA1 expression overlying 
high risk AJCC stage I melanomas. Moreover, this highlights the potential influence of 
the interaction of Vitamin D with its receptors may have on TGF-β2-induced down 
regulation of AMBRA1 and melanoma prognosis i.e. peri-tumoural keratinocytes and 
endothelial cells may have enhanced or reduced sensitivity to the pro-metastatic 
effects of melanoma TGF-β2 secretion depending on Vitamin D levels and/or receptor 
status. Therefore, melanomas that secrete high levels of TGF-β2 leading to epidermal 
AMBRA1 down regulation may be protected against the pro-metastatic effect of TGF- 
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β2 in the endothelium where there is adequate Vitamin D and receptor status. This 
may explain why some melanoma tumours scored as AMLo high risk with loss of 
epidermal AMBRA1 do not lose expression of peri-tumoural endothelial AMBRA1 and 
do not metastasise. To investigate this association however, further studies of TGF-β 
signalling and Vitamin D levels and receptor status in melanoma would be required. 
Collectively, results in this chapter support the targeting of TGF-β2 signalling as a 
viable therapeutic strategy to prevent the ulceration and metastases of high risk AJCC 
stage I melanomas following primary excision. In the management of early AJCC stage 
I melanoma however, as the whole tumour along with the overlying epidermis is 
removed at the time of primary excision, the definition of an optimal strategy which to 
target TGF-β2 signalling in the endothelium is therefore crucial in order to preserve 
endothelial and endo-lymphatic integrity, which if disrupted, provides a potential route 
for melanoma metastasis. Further work focussed on TGF-β signalling in the 
endothelium and the mechanisms leading to endothelial AMBRA1 down regulation are 
discussed in the following chapter. 
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Summary 
 
 Loss of epidermal AMBRA1 overlying AJCC stage I melanomas correlates with 
increased tumoural TGF-β2. 
 AJCC stage I melanomas defined as high risk by the combined loss of epidermal 
AMBRA1 and Loricrin (AMLo) display increased tumoural TGF-β2 expression. 
 High risk AJCC stage I melanomas that subsequently develop metastases 
display higher tumoural TGF-β2 expression compared with tumours that remain 
localised. 
 Treatment of calcium-induced differentiated primary keratinocytes with 
recombinant TGF-β2 results in the dose dependent down regulation of AMBRA1 
and the terminal differentiation marker Loricrin. 
 Treatment of HUVEC endothelial cells and primary HDLECs with exogenous 
TGF-β2 results in the down regulation of AMBRA1 and endothelial cell 
junctional proteins. 
 Treatment of HUVECs and HDLECs with TGF-β2 rich supernatant derived from 
the melanoma cell line A375 results in the down regulation of AMBRA1 and 
Claudin-5, an effect that is partially prevented by TGF-β2 blockade in melanoma 
cells. 
 Expression of endothelial AMBRA1 is concurrently lost in AJCC stage I 
melanomas in which AMBRA1 expression in the overlying tumour epidermis is 
lost and which go on to develop metastatic disease. 
 Expression of endothelial AMBRA1 is lost in metastatic AJCC stage I 
melanomas stratified as high risk by AMLo scoring. 
 Targeting of TGF-β2 signalling may be a viable therapeutic strategy to prevent 
the ulceration and metastases of high risk AJCC stage I melanomas following 
primary excision, for which the combined loss of epidermal AMBRA1 and 
Loricrin (AMLo) expression is a companion biomarker.
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5.1 Introduction 
Data presented so far support a pathogenic role for TGF-β2 in melanoma progression, 
and suggest the targeting of TGF-β2 signalling may prove a valuable therapeutic 
strategy to prevent the development of metastasis in high risk AJCC stage I 
melanomas, for which the loss of epidermal AMBRA1 and Loricrin may be a companion 
biomarker. To date, several approaches have evaluated the potential for targeting 
TGF-β signalling including agents that inhibit the ligand, receptors or downstream 
signalling [161].  Fresolimumab (GC1008), a pan inhibitor of TGF-β1, 2 and 3 ligands, 
has been clinically evaluated in advanced melanoma patients in phase I/II trials. 
Despite initial evidence for anti-tumour activity [151] however, the use of Fresolimumab 
was associated with the development of eruptive keratoacanthomas or SCCs, 
mediated by the inhibition of TGF-β1 [152], further emphasising the need for isoform 
specific TGF-β inhibitors and specifically a selective inhibitor of TGF-β2 signalling.  To 
this aim a TGF-β2 antisense vaccine, LucanixTM (Belangenpumatucel-L, NovaRx, 
San Diego, CA, USA), has been developed, for which phase III trials in advanced stage 
non-small cell lung cancer demonstrated survival benefits, but which to date has not 
been evaluated in melanoma [153].  
Rather than targeting the TGF-β2 ligand, perhaps a more effective approach in 
melanoma may be to target the TGF-β2 receptor complex thereby preventing non-
specific receptor activation, downstream signalling and off target effects. To consider 
this possibility and inform the design of an appropriate TGF-β2 receptor target, it is 
important to understand the downstream mechanisms by which tumoural TGF-β2 
secretion engages canonical or non-canonical TGF-β2 mediated signalling.  
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TGF-β Receptor II (TGF-βRII)/ALK5 is the predominant receptor complex responsible 
for canonical down-stream TGF-β2 mediated signal transduction in most cell types. 
Canonically TGF-β2 ligand binds to TGF-βRII/ALK5 receptor dimers present on most 
cells including keratinocytes resulting in activation or phosphorylation of Smad 2 and 
3, and evoking downstream signalling mechanisms, which in endothelial cells has been 
shown to inhibit cell proliferation and migration [129]. In addition, TGF-β2 ligand may 
also bind to TGF-βRII/ALK1 receptor dimer complexes, activating non-canonical 
signalling, activation/phosphorylation of Smad 1/5 and which in endothelial cells may 
promote cell proliferation and migration [129, 132]. Since ALK1 is predominantly 
expressed in endothelial cells and at sites of epithelial-mesenchymal interactions and 
is known to activate Smad 1 and Smad 5 [129, 131], this may be the predominant 
mechanism by which TGF-β2 secreted by melanomas transduces downstream 
signalling and perhaps the mechanism by which the expression of AMBRA1 in both 
the epidermis and the endothelium is down regulated (Figure 5.1).
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Figure 5.1: Schematic model for activation of TGF-β2 mediated ALK1 and ALK5 signalling in 
endothelial cells. Active TGF-β2 binds to TGF-βRII, which recruits and activates ALK5, which in turn 
can recruit ALK1 into the complex. Activated ALK1 and ALK5 phosphorylates Smad 1/5 and Smad 2/3 
respectively with opposing downstream effects where ALK 5 inhibits endothelial cell migration and 
proliferation whereas ALK1 stimulates both these processes [129]. The ratio between their expressions 
may determine if TGF-β2 functions as a tumour suppressor or promoter of tumour progression leading 
to the down regulation of AMBRA1 and endothelial junctional proteins [129].  
 
 
To test these hypotheses, the aim of the present chapter was thus to characterise ALK 
1 and ALK5 expression in keratinocytes and endothelial cells and determine the 
mechanisms by which melanoma secretion of TGF-β2 leads to the down regulation of 
AMBRA1, resulting in loss of epidermal and endothelial integrity.
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5.2 Results 
5.2.1 Bioinformatics analysis of the AMBRA1 promoter identifies TGF-β2 
responsive elements 
To further decipher the downstream signalling evoked by melanoma secretion of TGF-
β2 and the mechanisms by which TGF-β2 mediates epidermal and or endothelial 
AMBRA1 down regulation, a bioinformatics approach was undertaken in collaboration 
with Dr Marco Corazzari, University of Rome ‘Tor Vergata’. Specifically, the on line 
MatInspector (Genomatix) matrix library tool was used to identify putative TGF-β2 
related transcription factor binding sites/responsive elements in the AMBRA1 promotor 
in which identified DNA sequences with confidence matrix simetry values of >0.8 were 
considered significant. Results identified responsive elements for Smad 1/5 and Smad 
3, further affirming the potential contribution of both canonical or non-canonical TGF-
β2 signalling to AMBRA1 down regulation (Figure 5.2). 
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Figure 5.2: Bioinformatics analysis of the AMBRA1 promoter identifies TGF-β responsive 
elements. AMBRA1 upstream promoter sequence highlighting TGF-β responsive elements for Smad 3 
(yellow) and Smad 1/5 (blue), identified following bioinformatics analysis for TGF-β related transcription 
factor binding sites/responsive elements using the MatInspector matrix library tool.
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5.2.2 ALK1 and ALK5 are differentially expressed in keratinocytes and 
endothelial cells  
Following the identification of TGF-β responsive elements for Smad 1/5 and Smad in 
the AMBRA1 promoter, mRNA expression levels of ALK1 and ALK5 in the retrovirus 
vector transformed keratinocyte cell line CCD1106 and HUVEC endothelial cells were 
quantified by qPCR, as well as in primary undifferentiated and calcium-induced 
differentiated keratinocytes in collaboration with Dr Gareth Inman, University of 
Dundee, UK.  
Results revealed expression of ALK5 by CCD1106 keratinocytes and both primary 
differentiated and undifferentiated keratinocytes (with no difference in expression 
between undifferentiated and differentiated primary keratinocytes) while in contrast 
there was no expression of ALK1 by these cell types  (Figure 5.3 A – B). Conversely, 
qPCR analysis revealed the expression of both ALK 1 and ALK5 mRNA by HUVEC 
endothelial cells with no significant difference in expression levels between the two 
receptors (Figure 5.3 C). Collectively, these data suggest that TGF-β2 mediated down 
regulation of AMBRA1 in the epidermis likely occurs via ALK 5 canonical TGF-β2 
signalling whereas in the endothelium, either pathway could be responsible for 
AMBRA1 down regulation given that both ALK1 and ALK5 are equally expressed.
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Figure 5.3: ALK1 and ALK5 are differentially expressed by the keratinocyte cell line CCD1106, 
primary keratinocytes and HUVEC endothelial cells. Relative mRNA levels for the expression of ALK 
1 and ALK 5 in A CCD1106 keratinocytes, B primary undifferentiated and differentiated keratinocytes 
(differentiated for 5 days by culture in 1.3 mM Calcium Chloride) or C HUVEC endothelial cells, 
normalized to L34 housekeeping gene expression and expressed as the 2-ΔΔCT mRNA fold change 
demonstrating no expression of ALK1 by CCD1106 or primary keratinocytes and expression of both 
ALK1 and ALK5 by HUVEC endothelial cells. Each bar represents the mean ± SD of three replicate 
experiments. 
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5.2.3 TGF-β2-induced deregulation of keratinocyte (CCD1106) differentiation 
and AMBRA1 down regulation is mediated by canonical TGF-β signalling 
To further characterize the differential contribution of canonical or non-canonical TGF-
β signaling to deregulated epidermal differentiation, CCD1106 keratinocytes were 
subjected to calcium-induced differentiation for 7 days (by switching to culture in Epilife 
media containing 1.3 mM CaCl2) in the presence of 10 ng/ml of recombinant TGF-β2 
for the last 24 hours, prior to the analysis of total or phosphorylated Smad 1, 3 or 5 
expression by Western Blotting. Results demonstrated calcium-induced differentiation 
of CCD1106 cells at 5 and 7 days was accompanied by the reduced expression of 
phosphorylated Smad 2 and Smad 3, which was then increased by subsequent 
incubation for 24 hours in the presence of exogenous TGF-β2 (Figure 5.4 A). 
Conversely, calcium-induced differentiation of CCD1106 cells for 5 or 7 days had no 
effect on the expression of phosphorylated Smad 1/5, the expression of which was 
also not altered by co-culture with exogenous TGF-β2 for 24 hours following the 
induction of differentiation (Figure 5.4 B). Collectively, these results therefore suggest 
that exogenous TGF-β2 activates evokes canonical TGF-β2 signalling in keratinocytes 
via binding to the ALK5 receptor complex and inducing the phosphorylation of Smad 2 
and Smad 3. Furthermore, these data are consistent with the likelihood of the 
contribution of TGF-β2-induced Smad 3 phosphorylation to the down regulation of 
epidermal AMBRA1 and Loricrin and the loss of epidermal integrity mediated by 
melanoma secretion of TGF-β2.
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Figure 5.4: Activation of canonical TGF-β signaling in calcium-induced differentiated CCD1106 
keratinocytes in response to exogenous TGF-β2. Representative western blot for A the expression 
of p-Smad 2 (60 kDA) and p-Smad 3 (52 kDA), Total Smad 2 (60 kDA) or  Smad 3 (60 kDA) or B, p-
Smad 1/5, total Smad 1 (60 kDA) or Smad 5 (60 kDA) in CCD1106 cells or CCD1106 cells following 5 
or 7 days switch to culture in medium with high calcium (1.3 mM Ca2+) in the presence or absence of 10 
ng/ml recombinant TGF-β2 for the last 24 hours or p-Smad 1/5, total Smad 1 or total Smad 5 expression 
in control HUVEC cells  
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In the clinical context of melanoma management however, the epidermis is removed 
along with the tumour at primary excision and hence in order to define a potential target 
to prevent metastasis of high risk AJCC stage I melanomas it is important to consider 
the signalling mechanisms by which tumoural secretion of TGF-β2 (by any remaining 
melanoma cells following primary excision) lead to the loss endothelial AMBRA1, and 
associated loss of junctional protein expression and endothelial integrity. The 
remaining data are hence focused towards defining the optimal strategy through which 
to target TGF-β2 signalling in the microvascular or lymphatic endothelium in order to 
preserve endothelial integrity and prevent melanoma metastasis. 
Chapter 5: Contribution of canonical and non-canonical TGF-β2 signalling to 
melanoma metastasis 
178 
 
 
5.2.4 TGF-β2 induces both canonical and non-canonical signalling in HUVEC 
endothelial cells 
Unlike in keratinocytes that only express ALK5, analysis of TGF-βRI expression in 
HUVEC endothelial cells revealed expression of both ALK1 and ALK5, suggesting 
melanoma secretion of TGF-β2 may potentially evoke either or both canonical or non-
canonical signalling in the endothelium, leading to AMBRA1 down regulation. To 
further test this hypothesis, HUVEC endothelial cells were treated with 10 ng/ml 
recombinant TGF-β2 for 2 or 8 hours, prior to western blot analysis for the expression 
of p-Smad 1/5 and p-Smad 3 or Total Smad 1, 3 or 5. Smad 2 signalling was 
disregarded since responsive elements for this transcription factor were not revealed 
in bioinformatics analysis of the AMBRA1 promoter (section 5.2.1).  Results revealed 
recombinant TGF-β2 induced increased early phosphorylation of Smad 1/5 following 
2 hours treatment which returned close to basal levels at 8 hours, with no significant 
change in total Smad 1 or 5 expression (One way ANOVA with Dunnett’s post-test 
correction ***P <0.001; Figure 5.5 A & C). Similarly, treatment of HUVEC endothelial 
cells with TGF-β2 induced the early phosphorylation of Smad 3 following 2 hours 
treatment which again returned close to basal levels at 8 hours, with no change in total 
Smad 3 (One way ANOVA with Dunnett’s post-test correction ***P <0.001) and 
confirming the activation of both canonical and non-canonical TGF-β signalling (Figure 
5.5 B & D). Collectively these data suggest melanoma secretion of TGF-β2 results in 
the activation of both canonical and non-canonical TGF-β2 signalling in endothelial 
cells. 
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Figure 5.5: TGF-β2 activates both canonical and non-canonical signalling in HUVEC endothelial 
cells. Representative western blot for the expression of A p-Smad 1/5 (60 kDA), Total Smad 1 (60 kDA), 
Total Smad 5 (60 kDA) and GAPDH (37 kDA) loading control or B p-Smad 3 (52 kDA), Total Smad 3 
(52 kDA) and GAPDH (37 kDA) loading control in HUVEC endothelial cells following treatment with 10 
ng/ml recombinant TGF-β2 or vehicle control for 2 or 8 hours. C Relative p-Smad 1/5, Total Smad 1 and 
Total Smad 5 protein expression or D Relative p-Smad 3 and Total Smad 3 protein expression 
normalised to time matched GAPDH loading control and expressed relative to the mean protein/GAPDH 
value for each experiment, following treatment for 2 or 8 hours with 10 ng/ml recombinant TGF-β2 or 
vehicle control. Each bar is the mean ± SD of 3 replicate experiments. One way ANOVA with Dunnett’s 
post-test correction ***P <0.001.
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5.2.5 Non-canonical TGF-β2 signalling is increased in the endothelium of 
metastatic AJCC stage I melanomas 
To further characterise whether canonical or non-canonical TGF-β2 signalling is 
preferentially activated or predominates in the peri-tumoural endothelium of high risk 
TGF-β2 secreting early stage melanomas, the immunohistochemical expression of p-
Smad 3 and p-Smad 1/5 was determined in a sub cohort of AJCC stage I melanomas. 
Specifically, IHC expression with VIP counterstaining for the expression of p-Smad 2/3 
or p-Smad 1/5 was performed manually in 10 AJCC stage I melanomas (6 metastatic 
and 4 that remained localised. Results revealed a trend for the presence of p-Smad 
2/3 expression and the absence of p-Smad 1/5 expression in the peri-tumoural 
endothelium of non-metastatic AJCC stage I melanomas (Figure 5.6 A). Conversely, 
the absence of p-Smad 2/3 expression was associated with a marked increase in p-
Smad 1/5 expression in the peri-tumoural endothelium of metastatic AJCC stage I 
melanomas (Figure 5.6 B). These data suggest that non-canonical TGF-β2 signalling 
is activated or predominates in the endothelium of high risk AJCC stage I melanomas 
and is associated with melanoma metastasis. Targeting non-canonical TGF-β2 
signalling may thus represent a novel adjuvant approach to prevent metastasis of 
AJCC stage I melanomas identified as high risk by loss of epidermal/endothelial 
AMBRA1. 
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Figure 5.6: Absence of p-Smad 2/3 and the presence of p-Smad 1/5 expression is associated with 
metastatic AJCC stage I melanomas. Representative IHC photomicrographs of the peri-tumoural 
endothelium of 2 AJCC stage I melanomas (A – B) depicting: A (i) positive p-Smad 2/3 staining and A 
(ii) negative p-Smad 1/5 expression in a non-metastatic AJCC stage I melanoma and B (i) negative p-
Smad 2/3 staining with B (ii) positive p-Smad 1/5 expression in a metastatic AJCC stage I melanoma 
revealed by VIP counterstaining (pink). Scale bar =100 μm.
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5.2.6 Inhibition of ALK5 prevents canonical TGF-β2 signalling-mediated down 
regulation of AMBRA1 in calcium-induced keratinocytes   
Data presented so far suggest melanoma secretion of TGF-β2 mediates AMBRA1 
down regulation in the epidermis by canonical signalling leading to the loss of 
epidermal integrity and tumour ulceration. To test the hypothesis that blocking ALK5 in 
keratinocytes may therefore prevent a means through which to prevent TGF-β2-
induced down regulation of AMBRA1 down regulation, CCD1106 keratinocytes were 
subjected to culture in high calcium medium (1.3 mM Ca2+) for 6 days in the presence 
or absence of 10 ng/ml recombinant TGF-β2 and or 10 μM of a selective ALK5 inhibitor 
for the last 24 hours, prior to western blot analysis for the expression of p-Smad 2/3, 
AMBRA1 and β-Actin loading control. Results revealed and confirmed calcium-induced 
differentiation of CCD1106 cells was accompanied by an increase in AMBRA1 
expression, the effect of which was partially prevented in the presence of 10 ng/ml 
TGF-β2, with a concurrent increase in the expression of p-Smad 2/3, thereby 
demonstrating activation of canonical TGF-β signalling. Addition of the ALK5 inhibitor 
however, prevented TGF-β2-induced p-Smad2/3 with a concurrent rescue of AMBRA1 
expression (Figure 5.7), collectively suggesting that blockade of ALK5 signalling in 
keratinocytes prevents TGF-β2 induced AMBRA1 down regulation, and further 
supporting the involvement of canonical TGF-β2 signalling in epidermal AMBRA1 
down regulation, loss of epidermal integrity and tumour ulceration.  
To preserve endothelial AMBRA, endothelial integrity and prevent melanoma 
metastasis would however require appropriate targeting of TGF-β2 signalling in the 
microvascular or lymphatic endothelium, for which the potential for inhibition of ALK1 
or ALK5 was next investigated and modelled using the HUVEC endothelial cell line.
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Figure 5.7: ALK5 inhibition results in blockade of canonical TGF-β2-induced down regulation of 
AMBRA1 in calcium-induced CCD1106 keratinocytes. A Representative western blot for the 
expression of AMBRA1 (132 kDA), p-Smad 2/3 (60 kDA) and β-Actin (45 kDA) loading control in 
CCD1106 keratinocytes cultured in Epilife media or induced to differentiate by culture in high calcium 
media (1.3 mM Ca2+) for  6 days in the presence or absence of 10 ng/ml recombinant TGF-β2 and/or 
10 μM ALK5 inhibitor for the last 24 hours of culture. B Relative expression of AMBRA1 and C p-Smad 
2/3 normalised to time matched β-Actin loading control in CCD1106 keratinocytes induced to 
differentiate by culture for 6 days in high calcium Epilife media (Ca2+) and expressed relative to 
undifferentiated CCD1106 keratinocytes cultured in Epilife media (vehicle control), following treatment 
with 10 ng/ml recombinant TGF-β2 or 10 μM ALK5 inhibitor (ALK5 inh) or both for the last 24 hours of 
culture.
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5.2.7 Inhibition of ALK5 in HUVEC endothelial cells exacerbates non-canonical 
TGF-β2 signalling and does not prevent TGF-β2-induced endothelial 
AMBRA1 down regulation.  
To explore the potential for ALK5 inhibition as a strategy to prevent TGF-β2-induced 
down regulation of endothelial AMBRA1 expression, HUVEC endothelial cells were 
treated with 10 μM of a selective ALK5 inhibitor in the presence or absence of 10 ng/ml 
recombinant TGF-β2 for 2 or 24 hours, prior to western blot analysis for the expression 
of AMBRA1, p-Smad 3 as well as control p-Smad 1/5. Results demonstrated, relative 
to GAPDH loading control, that TGF-β2-induced early phosphorylation of Smad 3 and 
markedly increased phosphorylation of Smad 1/5 at 2 hours in the presence of the 
ALK5 inhibitor but with no apparent change in AMBRA1 expression. In addition, 
despite phosphorylation of Smad 1/5 or 3 typically returning back to baseline levels by 
24 hours, interestingly phosphorylation of Smad 1/5 was sustained at 24 hours in the 
presence of the ALK5 inhibitor (Figure 5.8 A). Given in the aforementioned studies 
(section 4.2.4), significant TGF-β2-induced AMBRA1 down regulation in HUVEC cells 
was only apparent after 72, possibly accounting for the lack of discernible change in 
AMBRA1 protein expression in the present results (Figure 5.8 A), qPCR analysis was 
additionally performed to assess AMBRA1 expression at mRNA level at 2 and 24 hours 
(Figure 5.8 B). Results revealed a trend for an initial increase in TGF-β2-induced 
AMBRA1 mRNA expression levels following 2 hours exposure to 10 ng/ml recombinant 
TGF-β2 with reduced levels at 24 hours, which was significantly decreased in the 
presence of the ALK5 inhibitor i.e. the decline in AMBRA1 mRNA expression levels 
following 24 hours exposure to TGF-β2 is enhanced in presence of the ALK5 inhibitor. 
(One way ANOVA with Tukey’s post-test correction *P <0.001, Figure 5.8 B). 
Collectively, these data demonstrate inhibition of ALK5 blocks canonical TGF-β2-
induced p-Smad3 in endothelial cells, but is accompanied by the concurrent 
enhancement/exacerbation of non-canonical TGF-β2-induced p-Smad1/5 and the 
continued down regulation of endothelial AMBRA1 expression thereby suggesting  
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AMBRA1 down regulation and loss of endothelial integrity is mediated by non-
canonical TGF-β2 signalling (Figure 5.8 C). 
 
 
Figure 5.8: ALK5 inhibition sustains TGF-β2 induced Smad 1/5 phosphorylation but does not 
prevent AMBRA1 down regulation in endothelial cells. A Representative western blot for the 
expression of AMBRA1 (132 kDA), p-Smad 3 (52 kDA), p-Smad 1/5 (60 kDA) and GAPDH (37 kDA) 
loading control in HUVEC endothelial cells cultured for 24 hours in the presence or absence of 10 μM 
ALK5 inhibitor, or HUVEC cells treated with 10 ng/ml recombinant TGF-β2 for 2 hours or 24 hours in the 
presence or absence of 10 μM ALK5 inhibitor. B Relative mRNA levels for the expression of AMBRA1 
in HUVEC endothelial cells cultured for 24 hours in the presence or absence of 10 μM ALK5 inhibitor 
(controls), or HUVEC cells following treatment with 10 ng/ml of recombinant TGF-β2 for 2 hours or 24 
hours in the presence or absence of 10 μM ALK5 inhibitor, normalized to L34 housekeeping gene and 
expressed as the 2-ΔΔCT mRNA fold change relative to siCtrl non treatment cells. Each bar represents 
3 replicates ± SD of an experiment. One way ANOVA with Tukey’s post-test correction ***P <0.001. C 
Schematic indicating blockade of canonical TGF-β2 signalling with an ALK5 inhibitor prevents 
phosphorylation of Smad 3 but exacerbates and sustains phosphorylation of Smad 1/5 and non-
canonical TGF-β2 signalling, leading to AMBRA1 down regulation in endothelial cells.
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5.2.8 SiRNA-mediated knockdown of ALK1 prevents non-canonical TGF-β2 
mediated endothelial AMBRA1 downregulation.  
Given lack of commercially available ALK1 inhibitors, to evaluate the potential for ALK1 
inhibition as a strategy to prevent canonical TGF-β2-induced down regulation of 
endothelial AMBRA1, siRNA mediated transient knockdown of ALK1 was performed 
in HUVEC endothelial cells. 3 different siRNA oligoribonucleotides: 
ACVRL1HSS100150 (siALK1#150), ACVRL1HSS100151 (siALK1 #151) and 
ACVRL1HSS100152 (siALK1 #152) targeting human ALK1 and a mixture of all 3 
siRNAs were initially evaluated for their potential to knockdown ALK1 expression in 
HUVEC cells with knockdown efficacy assessed by qPCR in comparison to a non-
targeting scrambled siRNA control as described in section 2.7. Successful transient 
knockdown of ALK1 in HUVEC cells (defined by >50% decrease in ALK1 mRNA by 
qPCR) was achieved with siALK1 #150 and siALK1 #151 siRNAs (Figure 5.9). For 
subsequent experiments, siALK1#150 siRNA was selected to assess the potential of 
transiently knocking down ALK1 to prevent TGF-B2 induced non-canonical signalling 
and AMBRA1 down regulation in HUVEC endothelial cells.  
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Figure 5.9: Efficacy of siRNA mediated knockdown of ALK1 in HUVEC endothelial cells. Relative 
mRNA levels of ALK1 in HUVEC endothelial cells following transfection for 48 hours with siCtrl, 
siALK #150, siALK1 #151, siALK1 #152 or siALK1 MIX of all three siRNAs normalized to L34 
housekeeping gene and expressed as 2-ΔΔCT values relative to siCtrl. Each bar represents 
the mean ± SD of 3 replicate qPCR reactions. 
 
Knockdown of ALK1 using siALK1#150 siRNA (Figure 5.10 B) with subsequent 
treatment of HUVEC cells with 10 ng/ml recombinant TGF-β2 for 2 hours revealed a 
reduction in the expression of p-Smad 1/5 with no change in expression of total Smad 
1 and 5 as well as the partial rescue of TGF-β2-induced AMBRA1 down regulation, 
sustained levels of which were still observable after 24 hours (Figure 5.10 A).  
To further evaluate the rescue of TGF-β2-induced AMBRA1 down regulation in 
HUVEC cells by knockdown of ALK1, in line with the early induction of phosphorylated 
Smad 1/5, AMBRA1 mRNA expression levels were additionally assessed by qPCR. In 
contrast to data derived by ALK5 blockade, siRNA-mediated knockdown of ALK1 in 
HUVEC endothelial cells resulted in significant prevention of TGF-β2–induced 
AMBRA1 down regulation at 24 hours (One way ANOVA with Tukey’s multiple 
comparison test **P <0.01, ***P <0.001, Figure 5.10 C).  
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Coupled with data demonstrating the lack of prevention of TGF-β2 –induced AMBRA1 
downregulation by blockade of ALK5 and canonical TGF-β2 signalling (section 5.2.6), 
these data further suggest the down regulation of endothelial AMBRA1 is mediated by 
non-canonical ALK1 signalling and that targeting ALK1 may represent a novel 
therapeutic strategy to prevent loss of endothelial integrity and metastasis in high risk 
melanomas (Figure 5.10 D). Nevertheless, to confirm this hypothesis, further studies 
will be required to confirm the effects of ALK 1 blockade on TGF-β2-induced 
endothelial cell junctional protein expression. 
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Figure 5.10: Knockdown of ALK1 prevents TGFβ2-induced Smad 1/5 phosphorylation and loss 
of endothelial AMBRA1. A Representative western blot for the expression of AMBRA1 (132 kDA), p-
Smad 1/5 (60 kDA), total Smad 1 (60 kDA) and total Smad 5 (60 kDA) in HUVEC endothelial cells 
following transfection of siControl (siCtrl) RNA or siALK1 RNA and treatment with 10mg/ml recombinant 
TGFβ2 for 2 or 24 hours. B Relative ALK1 mRNA levels in HUVEC endothelial cells following two 
transfections with 20 μM siALK1#150 siRNA  (siALK1) or ctrl siRNA for 24 hours and confirming >50% 
knockdown of ALK1. C Relative AMBRA1 mRNA in HUVEC cells following transfection with siCtrl or 
siALK1 in the absence (Ctrl) or presence of treatment with 10ng/ml recombinant TGF-β2 for 2 hours or 
24 hours, normalized to L34 housekeeping gene and expressed as the 2-ΔΔCT mRNA fold change 
relative to siCtrl non treatment HUVEC cells. Each bar represents 3 replicates ± SD of an experiment. 
One way ANOVA with Tukey’s multiple comparison test **P <0.01, ***P <0.001. D Schematic indicating 
blockade of non-canonical TGF-β2 signalling with ALK1 siRNA prevents TGF-β2-induced 
phosphorylation of Smad 1/5 and partially rescues TGF-β2 induced AMBRA1 down regulation in 
endothelial cells.
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5.2.9 Inhibition of canonical TGF-β2 signaling by ALK5 inhibition promotes 
endothelial cell proliferation 
The formation of neovasculature from pre-existing blood vessels is widely considered 
an essential process to ensure nutrient and oxygen supply for melanoma tumour 
survival as well as provide a potential route for tumour cell entry and metastasis [196], 
a process mediated by several pro-angiogenic factors [197]. In endothelial cells, TGF-
β2 has been shown to transduce signals via ALK1 and 5 with both pathways having 
opposing effects where signalling via ALK5 has been shown to inhibit endothelial cell 
migration and proliferation whereas ALK1 stimulates both these processes [129, 132]. 
To test any potential effect of exogenous TGF-β2 on endothelial cell proliferation, 
HUVEC endothelial cells and primary HDLECs were first treated with 10 ng/ml or 20 
ng/ml human recombinant TGF-β2 prior to assessment of cell viability over 72 hours 
via a commercial MTS cell viability assay. Results demonstrated a significant decrease 
in HUVEC cell proliferation following treatment with 20 ng/ml recombinant TGF-β2 for 
72 hours, however there was no significant difference in HDLEC cell proliferation 
following 72 hour treatment with either 10 ng/ml or 20 ng/ml recombinant TGF-β2 (One 
way ANOVA with Dunnett’s post-test correction P <0.04, Figure 5.11). Given that TGF-
β2 signals via both ALK1 and AK5 in endothelial cells, maintenance of balance 
between activation of both canonical and non-canonical signalling pathways may have 
accounted for the lack of effect on endothelial cell proliferation observed.  
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Figure 5.11: Effect of recombinant TGF-β2 on HUVEC and primary HDLEC endothelial cell 
proliferation. Relative cell viability of A HUVEC or B HDLEC endothelial cells (presented relative to the 
mean cell viability value for each experiment) in the presence of treatment for 72 hours with 10 or 20 
ng/ml recombinant TGF-β2 or equal volume vehicle control (Ctrl). Each bar represents the mean ± SD 
of 3 replicate experiments. One way ANOVA with Dunnett’s post-test correction P <0.04. 
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Given previous results demonstrating TGF-β2-enhanced Smad 1/5 phosphorylation in 
HUVEC cells in the presence of ALK5 inhibition, and the possibility that ALK5 inhibition  
exacerbates non-canonical TGF-β2 signalling, this led to the hypothesis that ALK5 
inhibition may in fact drive endothelial cell proliferation. To test this hypothesis, HUVEC 
cells were next treated with 10 ng/ml recombinant TGF-β2 for 72 hours in the presence 
or absence of 10 µM ALK5 inhibitor prior to assessing relative cell viability. Results 
demonstrated, ALK5 inhibition alone did not significantly alter HUVEC cell proliferation, 
however, in response to treatment with exogenous treatment with TGF-β2 for 72 hours, 
ALK5 inhibition significantly increased cell proliferation compared to cell viability of 
control untreated HUVEC cells and cell viability derived by treatment of HUVEC cells 
treated with 10 ng/ml recombinant TGF-β2 alone (One way ANOVA with Tukey’s 
multiple comparisons test *P <0.05, **P <0.01, Figure 5.12 A). 
 
 
 
 
.  
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Figure 5.12: ALK5 blockade results in increased TGF-β2 induced stimulation of HUVEC 
endothelial cell proliferation. A Relative cell viability of HUVEC endothelial cells following treatment 
with 10 ng/ml recombinant TGF-β2 for 72 hours in the presence or absence of 10 μM ALK5 inhibitor 
presented relative to the mean cell viability value for each experiment. Each bar represents the mean ± 
SD of 3 replicate experiments. One way ANOVA with Tukey’s multiple comparison test *P <0.05, **P 
<0.01. B Schematic reflecting derived results and ALK5 inhibition-mediated enhanced activation of non-
canonical TGF-β2-induced stimulation of HUVEC endothelial cell proliferation.  
 
 
Collectively, these data thus support the hypothesis that ALK5 blockade results in the 
enhancement of non-canonical TGF-β2-induced endothelial proliferation (Figure 5.12 
B). Studies of the effects of ALK1 inhibition on melanoma TGF-β2 mediated endothelial 
cell proliferation are nevertheless required to confirm whether or not ALK1 inhibition 
may specifically inhibit HUVEC or HDLEC cell proliferation.
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5.3 Discussion 
 
The secretory polypeptide TGF-β2 exerts multiple effects on numerous key biological 
functions including cellular proliferation, differentiation and apoptosis [119]. Activated 
TGF-β2 initiates its signalling cascade via heterotetrameric TGF-β receptor complexes 
consisting of 2 TGFβ-RIs (ALK 1-7) and 2 TGF-βRIIs which when activated, evoke 
downstream TGF-β2 signalling through phosphorylation of Smad proteins that 
translocate into nuclei of cells to modulate gene expression [122, 123]. Despite all 3 
isoforms of TGF-β signalling in this manner, there is a distinction in downstream 
signalling and target effects depending on the composition of the TGF-β receptor 
complex. In endothelial cells, ALK1 activation phosphorylates Smad 1/5 whereas ALK5 
activates Smad 2/3, driving differential responses to TGF-β2 that maintains a 
homeostatic balance in the endothelium. Disruption to this balance has been shown to 
exert opposing effects on endothelial cells where preferential canonical signalling via 
ALK5 inhibits cellular proliferation and migration whereas non-canonical signalling via 
ALK1 stimulates these processes [120, 129]. 
Results presented in the previous chapter demonstrated the potential contribution of 
TGF-β2 secretion by high risk early AJCC stage primary melanomas to AMBRA1 and 
endothelial junctional protein down regulation leading to loss of epidermal and 
endothelial integrity, and highlighting the targeting of TGF-β2 signalling as a potential 
therapeutic strategy to prevent melanoma metastasis within this subgroup. To further 
understand the mechanisms leading to TGF-β2 mediated AMBRA1 down regulation, 
bioinformatics analysis of the upstream AMBRA1 promoter was undertaken which 
identified TGF-β responsive elements for Smads 1/5 and 3 further supporting the 
involvement of canonical or non-canonical TGF-β2 signalling to AMBRA1 down 
regulation. This was further characterized by results demonstrating the expression of 
both ALK1 and ALK5 by endothelial cells while only ALK5 was expressed by 
keratinocytes and suggesting that TGF-β2 down regulation of AMBRA1 in the  
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epidermis likely occurs via ALK 5 mediated canonical TGF-β2 signalling whereas in 
the endothelium, either pathway could be responsible for AMBRA1 down regulation.  
To confirm the activation of canonical or non-canonical TGF-β2 signalling in both the 
epidermis and endothelium in response to exogenous TGF-β2, p-Smad 1/5 or 3 
expression was analysed in calcium-induced differentiated CCD1106 keratinocytes 
and HUVEC endothelial cells following treatment with recombinant TGF-β2. Results 
revealed activation of canonical signalling via ALK5 in CCD1106 keratinocytes and 
confirmed the lack of non-canonical signalling due to absence of ALK1 expression. 
More importantly, the apparent activation of ALK5 signalling was linked to TGF-β2-
induced down regulation of AMBRA1 and Loricrin in calcium-induced differentiated 
CCD1106 keratinocytes, further supporting the contribution of canonical TGF-β2 
signalling to the loss of epidermal integrity overlying primary melanomas. In HUVEC 
endothelial cells however, treatment with recombinant TGF-β2 induced 
phosphorylation of both Smad 1/5 and Smad 3, suggesting concurrent activation of 
canonical and non-canonical signalling in response to exogenous TGF-β2. These 
findings are in line with studies demonstrating TGF-β signalling in endothelial cells 
occurring via both ubiquitously expressed ALK5 receptors and endothelial cell 
predominant ALK1 receptors with a fine balance maintained between canonical and 
non-canonical signalling, where both signalling pathways have opposing effects  [162, 
198, 199]. TGF-β stimulation of ALK1 has been shown to promote endothelial cell 
proliferation and migration whereas signalling via ALK5 inhibits these processes [199]. 
In addition, transcriptional profiling of endothelial cells demonstrated significant 
differences in the molecular output obtained from ALK1 and ALK5 signalling, further 
supporting the divergent roles of each receptor in vascular development [200]. 
To determine the potential contribution of canonical or non-canonical TGF-β2 
signalling to loss of integrity of the  peri-tumoural endothelium of high risk melanomas 
that are known to secrete high levels of TGF-β2, the expression of endothelial p-Smad 
1/5 and p-Smad 2/3 (Smad 2 and Smad 3 functions as a dimer) were compared in  
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metastatic and non-metastatic AJCC stage I melanomas in vivo. Results revealed a 
trend for an increase in p-Smad 1/5 but not p-Smad 2/3 in high risk tumours while 
expression levels of p-Smad 1/5 were minimal in the endothelium surrounding AJCC 
stage I melanomas that remained localized. These findings hence suggest that non-
canonical TGF-β2 signalling rather than canonical TGF-β2 signalling is implicated in 
the down regulation of endothelial AMBRA1 and junctional protein expression leading 
to the loss of endo-vascular/lymphatic integrity and highlights the targeting of ALK1 as 
a potentially viable therapeutic strategy to prevent melanoma metastasis. In addition, 
given ALK1 is predominantly expressed in endothelial cells and at sites of epithelial-
mesenchymal interactions [129, 131] specific targeting of ALK1 in the vascular or 
lymphatic endothelium may prove an optimal strategy to prevent metastasis in the 
clinical context of early AJCC stage high risk melanomas, as the tumour along with the 
overlying epidermis is removed at primary excision. Furthermore, given the wide range 
of essential cellular processes dependent on TGF-β signalling such as cell 
proliferation, differentiation, apoptosis and immune suppression [201], inhibition of the 
TGF-β2 ligand or pan TGF-β receptor complex inhibition would not be ideal strategy to 
target TGF-β2 signalling due to significant off-target effects. 
Finally, supporting a link between the induction of non-canonical TGF-β2 signalling and 
the down regulation of endothelial AMBRA1, blockade of ALK5 resulted in further and 
sustained induction of Smad 1/5 phosphorylation and failure to rescue TGF-β2-induced 
AMBRA1 downregulation thereby suggesting ALK5 blockade exacerbates non-
canonical TGF-β2 signalling. Conversely, siRNA mediated ALK1 knockdown in 
HUVEC endothelial cells resulted in reduced phosphorylation of p-Smad 1/5 and the 
partial rescue of TGF-β2-induced down regulation of AMBRA1 down regulation, further 
supporting the notion that the down regulation of endothelial AMBRA1 and endothelial 
integrity is mediated by non-canonical TGF-β2 signalling, although the effects of ALK1 
inhibition on TGF-β2-induced junctional protein expression require further 
confirmation. Coupled with observations that activated TGF-β/ALK5 signalling in 
endothelial cells recruits ALK1 and propagates signalling down the non-canonical  
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pathway, which directly antagonizes ALK5 signalling [129, 199], these results shed 
light on how non-canonical ALK1 signalling may become predominant in the peri-
tumoural endothelium in response to hyperactive or enhanced TGF-β signalling in 
melanoma, leading to down regulation of AMBRA1 and loss of endothelial integrity. 
During metastatic dissemination, melanoma cells enter the circulation by intravasation 
through endothelial cell junctions [19], facilitated by secretory factors from cancer cells 
or macrophages such as VEGF or TGF-β that induce remodelling of endothelial 
junctions or cleavage of vascular endothelial Cadherin (VE-Cadherin), leading to the 
opening of endothelial cell junctions and loss of endothelial integrity [22, 23]. 
Endothelial cell junctions are made up of adherens and tight junctions that are 
intermingled throughout endothelial cell-cell contact areas where their functional 
interaction is required for maintenance of barrier integrity [27]. As such, intact 
endothelial barrier function requires the functional adhesive activity of key adherens 
junction proteins such as VE-Cadherin, where if disrupted, may also result in 
compromise of tight junctional proteins (Claudin-5), leading to loss of endothelial 
barrier integrity [29, 30]. Coupled with results in chapter 4 demonstrating down 
regulation of AMBRA1 and endothelial cell junction proteins VE-Cadherin and Claudin-
5 in response to melanoma TGF-β2, results from the present chapter further supports 
blockade of non-canonical TGF-β2 signalling by targeting ALK1 as a viable therapeutic 
strategy to prevent endothelial AMBRA and cell junctional protein function and 
maintain endothelial barrier integrity. 
TGF-β2 is known to play a pivotal role in regulating key mechanisms of tumour 
progression such as proliferation and angiogenesis in a variety of malignant tumours 
[202]. Tumour induced angiogenesis results in formation of new blood vessels that 
have weak intercellular junctions, where barrier function is further reduced by locally 
secreted factors within the tumour microenvironment, enabling tumour cell entry into 
the vasculature [18]. Despite the apparent lack of any direct effect of exogenous TGF-
β2 on enhanced endothelial cell proliferation, blockade of ALK5 enhanced the 
proliferation of HUVEC cells in the presence of exogenous TGF-β2, which combined  
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with its effect on increased TGF-β2-induced pSmad 1/5, further supports the role of 
non-canonical TGF-β2 signalling in melanoma metastasis. Moreover, ALK1 has also 
been reported to be expressed by lymphatic endothelial cells where inhibition of ALK1 
signalling diminishes neonatal lymphangiogenesis [203, 204]. In addition, ALK1 and 
VEGF receptor-3 signalling has been shown to regulate lymph vessel development 
[204, 205], likely accounting for the similar effect of TGF-β2-induced AMBRA1 and 
endothelial junctional protein down regulation in HUVECS also observed in HDLECs, 
as discussed in chapter 4. Given the lymphatics represent one of the earliest potential 
points for tumour cell entry with metastases from melanoma most commonly first 
presenting at regional lymph nodes [181], the potential for TGF-β2 to mediate 
lymphangiogenesis as well as breach of lymphatic endothelial integrity, further 
highlight its pro-metastatic role but would warrant further investigation. 
Taken together, results from the present chapter suggest that high risk TGF-β2 
secreting AJCC stage I melanomas evoke non-canonical TGF-β2 signalling in the peri-
tumoural endothelium, resulting in the down regulation of AMBRA1 and junctional 
protein expression that leads to loss of endothelial integrity as well as increased 
melanoma neo-vascularisation, increasing the risk of metastasis. Targeting ALK1 may 
therefore represent an ideal strategy to prevent melanoma metastasis while preserving 
canonical TGF-β2 signalling. 
In the recent years, ALK1 inhibition has gained attention as an attractive therapeutic 
target in cancer therapy given the presence of its expression and signalling within the 
vasculature of several tumour types [206]. With regards to specific ALK1 inhibitors, 
Dalantercept (Acceleron Pharma, MA, USA) an ALK1 ligand trap that inhibits activation 
of endogenous ALK1 by binding with high affinity to the ligands bone morphogenetic 
proteins (BMP 9 and 10), was initially evaluated for clinical use in head and neck and 
renal carcinomas but failed to progress through phase II clinical trials due to lack of 
efficacy [163-165]. 
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 PF03446962 (Pfizer, NY, USA) a monoclonal antibody targeting ALK1 has emerged 
from phase I clinical trials with encouraging results observed in solid tumours and 
hepatocellular carcinoma with good side effect profile and tolerability [166, 167] 
however, to date the therapeutic use of ALK1 inhibitors has not been evaluated in 
malignant melanoma. 
Ultimately, validation of ALK1 as a therapeutic target to prevent metastasis in early 
AJCC stage high risk melanomas will inform the drug development of novel ALK1 
inhibitors for which the combined loss of epidermal AMBRA1 and Loricrin (AMLo) is a 
companion biomarker. Definition of this targetable pathway will alter the current 
landscape of the management of early AJCC stage melanomas, which presently lacks 
novel adjuvant targeted therapy for early stage disease to prevent the development of 
metastasis.  
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Summary 
 
 Bioinformatics analysis of the upstream AMBRA1 promoter identified TGF-β 
signalling responsive elements/binding sites for Smad 1/5 and 3, supporting the 
role of canonical and non-canonical TGF-β2 signalling in AMBRA1 down 
regulation and loss of epidermal and endothelial integrity. 
 Epidermal AMBRA1 down regulation is mediated by canonical TGF-β2 
signalling. 
 Endothelial cells express ALK1 and ALK5, mediating activation of both 
canonical and non-canonical signalling in response to treatment with exogenous 
TGF-β2. 
 Non-canonical TGF-β2 signalling is increased in the endothelium of metastatic 
AJCC stage I melanomas demonstrated by increased endothelial p-Smad 1/5 
and absence of p-Smad 2/3 expression.  
 ALK5 inhibition resulted in exacerbated non-canonical TGF-β2 signalling and 
sustained TGF-β2-induced downregulation of endothelial AMBRA1 expression 
in HUVEC cells.   
 siRNA-mediated knockdown of ALK1 in HUVEC cells resulted in blockade of 
non-canonical TGF-β2 signaling and the partial rescue of TGF-β2-induced 
AMBRA1 down regulation 
 Enhancement of ALK1 non-canonical TGF-β2 signalling by blockade of ALK5 
results in increased HUVEC endothelial cell proliferation. 
 Targeting of ALK1 may represent a novel therapeutic strategy to prevent loss of 
endothelial integrity and melanoma metastasis for which AMLo is a companion 
biomarker.
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6.1 AMLo as a follow-up stratification tool for AJCC stage I melanoma 
following primary melanoma excision 
 
To date there is still a lack of evidence based guidelines or an international consensus 
as to which surveillance strategies are most effective following primary melanoma 
excision, leading to significant variation in practices worldwide with no internationally 
accepted standardised model of patient follow up [177, 178]. In view of this, identifying 
and validating robust, evidence based surveillance programs with an emphasis on 
efficient prognostication and personalised treatment options for melanoma patients 
should underpin the focus of future work to translate better outcomes for patients. 
Current practice is to treat all patients with melanoma by initial surgical excision of the 
primary tumour with continued surveillance until metastasis ensues. With still no 
consistently beneficial treatments for metastatic melanoma however, there is a push 
towards informing clinical decisions at the outset.  
The identification and validation of AMLo as a novel prognostic biomarker for early 
AJCC stage I melanoma addresses an unmet need in melanoma management by 
enabling risk-stratification of the earliest stage tumours, potentially altering future 
management and surveillance practices for patients with early stage AJCC 
melanomas. To date there have been no other accurate means of identifying high risk 
AJCC stage I melanomas at risk of metastasis, with an umbrella approach of ‘excision 
followed by watchful waiting’ currently employed by skin cancer services in the 
management of patients with such tumours. Similarly, as there have also been no 
previous means of accurately identifying high risk AJCC stage I melanomas, current 
drug trials for the treatment of melanoma have primarily focussed on the recruitment 
of patients already with advanced metastatic disease. Instead, utility of AMLo in a 
clinical setting will henceforth allow a more personalised approach to management of 
AJCC stage I melanomas, allowing closer surveillance practices, further radiological 
investigation and longer follow up duration if required for high risk tumours or facilitating 
discharge following primary excision for low risk tumours, as well as informing and  
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stratifying patients with high risk tumours for earlier novel targeted adjuvant therapy.  
In addition, due to the rapidly increasing incidence of melanoma, NHS costs for all skin 
cancers are expected to climb from £106 – £112 million in 2008 to over £180 million in 
2020 [207], placing increasing burden on an already stretched national health service. 
The high NPV afforded by AMLo as a prognostic biomarker will therefore potentially 
have significant positive impact on the cost of skin cancer care by aiding discharge 
decisions of low risk early stage tumours, given up to 91% of all melanomas are 
diagnosed in the UK fall within stage I or II, each requiring follow up between 1 – 5 
years [32]. Future work will therefore include an application to the National Institute for 
Health Research (NIHR) health technology assessment programme to determine the 
prognostic performance of currently available prognostic biomarkers used in risk 
stratification, surveillance and follow up strategies of patients with AJCC stage I 
melanoma as well as evaluate the cost-effectiveness of such strategies. Results 
derived from such studies will further aid the evaluation and potential impact of the 
clinical utility of AMLo in the management of melanoma on the health economics of 
skin cancer care. 
Overall, results from the present AMLo biomarker validation study presented in chapter 
3 suggest that going forwards with the staging changes brought in by the new 8th 
edition AJCC guidelines, the combined loss of AMLo overlying melanoma tumours will 
enable prognostic evaluation of both AJCC stage IA and IB melanomas, with further 
validation work already commenced in a further independent ‘prospective 
retrospective’ cohort of AJCC stage I melanomas derived from County Durham & 
Darlington NHS Trust in collaboration with histopathologist Dr Paul Barrett, University 
Hospital of North Durham, UK.  
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Based on the recommendations of the REMARK guidelines however, validation of a 
biomarker should be performed in a large randomised control trial setting(Appendix 1) 
[75]. Nonetheless, the high prognostic potential of AMLo derived from initial studies in 
predicting melanoma metastasis will give rise to ethical implications of withholding 
prognostic information or failure to offer or modify surveillance practices in the 
management of patients identified as high risk, as would be the case in a randomised 
prospective study. Given the huge impact the clinical utility of AMLo could potentially 
afford to melanoma cancer care, it would also be clinically beneficial for rapid validation 
of AMLo as a prognostic biomarker in AJCC stage I melanoma and incorporation into 
cancer care guidelines, compared to a prospective trial that will require at least 8 year 
follow-up data and will require costly funding. In view of this, results derived from AMLo 
biomarker validation within this study were presented at the National Cancer Research 
Institute (NCRI) UK Clinical Studies Group (CSG) meeting in November 2016. 
Feedback obtained from an expert panel recommended clinical validation of the 
prognostic potential of AMLo in a further independent, geographically distinct cohort of 
AJCC stage I melanomas, in addition to validation in the County Durham & Darlington 
NHS Trust melanoma cohort will be required to support application its adoption into 
NICE clinical guidelines without the need for a prospective clinical trial. 
All work to date has employed the use of commercially available research grade 
antibodies, use of such antibodies is however unsuitable in a clinical test setting.  
Supporting the continued development of AMLo as a prognostic biomarker for AJCC 
stage I melanoma, work is therefore already underway to produce recombinant clinical 
grade antibodies to the same protein epitopes that will validated by comparison with 
results derived from the present study using research grade antibodies and  CE 
marked to allow their use as a clinical diagnostic tool. Completion of these studies will 
hopefully support future adoption of AMLo as a prognostic biomarker into NICE 
guidelines and eventual incorporation as a prognosticator in AJCC staging criteria for 
melanoma, facilitating its use in a wider context.
Chapter 6: Final discussion and future perspectives 
206 
 
 
6.2 AMLo as a companion biomarker for adjuvant therapy targeting 
TGF-β2 signalling 
 
In this current era of personalised medicine, there is a constant drive towards 
identifying novel companion biomarkers to inform and guide targetable therapeutic 
avenues in cancer care. Companion biomarkers are biomarkers that can be used to 
prospectively predict likely response, resistance or toxicity risk in combination with 
specific therapies [208] i.e. biomarkers that are able to predict success of a specific 
treatment in each individual, enabling rational stratification for therapy. Historically, 
systemic treatment for advanced melanoma has incorporated chemotherapy with 
agents such as Dacarbazine or immunotherapy with interleukin-2 with limited success 
[209, 210],  where treatment strategies were largely guided by AJCC staging with other 
factors such as patient age and performance status taken into consideration. With the 
advent of novel targeted therapies and immunotherapies for advanced melanoma in 
the past decade, the importance of companion biomarkers has become more apparent 
in stratifying patients for the most appropriate systemic therapy. In addition, companion 
biomarkers may also inform on selection of appropriate therapeutic doses or alert 
physicians to patients with likelihood of severe toxicity for closer monitoring, forming 
the basis of personalised medicine i.e. the use of molecular diagnosis of disease to 
prescribe optimal treatment for the right patient [211]. 
Two of the best examples where companion biomarkers have been developed in 
parallel with targeted cancer therapy include stratification of patients with EML4-ALK-
positive non-small cell lung cancer for treatment with Crizitonib [212, 213] or the 
evaluation of BRAFV600 mutation status to stratify patients for therapy with BRAF 
inhibitors [97, 98]. In both these examples, the relevant biomarkers were incorporated 
in clinical trials at stage I where co-development with drug therapy resulted in rapid 
approval of their widespread clinical utility [208].  
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Results presented in chapter 2 demonstrate the targeting of TGF-β2 signalling as a 
viable therapeutic strategy to prevent ulceration and metastases of high risk AJCC 
stage I melanomas following primary excision, for which AMLo expression is a 
companion biomarker. More specifically, studies of TGF-β2 signalling in the 
endothelium, presented and discussed in chapter 3, suggest the targeting of non-
canonical ALK1-mediated TGF-β2 signalling may represent an optimal strategy to 
inhibit TGF-β2-mediated AMBRA1 and junctional protein down regulation, thereby 
potentially preventing melanoma metastasis. Given loss of epidermal AMLo overlying 
AJCC stage I melanomas was found to be associated with loss of peri-tumoural 
endothelial AMBRA1 expression in metastatic AJCC stage I melanoma as discussed 
in chapter 2, epidermal AMLo expression may therefore serve as an ideal companion 
biomarker to stratify patients for adjuvant therapy with ALK1 specific inhibitors. Further 
studies in a larger AJCC stage I melanoma cohort investigating the correlation between 
epidermal AMLo expression and endothelial AMBRA1 as well as melanoma prognosis 
will however, be required to validate this association and ideally can be undertaken in 
the ‘prospective-retrospective’ AJCC stage I melanoma cohort derived from Country 
Durham & Darlington NHS Foundation Trust. 
Despite the recent emergence of ALK1 inhibitors as a target for anti-angiogenic cancer 
therapy with evaluation in several clinical trials for treatment of various malignancies, 
to date the therapeutic utility of this approach has not been evaluated in malignant 
melanoma [162]. Future work will hence require further validation of ALK1 as a 
therapeutic target for drug development in high risk AJCC stage I melanoma using 
siRNA mediated ALK1 knockdown as well as chemical validation in vitro using 
rationally designed ALK1 inhibitor compounds to evaluate the effect of ALK1 inhibition 
on AMBRA1 down regulation and endothelial cell junction integrity. In addition, 
evaluation of the potential for novel ALK1 inhibitors to prevent melanoma invasion in 
fully humanised melanoma skin equivalents as well as in vivo in established xenograft 
models of human metastatic melanoma will inform novel drug development and 
ultimately clinical drug trials for which AMLo may serve as a companion biomarker to 
stratify high risk patient subgroups. 
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6.3 The role of Vitamin D in TGF-β2 mediated AMBRA1 down regulation 
and melanoma metastasis 
 
In the recent years, there has been much debate regarding the role of Vitamin D in 
melanoma progression. Certainly in melanoma, low levels of serum 25-hydroxyvitamin 
D at primary melanoma diagnosis has been associated with high risk melanomas with 
thicker primary tumours and a poorer prognosis, despite conflicting evidence on overall 
survival and insufficient evidence to establish cause-effect [78-82]. However, given 
vitamin D is primarily synthesised in the skin following exposure to UV exposure which 
has been historically linked to UVR-induced melanoma genesis, the association 
between increased vitamin D levels and reduced melanoma risk remains a 
controversial topic. 
Despite lower Vitamin D levels being associated with ulceration of primary melanomas 
and a poorer melanoma specific survival, the underlying biology of this remains 
uncertain. Following on from their previous work linking low levels of Vitamin D to 
melanoma ulceration and poor survival in a melanoma cohort derived from Leeds [78], 
a further study by Newton-Bishop et al recently suggested that the protective effect of 
Vitamin D may in fact be reduced by high serum Vitamin A (retinoic acid) levels [214].  
Interestingly, functional interactions between Vitamin A and TGF-β have long been 
observed underlying regulatory events controlling cellular proliferation and 
differentiation [215]. Vitamin A has been shown to regulate TGF-β expression in vivo, 
where basal expression of TGF-β2 was diminished in Vitamin A deficient conditions 
and treatment with retinoic acid resulted in induction of TGF-β2 and TGF-β3 in the 
epidermis, tracheobronchial and alveolar epithelium as well as intestinal mucosa [216]. 
Additionally, retinoic acid receptors have been shown to interfere with the TGF-β/Smad 
signalling pathway with suggestion that retinoic acid receptors (RAR) may function as 
co-activators of Smad signalling [217]. 
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A recent study by O’Shea et al investigating the enigma of melanoma ulceration and 
poor melanoma specific survival evaluated gene expression patterns associated with 
ulceration and demonstrated upregulation of pro-inflammatory cytokines IL-6 and IL-8, 
as well as establishing an association between co-morbidities associated with systemic 
inflammation such as smoking, diabetes and obesity with melanoma ulceration, 
suggesting that ulceration is driven by inflammation [86, 218]. There is also strong 
evidence in literature linking low Vitamin D levels to higher C-Reactive protein levels 
(marker of systemic inflammation) [219], further supporting the role of Vitamin D in 
melanoma ulceration. Interestingly, TGF-β has been reported to be an important 
regulator of IL-6 and IL-8 production with studies demonstrating that TGF-β can 
augment or inhibit IL-6 production in human fibroblasts as well as enhance IL-6 
secretion by intestinal epithelial cells [220, 221] and induce increased expression of IL-
1 and IL-8 in rat alveolar epithelial cells [222] as well as overexpression of IL-8 in 
human prostate cancer [223]. As previously discussed in chapter 2, Vitamin D is known 
to be a regulator of TGF-β signalling [191, 192] where impaired Vitamin D receptor 
signalling with reduced expression of VDR and decreased levels of its ligand have 
been shown to contribute to enhanced sensitivity of epithelial cells to the effects of 
TGF-β and result in hyperactive TGF-β signalling [189]. Collectively, this highlights the 
possibility of interplay between Vitamin D and TGF-β where low levels of Vitamin D or 
receptor could enhance the effect or increase expression/secretion of melanoma TGF-
β2 leading to pro-inflammatory conditions and melanoma ulceration. 
 
 
 
 
 
 
Chapter 6: Final discussion and future perspectives 
 210  
 
 
Collectively, literature discussed above highlights the potential interaction Vitamin D 
and its receptor expression may have on TGF-β2-induced down regulation of AMBRA1 
and melanoma prognosis observed in the present study cohort where melanomas that 
secrete high levels of TGF-β2 leading to activation of canonical TGF-β2 signalling and 
epidermal AMBRA1 down regulation may be protected against the pro-metastatic 
effect of TGF-β2 in the endothelium where there is adequate Vitamin D and receptor 
status (Figure 6.1 B). Equally, melanomas that have low Vitamin D or receptor status 
may display enhanced sensitivity or hyperactive TGF-β signalling resulting in 
epidermal ulceration, whereby exacerbated canonical signalling in response to TGF-
β2 may tip the balance towards favouring non-canonical signalling in the endothelium, 
resulting in loss of endothelial integrity and metastasis; an effect that will be further 
compounded in high risk melanomas that secrete higher levels of TGF-β2 (Figure 6.1 
A). This may explain why some melanoma tumours within the present study cohort 
scored as AMLo high risk with loss of epidermal AMBRA1 did not display any loss in 
expression of peri-tumoural endothelial AMBRA1 and develop metastases and equally 
why some AMLo low risk melanomas develop metastatic disease. Overall, these 
findings suggest that it may not only be high levels of TGF-β2 that determine metastatic 
risk but rather the effect of other factors contributing to enhanced or reduced signalling 
that determine metastatic risk and emphasising why the expression of tumoural TGF-
β2 itself is unsuitable as a biomarker for disease progression.  
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Figure 6.1: Hypothesis of the role of Vitamin D in TGF-β2 induced loss of epidermal/endothelial 
integrity and melanoma metastasis. A Melanomas that secrete high levels of TGF-β2 have enhanced 
TGF-β2 signalling in the presence of low Vitamin D levels leading to AMBRA1 downregulation and 
ulceration in the epidermis. In the endothelium, this results in increased recruitment of ALK1 thereby 
further enhancing non-canonical TGF-β2 signalling which becomes predominant, leading to stimulation 
and proliferation of endothelial cells, endothelial AMBRA1 down regulation, loss of endothelial cell 
integrity, tumour cell entry and metastasis. B In the presence of sufficient Vitamin D levels, TGF-β2 
signalling is diminished. Here, high levels of TGF-β2 secreted by some melanomas may still be sufficient 
to down regulate AMBRA1 in the epidermis and cause ulceration however, will not be sufficient to tip 
the balance of TGF-β2 signalling in the endothelium to favour non-canonical signalling, instead favouring 
canonical signalling which is protective against metastasis. 
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In addition reported findings that high Vitamin A levels negate the protective effects of 
Vitamin D on melanoma survival [214]  and that Vitamin A antagonises the effects of 
Vitamin D in vivo [224] but induce TGF-β signalling as discussed above, further 
highlight the potential crosstalk between these two steroid hormone receptor family 
members  with TGF-β2 signalling and AMBRA1 down regulation. It may be that low 
risk melanoma tumours that would normally be protected from the pro-metastatic 
effects of TGF-β2 due to adequate Vitamin D status, lose that protective effect in the 
presence of high Vitamin A levels (Table 6.1). Future work should therefore incorporate 
IHC analysis or mRNA expression analysis of Vitamin A and D receptor status in 
association with TGF-β2 signalling (by IHC expression of p-Smads), analysis of which 
could be undertaken in the AJCC stage I melanoma cohort derived from County 
Durham & Darlington NHS Foundation trust in order to further evaluate this link given 
the possibility that the utility of Vitamin A or D status in conjunction with AMLo as a 
biomarker may further improve the prognostic potential of AMLo alone. 
Equally interesting, is the association of Vitamin D with a plethora of other 
dermatological conditions such as psoriasis, disorders of keratinisation and skin 
fibrosis that have been traditionally treated with Vitamin D analogues, where the 
precise mechanisms underlying their therapeutic efficacy are still not completely 
understood [225]. The epidermal hyperkeratosis and dysregulated epidermal 
differentiation observed overlying melanoma tumours with loss of AMBRA1 expression 
mirrors in some ways, the changes observed in psoriasis and other disorders of 
keratinisation, shedding light on the potential role of TGF-β2 signalling in these 
disorders. In addition, the indisputable role TGF-β plays in fibrosis has long led to 
studies identifying pathways targeting its signalling to prevent fibrosis in a variety of 
fibrotic diseases such as renal and hepatic fibrosis or fibrosing lung conditions [226-
228]. 
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This opens doors to endless possibilities on the potential of targeting TGF-β2 signalling 
not only in the treatment of high risk melanomas, but also for its widespread application 
in several other diseases not limited to a dermatology setting. Ultimately, further and 
more in-depth studies into the relationship between Vitamin A and D and TGF-β2 
signalling will be required to understand the precise mechanisms underpinning the 
interaction between these three very complex signalling pathways. 
 
 
Prognosis of 
AJCC stage I 
melanoma 
High melanoma TGF-β2 Low to average melanoma TGF-β2 
Vitamin D Vitamin D 
High Low High Low 
Ulcerated 
epidermis 
Yes Yes No Possible 
Loss of 
endothelial 
integrity & 
metastasis 
No Yes No Possible 
Prognosis 
Incorporating 
Vitamin A 
status 
Vitamin A Vitamin A Vitamin A Vitamin A 
High Low High Low High Low High Low 
Ulcerated 
epidermis 
Yes Yes Yes Yes Possible No Possible Possible 
Loss of 
endothelial 
integrity & 
metastasis 
Possible No Yes Yes Possible No Possible Possible 
 
Table 6.1: Potential effect of Vitamin D and Vitamin A status on prognosis of AJCC stage I 
melanomas in association with melanoma TGF-β2 secretion.
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REporting recommendations for tumour MARKer prognostic studies 
(REMARK) guidelines [75] 
 
Introduction 
1. State the marker examined, the study objectives, and any prespecified 
hypotheses. 
Materials and Methods 
Patients 
2. Describe the characteristics (e.g. disease stage or comorbidities) of the study 
patients, including their source and inclusion and exclusion criteria. 
3. Describe treatments received and how chosen (e.g. randomised or rule-based). 
Specimen characteristics 
4. Describe type of biological material used (including control samples), and 
methods of preservation and storage. 
 Assay methods 
5. Specify the assay method used and provide (or reference) a detailed protocol, 
including specific reagents or kits used, quality control procedures, 
reproducibility assessments, quantitation methods, and scoring and reporting 
protocols. Specify whether and how assays were performed blinded to the study 
end point. 
Study design  
6. State the method of case selection, including whether prospective or 
retrospective and whether stratification or matching (e.g. by stage of disease or 
age) was employed. Specify the time period from which cases were taken, the 
end of the follow-up period, and the median follow-up time. 
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7. Precisely define all clinical end points examined. 
8. List all candidate variables initially examined or considered for inclusion in 
models. 
9. Give rationale for sample size; if the study was designed to detect a specified 
effect size, give the target power and effect size. 
Statistical analysis methods 
10. Specify all statistical methods, including details of any variable selection 
procedures and other model-building issues, how model assumptions were 
verified, and how missing data were handled. 
11. Clarify how marker values were handled in the analyses; if relevant, describe 
methods used for cutpoint determination. 
 
Results 
Data 
12. Describe the flow of patients through the study, including the number of patients 
included in each stage of the analysis (a diagram may be helpful) and reasons 
for dropout. Specifically, both overall and for each subgroup extensively 
examined report the numbers of patients and the number of events. 
13. Report distributions of basic demographic characteristics (at least age and sex), 
standard (disease-specific) prognostic variables, and tumour marker, including 
numbers of missing values. 
Analysis and presentation 
14. Show the relation of the marker to standard prognostic variables. 
15. Present univariate analyses showing the relation between the marker and 
outcome, with the estimated effect (e.g. hazard ratio and survival probability). 
Preferably provide similar analyses for all other variables being analysed. For 
the effect of a tumour marker on a time-to-event outcome, a Kaplan–Meier plot 
is recommended. 
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16. For key multivariable analyses, report estimated effects (e.g. hazard ratio) with 
confidence intervals for the marker and, at least for the final model, all other 
variables in the model. 
17. Among reported results, provide estimated effects with confidence intervals 
from an analysis in which the marker and standard prognostic variables are 
included, regardless of their significance. 
18. If done, report results of further investigations, such as checking assumptions, 
sensitivity analyses, internal validation. 
Discussion 
19. Interpret the results in the context of the pre-specified hypotheses and other 
relevant studies; include a discussion of limitations of the study. 
20. Discuss implications for future research and clinical value. 
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